# THE LANCET

## Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: COVID-19 Forecasting Team. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. *Lancet* 2023; published online Feb 16. https://doi.org/10.1016/S0140-6736(22)02465-5.

# Supplementary appendix "Past COVID-19 infection protection against reinfection: systematic review and meta-analysis"

This appendix provides further supplemental figures and more detailed results.

The appendix is organised into broad sections following the structure of the main paper.

#### **Table of Contents**

Table of C	Contents	2
Section 1	List of acronyms and abbreviations	3
Section 2	Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) compliance	4
Section 3	Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) compliance	5
Section 4	Supplementary figures and tables	8
Figure S1	Forest plots of meta-analysis results by variant and outcome	9
Figure S2	Sensitivity analysis according to Risk of Bias assessment	13
Figure S3	Sensitivity analysis according to adjusted/unadjusted results	18
Figure S4	Publication bias assessment	25
Table S1	Data inputs and characteristics of included studies	28
Table S2	Protection against reinfection, symptomatic, and severe disease by time since infection	50
Table S3	Risk of Bias Assessment for Case-Control Studies	78
Table S4	Risk of Bias Assessment for Cohort Studies	80
Section 5	Reference list	84

### Section 1 List of acronyms and abbreviations

Abbreviation/acronym	Full phrase
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
PCR	Polymerase chain reaction
RAT	Rapid antigen test
GATHER	Guidelines for Accurate and Transparent Health Estimates Reporting
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
UI	Uncertainty Interval
MR-BRT	Meta-regression—Bayesian, regularised, trimmed
GHDx	Global Health Data Exchange

# Section 2 Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) compliance

This study complies with GATHER recommendations, <sup>1</sup> See table S2 below for the GATHER checklist. The GATHER recommendations can be found on the <u>GATHER website</u>.

#### **GATHER checklist**

Item #	Checklist item	Reported location
		neported roddion
Objectives	Define the indicator(s), populations (including age, sex, and geographic entities),	A dath and a (Charda and anti-san and data automation)
1	and time period(s) for which estimates were made.	appendix Table S1
2	List the funding sources for the work.	· ·
Data Innut		Summary
Data Input		
FOI all dat	a inputs from multiple sources that are synthesized as part of the study:	8 Anthony (Overview)
3	Describe how the data were identified and how the data were accessed.	Methods (Overview)
4	Specify the inclusion and exclusion criteria. Identify all ad-hoc exclusions.	Methods (Inclusion and exclusion criteria)
		Appendix Table S1
5	For each data source used, report reference information or contact name/institution, population represented, data collection method, year(s) of data collection, sex and age range, diagnostic criteria or measurement method, and sample size, as relevant.	
6		Methods (Risk of bias assessment); (appendix, table S3 and S4 page 78 and 80
For data in	nputs that contribute to the analysis but were not synthesized as part of the study	:
7	Describe and give sources for any other data inputs.	NA
For all dat	a inputs:	
8	Provide all data inputs in a file format from which data can be efficiently extracted (e.g., a spreadsheet rather than a PDF), including all relevant metadata listed in item 5. For any data inputs that cannot be shared because of ethical or legal reasons, such as third-party ownership, provide a contact name or the name of the institution that retains the right to the data.	Appendix, table S1 page 28
Data analy		
9		Methods (Data analysis)
10	Provide a detailed description of all steps of the analysis, including mathematical formulae. This description should cover, as relevant, data cleaning, data preprocessing, data adjustments and weighting of data sources, and mathematical or statistical model(s).	Methods (Data analysis)
11	Describe how candidate models were evaluated and how the final model(s) were selected.	NA
12	Provide the results of an evaluation of model performance, if done, as well as the results of any relevant sensitivity analysis.	Appendix, figure S2 and S3, page 13 and 18
13	Describe methods for calculating uncertainty of the estimates. State which sources of uncertainty were, and were not, accounted for in the uncertainty analysis.	Methods (Data analysis)
14	State how analytic or statistical source code used to generate estimates can be accessed.	GitHub URL(s) will be made available
Results and	d Discussion	
15	extracted.	Appendix, table S1 page 28
16	Report a quantitative measure of the uncertainty of the estimates (e.g. uncertainty intervals).	Results
17	Interpret results in light of existing evidence. If updating a previous set of estimates, describe the reasons for changes in estimates.	Discussion
18	Discuss limitations of the estimates. Include a discussion of any modelling assumptions or data limitations that affect interpretation of the estimates.	Discussion

# Section 3 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) compliance

This study complies with PRISMA 2020 recommendations.<sup>2</sup> See table S3 below for the PRISMA 2020 checklist. The PRISMA recommendations can be found on the <u>PRISMA website</u>.

#### PRISMA 2020 checklist

Section and	Item	Checklist item	Location where
topic	#		item is reported
TITLE	1		5
Title	1	Identify the report as a systematic review.	Paper title
ABSTRACT	1 -	La	
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	N/A
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Main text introduction, paragraph 3
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Final sentence of main text introduction
METHODS	•		
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Main text methods "inclusion and exclusion criteria" section
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Main text methods "overview," paragraph 1
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Main text methods "overview," paragraph 1
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Main text methods "study selection and data extraction" section, paragraph 1
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Main text methods "study selection and data extraction" section
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Main text methods "outcomes assessed" section
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Main text methods "study selection and data extraction" section, paragraph 2
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Main text methods "risk of bias assessment" section
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Main text methods "data analysis" section


Section and topic	Item #	Checklist item	Location where item is reported
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	N/A
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	N/A
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Main text methods "data analysis" section
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Main text methods "data analysis" section
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Main text methods "data analysis" section
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Main text methods "data analysis" section
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	Main text methods "Risk of bias assessment" section
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Main text methods "data analysis" section
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Main text results, paragraphs 1 and 2
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	N/A
Study characteristics	17	Cite each included study and present its characteristics.	Appendix Table S1
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Appendix tables S3 and S4
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Appendix table S1
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Main text results, paragraph 8
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Main text results, paragraphs 3–7
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	NA
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Main text results, paragraphs 9
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	NA
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	95% uncertainty intervals (UIs) are presented for all mean estimates in the main text results section and in all figures, as relevant
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Main text discussion,

Section and	Item	Checklist item	Location where
topic	#	Checklist item	item is reported
			particularly
			paragraph 3
	23b	Discuss any limitations of the evidence included in the review.	Main text
			discussion,
			paragraph 5
	23c	Discuss any limitations of the review processes used.	Main text
			discussion,
			paragraph 5
	23d	Discuss implications of the results for practice, policy, and future research.	Main text
			discussion,
			paragraph 4;
			conclusion
OTHER INFORM	1ATION		
Registration	24a	Provide registration information for the review, including register name and registration	Main text
and protocol		number, or state that the review was not registered.	methods
			"overview,"
			second paragraph
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not	Main text
		prepared.	methods
			"overview,"
			second paragraph
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	N/A
Support	25	Describe sources of financial or non-financial support for the review, and the role of the	Main text
		funders or sponsors in the review.	methods "role of
			the funding
			source" section,
			acknowledgments
			section
Competing	26	Declare any competing interests of review authors.	Main text
interests			declaration of
			interests section
Availability of	27	Report which of the following are publicly available and where they can be found: template	Main text data
data, code		data collection forms; data extracted from included studies; data used for all analyses;	sharing section,
and other		analytic code; any other materials used in the review.	methods
materials			"overview,"
			second
			paragraph;
			Appendix table S1

### Section 4 Supplementary figures and tables

Figure S1 Forest plots of meta-analysis results by variant and outcome **Protection against reinfection** Alpha Ancestral Protection (95% UI) 78.8 (74.9-82.1) 74.0 (47.0-87.0) Letizia A United States 84.0 (75.0-90.0) 94.0 (86.0 98.0) 90.9 (89.4 92.0) 96.0 (79.0 99.0) Leidi A ONS Jeffery-Smith 83.0 (80.0-88.0) 97.0 (76.0-99.0) 61.0 (18.0-81.0) 97.0 (93.6-98.6) Kruttkov M 85.0 (56.0-95.0) 90.0 (89.0-91.0) 88.3 (48.0-97.4) 96.4 (92.1-98.3) Petras M 92.5 (76.5-97.6) 74.0 (66.0-79.0) 91.0 (89.0-92.0) 93.0 (91.0-95.0) 97.0 (88.0-99.0) 78.0 (77.0-78.0) Lacy J 77.3 (75.4-79.0) 72.0 (8.0-91.0) 83.2 (78.0-87.3) 97.3 (80.5-99.6) 87.0 (86.0-87.0) 90.0 (54.8-98.4) 84.9 (72.8-91.8) Multiple countries: Belgium, Brazil, Colombia, The Philippines, and South Africa Multiple countries: Belgium, Brazil, Colombia, The Philippines, and South Africa. Krutikov M (two different age groups: 18-64 and 65-90) Massimo V (three different primary infection variants: ancestral, Alpha, and Delta) Beta Delta 82.1 (81.0-83.1) 79.0 (77.0-81.0) 72.0 (61.3-87.2) 85.7 (83.4-87.7) 82.0 (63.5-91.9) Multiple countries: Belgium, Brazil, Colombia, The Philippines, and Multiple countries: Belgium, Brazil, Colombia, The Philippines, and South Africa South Africa Omicron BA.1


9





Carazo S (four different primary infection variants: mixed variant, ancestral, Alpha, and Delta)


Massimo V (three different primary infection variants: ancestral, Alpha,

Rothberg M (three different primary infection variants: ancestral, Alpha,


















Multiple countries: Belgium, Brazil, Colombia, The Philippines, and South Africa




Multiple countries: Belgium, Brazil, Colombia, The Philippines, and South Africa

#### Delta

#### z = 0.000428, p = 0.999659

Fair and Good Good




Mean estimate 81.9 (80.842.9)


Multiple countries: Belgium, Brazil, Colombia, The Philippines, and South Africa

Multiple countries: Belgium, Brazil, Colombia, The Philippines, and South Africa

#### **Omicron BA.1**

#### z = 0.165204, p = 0.868783






#### Protection against symptomatic disease Ancestral

#### Ancestrai

z = -0.39889, p = 0.689973




Good Author: Cohen C Country: South Africa

Protection (95% UI): 60.0 (10.0-80.0)

Alpha

z = -0.20574, p = 0.836995

Fair and Good Good











Figure S3 Sensitivity analysis according to adjusted/unadjusted results























 $Table \ S1 \quad \ Data \ inputs \ and \ characteristics \ of \ included \ studies$ 

First author name	Study design	Age or medin a age	Country	Variant (1st infection )	Variant (2 <sup>nd</sup> infection )	Outcome	Para meter	Adjustmen t	Mean efficacy	Low er 95% CI	Upp er 95% CI	Interva l or mean time since infecti on (in weeks)
Berec L <sup>3</sup>	retrospecti ve cohort	>12	Czechia	mixed variant	all variant	infection	1 - aHR	Age and sex	0.99	0.98	0.99	0-8
				mixed	all	infection	1 -		0.97	0.96	0.97	9-16
				variant	variant		aHR			5	5	
				mixed	all	infection	1 -		0.91	0.90	0.91	17-24
				variant	variant		aHR			5	5	
				mixed	all	infection	1 -		0.92	0.91	0.92	25-32
				variant	variant		aHR			5	5	
				mixed	all	infection	1 -		0.9	0.89	0.90	33-40
				variant	variant		aHR			5	5	
				mixed	all	infection	1 -		0.84	0.83	0.84	41-48
				variant	variant		aHR			5	5	
				mixed	all	infection	1 -		0.79	0.78	0.8	49-56
				variant	variant		aHR					
				mixed	all	infection	1 -		0.71	0.68	0.72	57-64
				variant	variant		aHR			5		
				mixed	all	infection	1 -		0.71	0.65	0.78	65-72
				variant	variant		aHR					
Hansen	retrospecti	>18	Denmark	Ancestra	Ancestra	infection	1 -	Age, sex,	0.788	0.74	0.82	NA
C <sup>4</sup>	ve cohort			1	1		aRR	and other	0.702	9	1	12.21
				Ancestra	Ancestra	infection	1 -	covariates	0.793	0.74	0.83	12_24
				1	1		aRR	4	0.777	4	3	25, 22
				Ancestra	Ancestra	infection	1 -		0.777	0.70	0.82	25_32
A 14 a ma	4 4	A 11	Onton	1 A == = = +t= :	A 1 1		aRR	A === ====	0.052	9 0.66	9	NA
Altarawn eh H <sup>5</sup>	test-	All	Qatar	Ancestra	Alpha	symptom atic	1 -	Age, sex, and other	0.953	0.66	0.99	INA
en n	negative	ages	Ootor	Angestra	Beta	1	aOR	covariates	0.854	0.72	0.92	NA
	case- control		Qatar	Ancestra	рега	symptom atic	aOR	covariates	0.854	4	0.92	INA
	Connor		Ootor	mixed	Delta	ł	1 -	1	0.902	0.81	0.94	NA
			Qatar	variant	Dena	symptom atic	aOR		0.902	9	6	INA
		L		varialit		auc	aUK	1		フ	U	

Qatar	mixed variant	Omicron (unspecif ied sub- lineage)	symptom atic	1 - aOR	0.619	0.48	0.72	NA
Qatar	Ancestra 1	Alpha	hospitalis ation & death	1 - aOR	0.694	0.01	0.96	NA
Qatar	Ancestra 1	Beta	hospitalis ation & death	1 - aOR	0.88	0.50 7	0.97	NA
Qatar	mixed variant	Delta	hospitalis ation & death	1 - aOR	0.999	0.43	0.99	NA
Qatar	mixed variant	Omicron (unspecif ied sub- lineage)	hospitalis ation & death	1 - aOR	0.878	0.47	0.97	NA
Qatar	Ancestra 1	Alpha	infection	1 - aOR	0.894	0.22 6	0.98 5	12_32
Qatar	Ancestra 1	Alpha	infection	1 - aOR	0.91	0.34 5	0.98 8	33_56
Qatar	Ancestra 1	Beta	infection	1 - aOR	0.926	0.76 7	0.97 6	12_32
Qatar	Ancestra 1	Beta	infection	1 - aOR	0.812	0.65 5	0.89 8	33_56
Qatar	mixed variant	Delta	infection	1 - aOR	0.934	0.87 6	0.96 5	12_32
Qatar	mixed variant	Delta	infection	1 - aOR	0.911	0.83	0.95 3	33_56
Qatar	mixed variant	Delta	infection	1 - aOR	0.871	0.59 4	0.95 9	>56
Qatar	mixed variant	Omicron (unspecif ied sub- lineage)	infection	1 - aOR	0.64	0.54	0.71	12_32
Qatar	mixed variant	Omicron (unspecif ied sub- lineage)	infection	1 - aOR	0.472	0.37	0.55	33_56

			Qatar	mixed variant	Omicron (unspecified sub- lineage)	infection	1 - aOR		0.596	0.50 7	0.67	>56
Rane M <sup>6</sup>	test- negative case- control	>12	US	mixed variant	Delta	Symptom atic	1 - aOR	Age, sex, and other covariates	0.9	0.87	0.93	34*
Smid M <sup>7</sup>	retrospecti ve cohort	>5	Czechia	mixed variant	Omicron (unspecif ied sub- lineage)	hospitalis ation	1 - aHR	Age and sex	0.87	0.73	0.94	2_24
				mixed variant	Omicron (unspecif ied sub- lineage)	hospitalis ation	1 - aHR		0.92	0.86	0.96	>24
				mixed variant	Delta	hospitalis ation	1 - aHR		0.99	0.98	0.99	2_24
				mixed variant	Delta	hospitalis ation	1 - aHR		0.95	0.93	0.96	>24
				mixed variant	Omicron (unspecif ied sub- lineage)	infection	1 - aHR		0.68	0.68	0.69	2_24
				mixed variant	Omicron (unspecif ied sub- lineage)	infection	1 - aHR		0.13	0.1	0.14	>24
				mixed variant	Delta	infection	1 - aHR		0.95	0.94	0.96	2_24
				mixed variant	Delta	infection	1 - aHR		0.83	0.82	0.84	>24
Abu- Raddad L <sup>8</sup>	retrospecti ve cohort	10-74	Qatar	Ancestra 1	Ancestra 1	infection	1 - aOR	Other covariates	0.927	0.91	0.93 9	17*
Hall V <sup>9</sup>	prospectiv e cohort	>18	UK	Ancestra 1	Alpha	infection	1 - aIRR	Age and sex	0.84	0.81	0.87	29*
Hall V <sup>10</sup>	prospectiv e cohort	>25	UK	all variant	all variant	infection	1 - aHR	Other covariates	0.86	0.81	0.89	0_51

				all variant	all variant	infection	1 - aHR		0.69	0.38	0.84	52_10 4
Pilz S <sup>11</sup>	retrospecti ve cohort	15-93	Austria	Ancestra 1	Ancestra 1	infection	1 - OR	No adjustment	0.91	0.87	0.93	30*
Rennert L <sup>12</sup>	retrospecti ve cohort	18-24	US	Ancestra 1	mixed variant	infection	1 - aRR	Age, sex, and other covariates	0.84	0.78	0.88	18*
Sheehan M <sup>13</sup>	retrospecti ve cohort	18-80	US	Ancestra 1	Ancestra 1	infection	1 - OR	No adjustment	0.818	0.76 6	0.85 8	20*
			US	Ancestra 1	Ancestra 1	Symptom atic	1 - OR		0.845	0.77 9	0.89	20*
Vitale J <sup>14</sup>	retrospecti ve cohort	18-80	Italy	Ancestra 1	Ancestra 1	infection	1 - aHR	Age, sex, and other covariates	0.94	0.92	0.95	34*
Wilkins J <sup>15</sup>	prospectiv e cohort	>18	US	Ancestra 1	Ancestra 1	infection	1 - aIRR	Age, sex, and other covariates	0.74	0.47	0.87	NA
Letizia A <sup>16</sup>	prospectiv e cohort	18-20	US	Ancestra 1	Ancestra 1	infection	1 - aOR	Age, sex, and other covariates	0.84	0.75	0.9	NA
Abo- Leyah H <sup>17</sup>	prospectiv e cohort	>18	UK	Ancestra 1	Ancestra 1	Symptom atic	1 - OR	No adjustment	0.85	0.65	0.94	11*
Lumley S <sup>18</sup>	longitudin al cohort	39*	UK	Ancestra 1	Alpha	Symptom atic	1 - aIRR	Age, sex, and other	0.98	0.82	0.99	NA
			UK	Ancestra 1	Alpha	infection	1 - aIRR	covariates	0.86	0.74	0.93	NA
Breathna ch A <sup>19</sup>	retrospecti ve cohort	50*	UK	Ancestra 1	Ancestra 1	infection	1 - RR	No adjustment	0.94	0.88	0.97	32*
Manica M <sup>20</sup>	retrospecti ve cohort	50*	Italy	Ancestra 1	Ancestra 1	Symptom atic	1 - aOR	Age, sex, and other covariates	0.946	0.83	0.99	NA
Leidi A <sup>21</sup>	retrospecti ve cohort	>12	Switzerla nd	Ancestra 1	Ancestra 1	infection	1 - HR	No adjustment	0.94	0.86	0.98	NA
Pouwels K <sup>22</sup>	prospectiv e cohort	>18	UK	Ancestra 1	Alpha	Symptom atic	1 - aOR	Age, sex, and other	0.8	0.75	0.84	NA
				Ancestra 1	Alpha	infection	1 - aOR	covariates	0.6	0.5	0.68	NA

				Ancestra l and Alpha	Delta	Symptom atic	1 - aOR		0.82	0.73	0.88	NA
				Ancestra l and Alpha	Delta	infection	1 - aOR		0.72	0.58	0.82	NA
Pritchard E <sup>23</sup>	prospectiv e cohort	>18	UK	Ancestra l and Alpha	Ancestra l and Alpha	infection	1 - aOR	Age, sex, and other covariates	0.28	0.1	0.43	0_15
				Ancestra l and Alpha	Ancestra l and Alpha	infection	1 - aOR		0.7	0.56	0.79	16_32
				Ancestra l and Alpha	Ancestra l and Alpha	Symptom atic	1 - aOR		0.67	0.5	0.88	0_15
			Ancestra l and Alpha	Ancestra l and Alpha	Symptom atic	1 - aOR		0.95	0.85	0.98 5	16_32	
				Ancestra l and Alpha	Alpha	infection	1 - aOR		0.42	0.19	0.58	0_15
				Ancestra l and Alpha	Alpha	infection	1 - aOR		0.81	0.66	0.9	16_32
Wang X <sup>24</sup>	test- negative	All ages	US	mixed variant	Delta	infection	1 - aOR	Age, sex, and other	0.87	0.85	0.89	NA
	case- control	ise-		mixed variant	Omicron (unspecif ied sub- lineage)	infection	1 - aOR	covariates	0.39	0.36	0.42	NA
				mixed variant	Omicron (unspecif ied sub- lineage)	infection	1 - OR	_	0.339	0.23 6	0.43	NA
Willett B <sup>25</sup>	test- negative	18- 108	Scotland	mixed variant	Delta	infection	1 - OR	No adjustment	0.774	0.71 5	0.82	NA
	case- control			mixed variant	Omicron (unspecif	infection	1 - OR		0.339	0.23 6	0.43 1	NA

					ied sub- lineage)							
Altarawn eh H <sup>26</sup>	test- negative case- control	All ages	Qatar	mixed variant	Omicron (unspecified sub- lineage)	Symptom atic	1 - OR	Age, sex, and other covariates	0.508	0.45	0.55 7	46*
				mixed variant	Omicron BA.1	Symptom atic	1 - OR		0.505	0.38	0.59 9	46*
			mixed variant	Omicron BA.2	Symptom atic	1 - OR		0.461	0.39	0.51	46*	
				mixed variant	Omicron (unspecified sub- lineage)	hospitalis ation	1 - OR		0.716	0.15	0.90	46*
				mixed variant	Omicron BA.2	hospitalis ation	1 - OR		0.734	0.00	0.92 9	46*
Starrfelt J <sup>27</sup>	retrospecti ve cohort	>18	Norway	mixed variant	Delta	infection	1 - aHR	Age, sex, and other covariates	0.931	0.92	0.93 9	NA
Cerqueira -Silva T <sup>28</sup>	test- negative case- control	>18	Brazil	mixed variant	Omicron (unspecif ied sub- lineage)	Symptom atic	1 - aOR	Age, sex, and other covariates	0.289	0.26 9	0.30 9	NA
				mixed variant	Omicron (unspecif ied sub- lineage)	hospitalis ation & death	1 - aOR		0.856	0.82 7	0.88	NA
				mixed variant	Omicron (unspecified sub- lineage)	hospitalis ation & death	1 - aOR		0.845	0.73	0.91	12_23
				mixed variant	Omicron (unspecified sub- lineage)	hospitalis ation & death	1 - aOR		0.895	0.86	0.92	24_51
				mixed variant	Omicron (unspecified sub- lineage)	hospitalis ation & death	1 - aOR		0.803	0.74	0.84	>52

				mixed variant	Omicron (unspecified sub-	Symptom atic	1 - aOR		0.528	0.48	0.56	12_23
				mixed variant	Omicron (unspecified sub-	Symptom atic	1 - aOR		0.327	0.30	0.35	24_51
				mixed variant	lineage) Omicron (unspecif ied sub- lineage)	Symptom atic	1 - aOR		0.147	0.10	0.18	>52
Carazo S <sup>29</sup>	test- negative case- control	>12	Canada	mixed variant	Omicron (unspecified sub- lineage)	infection	1 - aOR	Age, sex, and other covariates	0.44	0.38	0.48	NA
				Ancestra 1	Omicron (unspecif ied sub- lineage)	infection	1 - aOR		0.29	0.2	0.37	NA
				Alpha	Omicron (unspecif ied sub- lineage)	infection	1 - aOR		0.44	0.26	0.57	NA
				Delta	Omicron (unspecif ied sub- lineage)	infection	1 - aOR		0.67	0.57	0.75	NA
				mixed variant	Omicron (unspecif ied sub- lineage)	hospitalis ation	1 - aOR		0.81	0.66	0.89	NA
				mixed variant	Omicron (unspecified sub- lineage)	infection	1 - aOR		0.66	0.57	0.73	12_23
				mixed variant	Omicron (unspecified sub- lineage)	infection	1 - aOR		0.49	0.32	0.61	24_35

				Ancestra 1	Omicron (unspecif ied sub- lineage)	infection	1 - aOR		0.35	0.21	0.47	36_47
				Delta	Omicron (unspecif ied sub- lineage)	infection	1 - aOR		0.29	0.17	0.38	48_75
				Alpha	Omicron (unspecif ied sub- lineage)	infection	1 - aOR		0.27	0.08	0.42	76_96
Nordstro m P <sup>30</sup>	retrospecti ve cohort	39.9*	Sweden	mixed variant	mixed variant	infection	1 - aHR	Age, sex, and other	0.48	0.47	0.48	2_12
				mixed variant	mixed variant	infection	1 - aHR	covariates	0.96	0.95	0.96	13_24
				mixed variant	mixed variant	infection	1 - aHR		0.92	0.91	0.93	25_36
				mixed variant	mixed variant	infection	1 - aHR		0.93	0.92	0.98	>36
				mixed variant	mixed variant	hospitalis ation	1 - aHR		0.89	0.86	0.91	13_24
				mixed variant	mixed variant	hospitalis ation	1 - aHR		0.85	0.09	0.78	25_36
				mixed variant	mixed variant	hospitalis ation	1 - aHR		0.78	0.08	0.66	>36
Office of National Statistics <sup>3</sup>	prospectiv e cohort	>2	UK	mixed variant	mixed variant	infection	NA	NA	0.909	0.89	0.92	NA
Imperial College <sup>32</sup>	test- negative case- control	NA	UK	mixed variant	Omicron (unspecif ied sub- lineage)	infection	1 - RR	No adjustment	0.19	0	0.27	NA
Jeffery- Smith A <sup>33</sup>	prospectiv e cohort	NA	UK	Ancestra 1	Ancestra 1	infection	1 - RR	No adjustment	0.96	0.79	0.99	NA
Gallais F <sup>34</sup>	prospectiv e cohort	39*	France	Ancestra 1	mixed variant	infection	1 - HR	No adjustment	0.97	0.76	0.99	NA

Krutikov M <sup>35</sup>	prospectiv e cohort	18-64	UK	Ancestra	mixed variant	infection	1 - aHR	Age, sex, and other	0.61	0.18	0.81	NA
111	Conort	>64	UK	Ancestra	mixed variant	infection	1 - aHR	covariates	0.85	0.56	0.95	NA
Harvey R <sup>36</sup>	retrospecti ve cohort	48*	US	Ancestra	Ancestra	infection	1 - RR	No adjustment	0.9	0.89	0.91	NA
Maier H <sup>37</sup>	prospectiv e cohort	0-96	US	mixed variant	mixed variant	infection	1 - OR	No adjustment	0.883	0.48	0.97	NA
			US	mixed variant	mixed variant	Symptom atic	1 - OR		0.936	0.51	0.99	NA
Chemaite lly H <sup>38</sup>	retrospecti ve cohort	All ages	Qatar	Omicron BA.1	Omicron BA.2	infection	1 - aHR	Age, sex, and other	0.942	0.89	0.96 9	NA
•				Omicron BA.2	Omicron BA.1	infection	1 - aHR	covariates	0.809	0.73 1	0.86 4	NA
Satwik R <sup>39</sup>	retrospecti ve cohort	NA	India	mixed variant	Delta	Symptom atic	1 - aHR	Age, sex, and other covariates	0.93	0.87	0.96	38*
Chin E <sup>40</sup>	test- negative case- control	>18	US	mixed variant	Omicron (unspecif ied sub- lineage)	infection	1 - aOR	Age, sex, and other covariates	0.257	0.23	0.31 6	59*
				Delta	Omicron (unspecif ied sub- lineage)	infection	1 - aOR		0.608	0.58 4	0.66 8	21*
Braeye T <sup>41</sup>	retrospecti ve cohort	0-84	Belgium	mixed variant	Delta	infection	1 - aOR	Age, sex, and other	0.79	0.75	0.83	NA
				mixed variant	Alpha	infection	1 - aOR	covariates	0.83	0.8	0.88	NA
				mixed variant	Delta	infection	1 - aOR		0.79	0.74	0.83	0_7
				mixed variant	Delta	infection	1 - aOR		0.64	0.61	0.66	21_28
H <sup>42</sup>	test- negative	All ages	Qatar	mixed variant	Alpha	infection	1 - aOR	Age, sex, and other	0.97	0.93 6	0.98 6	NA
	case- control			mixed variant	Beta	infection	1 - aOR	covariates	0.855	0.82 4	0.88	NA

Chemaite lly H <sup>43</sup>	retrospecti ve cohort	All ages	Qatar	mixed variant	Alpha	infection	1 - aHR	Age, sex, and other	0.964	0.92	0.98	NA
,				mixed variant	Beta	infection	1 - aHR	covariates	0.864	0.82	0.89	NA
Petras M <sup>44</sup>	retrospecti ve cohort	All ages	Czechia	mixed variant	mixed variant	infection	1 - aIRR	Age, sex, and other covariates	0.925	0.76	0.97	NA
Carazo S <sup>29</sup>	test- negative	>18	Canada	mixed variant	Omicron BA.2	infection	1 - aOR	Age, sex, and other	NA	NA	NA	4_7
	case- control			mixed variant	Omicron BA.2	infection	1 - aOR	covariates	NA	NA	NA	8_11
				mixed variant	Omicron BA.2	infection	1 - aOR		0.42	-0.47	0.77	12_23
				mixed variant	Omicron BA.2	infection	1 - aOR		0.39	0	0.63	24_51
				mixed variant	Omicron BA.2	infection	1 - aOR		0.42	0.17	0.6	>51
				Omicron BA.1	Omicron BA.2	infection	1 - aOR		0.82	0.49	0.94	4_7
				Omicron BA.1	Omicron BA.2	infection	1 - aOR		0.76	0.63	0.85	8_11
				Omicron BA.1	Omicron BA.2	infection	1 - aOR		0.7	0.61	0.77	12_23
				Omicron BA.1	Omicron BA.2	infection	1 - aOR		NA	NA	NA	24_51
				Omicron BA.1	Omicron BA.2	infection	1 - aOR		NA	NA	NA	>51
eh H <sup>45</sup> ne cas	test- negative case-	All ages	Qatar	mixed variant	Omicron BA.4/BA	infection	1 - OR	Age, sex, and other covariates	0.286	0.11 8	0.42	NA
	control			mixed variant	Omicron BA.4/BA	Symptom atic	1 - OR		0.149	- 0.47 5	0.50 9	NA
				Omicron (unspecified sub- lineage)	Omicron BA.4/BA .5	infection	1 - OR		0.797	0.74	0.84	NA

				Omicron (unspecif ied sub- lineage)	Omicron BA.4/BA .5	Symptom atic	1 - OR		0.761	0.54	0.87	NA
Abu- Raddad LJ <sup>46</sup>	retrospecti ve cohort	All ages	Qatar	Ancestra 1	Alpha	infection	1 - IRR	No adjustment	0.975	0.95 7	0.98 6	NA
Bertollini R <sup>47</sup>	retrospecti ve cohort	33*	Qatar	mixed variant	mixed variant	infection	1- RR	Age, sex, and other covariates	0.74	0.66	0.79	NA
Chemaite lly H <sup>48</sup>	retrospecti ve cohort	All ages	Qatar	mixed variant	mixed variant	infection	1 - aHR	Age, sex, and other	0.806	0.77 8	0.83 1	0-16
		Qatar	mixed variant	mixed variant	infection	1 - aHR	covariates	0.863	0.83 8	0.88 7	17-20	
			Qatar	mixed variant	mixed variant	infection	1 - aHR		0.887	0.86 2	0.90 9	21-24
			Qatar	mixed variant	mixed variant	infection	1 - aHR		0.905	0.88 1	0.92 6	25-28
			Qatar	mixed variant	mixed variant	infection	1 - aHR		0.9	0.87 7	0.92 2	29-32
			Qatar	mixed variant	mixed variant	infection	1 - aHR		0.888	0.86 6	0.90 9	33-36
			Qatar	mixed variant	mixed variant	infection	1 - aHR		0.864	0.83 8	0.88 5	37-40
			Qatar	mixed variant	mixed variant	infection	1 - aHR		0.824	0.79 5	0.85 1	41-44
			Qatar	mixed variant	mixed variant	infection	1 - aHR	-	0.754	0.70 4	0.79 9	45-48
			Qatar	mixed variant	mixed variant	infection	1 - aHR		0.785	0.69 6	0.85 1	49-52
			Qatar	mixed variant	mixed variant	infection	1 - aHR		0.755	0.57 7	0.86 2	53-56
			Qatar	mixed variant	mixed variant	infection	1 - aHR		0.751	0.53 8	0.87	57-60
			Qatar	mixed variant	mixed variant	infection	1 - aHR		0.716	0.42	0.86	>60
			Qatar	Ancestra 1	Omicron (unspecif	infection	1 - aHR		0.381	0.35 6	0.40 6	48*

		ied sub- lineage)						
Qatar	Ancestra 1	Omicron (unspecified sub- lineage)	infection	1 - aHR	0.484	0.46	0.50 7	46*
Qatar	Ancestra 1	Omicron (unspecif ied sub- lineage)	infection	1 - aHR	0.519	0.48	0.54	62*
Qatar	Alpha	Omicron (unspecif ied sub- lineage)	infection	1 - aHR	0.17	0.14 6	0.19	32*
Qatar	Beta	Omicron (unspecif ied sub- lineage)	infection	1 - aHR	0.317	0.29 7	0.34	24*
Qatar	Delta	Omicron (unspecif ied sub- lineage)	infection	1 - aHR	0.571	0.55	0.59	8*
Qatar	mixed variant	mixed variant	hospitalis ation & death	1 - aHR	0.934	0.78	0.98	0-16
Qatar	mixed variant	mixed variant	hospitalis ation & death	1 - aHR	0.99	0.90 4	0.99	17-20
Qatar	mixed variant	mixed variant	hospitalis ation & death	1 - aHR	0.99	0.90 4	0.99	21-24
Qatar	mixed variant	mixed variant	hospitalis ation & death	1 - aHR	0.943	0.56 7	0.99 6	25-28
Qatar	mixed variant	mixed variant	hospitalis ation & death	1 - aHR	0.99	0.90	0.99	29-32
Qatar	mixed variant	mixed variant	hospitalis ation & death	1 - aHR	0.942	0.81	0.98 5	33-36

			Qatar	mixed variant	mixed variant	hospitalis ation & death	1 - aHR		0.981	0.85	0.99	37-40
			Qatar	mixed variant	mixed variant	hospitalis ation & death	1 - aHR		0.98	0.85	0.99	41-44
			Qatar	mixed variant	mixed variant	hospitalis ation & death	1 - aHR		0.99	0.83 5	0.99	45-48
			Qatar	mixed variant	mixed variant	hospitalis ation & death	1 - aHR		0.99	0	0.99	49-52
			Qatar	mixed variant	mixed variant	hospitalis ation & death	1 - aHR		0.952	0.51 6	0.99	53-62
Vicentini M <sup>49</sup>	retrospecti ve cohort	All ages	Italy	Ancestra 1	mixed variant	infection	1 - aHR	Age, sex, and other	0.91	0.89	0.92	NA
			Italy	Alpha	mixed variant	infection	1 - aHR	covariates	0.93	0.91	0.95	NA
			Italy	Delta	mixed variant	infection	1 - aHR		0.97	0.88	0.99	NA
			Italy	Ancestra 1	Omicron (unspecif ied sub- lineage)	infection	1 - aHR		0.51	0.49	0.54	NA
			Italy	Alpha	Omicron (unspecified sub- lineage)	infection	1 - aHR		0.62	0.64	0.6	NA
			Italy	Delta	Omicron (unspecif ied sub- lineage)	infection	1 - aHR		0.63	0.58	0.67	NA
Abu- Raddad LJ <sup>50</sup>	retrospecti ve cohort	All ages	Qatar	mixed variant	mixed variant	hospitalis ation & death	1 - aOR	Age, sex, and other covariates	0.9	0.75	0.97	NA
Michlma yr D <sup>51</sup>	retrospecti ve cohort	>2	Denmark	mixed variant	Alpha	infection	1 - aHR	Age, sex, and other	0.852	0.83 7	0.86 6	NA
7.2				mixed variant	Delta	infection	1 - aHR	covariates	0.821	0.81	0.83 1	NA

mixed variant	Omicron (unspecified sub-	infection	1 - aHR	0.334	0.32	0.34	NA
mixed variant	lineage) Alpha	Symptom atic	1 - aHR	0.908	0.89	0.92	NA
mixed variant	Delta	Symptom atic	1 - aHR	0.85	0.83	0.86	NA
mixed variant	Omicron (unspecif ied sub- lineage)	Symptom atic	1 - aHR	0.39	0.37	0.40 9	NA
mixed variant	Alpha	hospitalis ation	1 - aHR	0.866	0.46	0.96 7	NA
mixed variant	Delta	hospitalis ation	1 - aHR	0.972	0.89	0.99	NA
mixed variant	Omicron (unspecif ied sub- lineage)	hospitalis ation	1 - aHR	0.698	0.51	0.81	NA
mixed variant	Alpha	infection	1 - aHR	0.867	0.84	0.88	12-25
mixed variant	Alpha	infection	1 - aHR	0.833	0.80	0.86	26-38
mixed variant	Alpha	infection	1 - aHR	0.702	0.56 8	0.79 4	39-51
mixed variant	Alpha	infection	1 - aHR	0.864	0.76 1	0.92 3	>51
mixed variant	Delta	infection	1 - aHR	0.913	0.89 7	0.92 7	12-25
mixed variant	Delta	infection	1 - aHR	0.84	0.82	0.85 6	26-38
mixed variant	Delta	infection	1 - aHR	0.767	0.74 6	0.78 7	39-51
mixed variant	Delta	infection	1 - aHR	0.714	0.66 9	0.75 3	>51
mixed variant	Omicron (unspecif	infection	1 - aHR	0.51	0.50 1	0.52	12-25

			1	T	1			1
	ied sub-							
	lineage)							
mixed	Omicron	infection	1 -		0.254	0.23	0.27	26-38
variant	(unspecif		aHR			3	3	
	ied sub-							
	lineage)							
mixed	Omicron	infection	1 -		0.251	0.23	0.27	39-51
variant	(unspecif		aHR			1	1	
	ied sub-							
	lineage)							
mixed	Omicron	infection	1 -		0.19	0.17	0.20	>51
variant	(unspecif		aHR			2	5	
	ied sub-							
	lineage)							
mixed	Alpha	Symptom	1 -		0.926	0.90	0.94	12-25
variant		atic	aHR			7		
mixed	Alpha	Symptom	1 -		0.89	0.85	0.91	26-38
variant		atic	aHR			6	6	
mixed	Alpha	Symptom	1 -		0.72	0.54	0.82	39-51
variant		atic	aHR			6	7	
mixed	Alpha	Symptom	1 -		0.932	0.81	0.97	>51
variant		atic	aHR			9	5	
mixed	Delta	Symptom	1 -		0.931	0.91	0.94	12-25
variant		atic	aHR			2	5	
mixed	Delta	Symptom	1 -		0.872	0.85	0.89	26-38
variant		atic	aHR			3		
mixed	Delta	Symptom	1 -		0.8	0.77	0.82	39-51
variant		atic	aHR			4	2	
mixed	Delta	Symptom	1 -		0.747	0.69	0.79	>51
variant		atic	aHR			4	<u> </u>	
mixed	Omicron	Symptom	1 -		0.551	0.53	0.56	12-25
variant	(unspecif	atic	aHR			3	8	
	ied sub-							
	lineage)							
mixed	Omicron	Symptom	1 -		0.311	0.27	0.34	26-38
variant	(unspecif	atic	aHR			9		
	ied sub-							
	lineage)							
mixed	Omicron	Symptom	1 -	]	0.314	0.28	0.34	39-51
variant	(unspecif	atic	aHR			4	3	

					ied sub-							
					lineage)							
				mixed	Omicron	Symptom	1 -		0.257	0.22	0.28	>51
				variant	(unspecif	atic	aHR			8	4	
					ied sub-							
					lineage)							
Lacy J <sup>52</sup>	retrospecti	>10	UK	Ancestra	mixed	infection	1 -	Age, sex,	0.78	0.77	0.78	NA
	ve cohort			1	variant		OR	and other				
				Ancestra	mixed	Symptom	1 -	covariates	0.77	0.74	0.8	NA
				1	variant	atic	OR					
				Ancestra	mixed	death	1 -		0.45	0.29	0.58	NA
				1	variant		aOR					
Ridgway	retrospecti	40*	US	Ancestra	mixed	Symptom	1 -	Age, sex,	0.85	0.82	0.87	NA
$JP^{53}$	ve cohort			1	variant	atic	aHR	and other				
				Ancestra	mixed	hospitalis	1 -	covariates	0.88	0.82	0.92	NA
				1	variant	ation	aHR					
				Ancestra	mixed	Symptom	1 -		0.85	0.79	0.9	12-14
				1	variant	atic	aHR					
				Ancestra	mixed	Symptom	1 -		0.86	0.8	0.91	15-21
				1	variant	atic	aHR					
				Ancestra	mixed	Symptom	1 -		0.86	0.78	0.91	22-28
				1	variant	atic	aHR					
				Ancestra	mixed	Symptom	1 -		0.88	0.8	0.95	29-35
				1	variant	atic	aHR					
Spicer	Retrospect	>20	US	Mixed	Mixed	Infection	1 –	No				NA
$KB^{54}$	ive cohort			variant	variant		RR	adjustment	0.77	0.75	0.79	
				Mixed	Mixed	Infection	1 –					12-16
				variant	variant		RR		0.70	0.66	0.74	
				Mixed	Mixed	Infection	1 –					17-20
				variant	variant		RR		0.79	0.75	0.82	
				Mixed	Mixed	Infection	1 –					21-24
				variant	variant		RR		0.81	0.78	0.85	
				Mixed	Mixed	Infection	1 –					25-28
				variant	variant		RR	_	0.74	0.67	0.79	
				Mixed	Mixed	Infection	1 –					29-32
				variant	variant		RR		0.70	0.59	0.78	
				Mixed	Mixed	Infection	1 –					33-36
				variant	variant		RR		0.79	0.65	0.88	

Cohen	prospective	All	South Africa	Mixed variant	Mixed variant	Symptom	1 -	Other				NA
Conen C <sup>55</sup>	prospectiv e cohort	ages	Airica	variant	variani	atic	aOR	covariates	0.6	0.1	0.8	
	CCOTTOTC	uges	South	Mixed	Mixed	Infection	1-	Other	0.0	0.1	0.0	12-24
	prospectiv	All	Africa	variant	variant		aRR	covariates	0.92	0.84	0.96	
Sun K <sup>56</sup>	e cohort	ages		Mixed	Mixed	Infection	1-					25-36
				variant	variant		aRR		0.87	0.78	0.92	
	test-	12-17	UK			Symptom		Age, sex,				NA
	negative					atic		and other		0.86	0.88	
	case-			Ancestral	Delta		1-aOR	covariates	0.876	8	4	
	control					Symptom				0.85	0.86	NA
				Alpha	Delta	atic	1-aOR		0.861	4	8	
						Symptom				0.91	0.92	NA
				Delta	Delta	atic	1-aOR		0.923	7	9	
					Omicron	Symptom						NA
					(unspecif	atic						
					ied sub-					0.27	0.37	
				Ancestral	lineage)		1-aOR	=	0.327	7	4	
					Omicron	Symptom						NA
					(unspecif	atic						
					ied sub-		4 00		0.255	0.32	0.40	
				Alpha	lineage)	6 .	1-aOR		0.366	9	1	NTA
					Omicron	Symptom						NA
					(unspecif ied sub-	atic				0.50	0.53	
				Delta	lineage)		1-aOR		0.524	9	0.55	
				Omicron	Omicron	Symptom	1-aUK	-	0.324	9	0	NA
Powell				(unspecif	(unspecif	atic						IVA.
A <sup>57</sup>				ied sub-	ied sub-	atic				0.46		
^				lineage)	lineage)		1-aOR		0.593	7	0.69	
Muruges	retrospecti	>18	India	mixed	mixed	Symptom	1-HR	Age, sex,	0.555	, 	0.03	NA
an M <sup>58</sup>	ve cohort			variant	variant	atic		and other		0.76	0.91	
								covariates	0.86	7	6	
Dhumal	retrospecti	34*	India	mixed	mixed	infection		Age, sex,				NA
S <sup>59</sup>	ve cohort			variant	variant			and other				
							1-aHR	covariates	0.72	0.08	0.91	

Corrao	test-	>18	Italy	mixed	mixed	Symptom		Other				NA
$G^{60}$	negative			variant	variant	atic		covariates				
	case-											
	control						1-aOR		0.91	0.85	0.95	
	clinical	>18	US	mixed	mixed	infection		No			0.87	NA
	trial			variant	variant		1-IRR	adjustment	0.832	0.78	3	
				mixed		infection				0.80		NA
				variant	Alpha		1-IRR		0.99	4	0.99	
				mixed		infection				0.33	0.89	NA
Smoleno				variant	Beta		1-IRR		0.722	1	9	
v I <sup>61</sup>				mixed		infection				0.61	0.87	NA
				variant	Delta		1-IRR		0.72	3	2	
	retrospecti	All	US					Age, sex,				NA
Reynolds	ve cohort	ages						and other				
S <sup>62</sup>				Ancestral	Ancestral	Infection	1-aHR	covariates	0.87	0.87	0.87	24.22
				Ancestral	Ancestral	Infection	1-aHR	1	0.88	0.87	0.88	24-32
				Ancestral	Ancestral	Infection	1-aHR		0.83	0.82	0.85	33-40
				Ancestral	Ancestral	Infection	1-aHR		0.85	0.82	0.87	41-48
Narraine	retrospecti	>18	UK					No		0.80	0.99	NA
n F <sup>63</sup>	ve cohort			Ancestral	Ancestral	Infection	1-OR	adjustment	0.973	5	6	
	prospectiv	0-4	Nicaragu	mixed	mixed	Symptom		No				NA
	e cohort		a	variant	variant	atic	1-RR	adjustment	0.61	0.2	0.8	
		5-9		mixed	mixed	Symptom						Na
				variant	variant	atic	1-RR		0.64	0.2	0.7	
Kubale J <sup>64</sup>		10-14		mixed	mixed	Symptom						NA
				variant	variant	atic	1-RR		0.49	0.3	0.9	
	retrospecti	All	US		Omicron			Age, sex,				NA
	ve cohort	ages			(unspecif			and other				
					ied sub-			covariates			0.22	
				Ancestral	lineage)	infection	1-aRR		0.18	0.13	7	
					Omicron							NA
					(unspecif							
					ied sub-					0.25	0.48	
				Alpha	lineage)	infection	1-aRR		0.381	2	9	
Rothberg					Omicron					0.63	0.74	NA
$M^{65}$				Delta	(unspecif	infection	1-aRR		0.692	4	1	

					ied sub- lineage)							
	retrospecti	>11	Netherla	mixed	64607			Age, sex,				NA
	ve cohort		nds	variant	Delta	infection	1-aOR	and other	0.79	0.77	0.81	
				mixed			1-aOR	covariates				4-8
				variant	Delta	infection			0.7	0.5	0.83	
				mixed			1-aOR					9-12
				variant	Delta	infection			0.95	0.85	0.99	
				mixed			1-aOR					13-17
				variant	Delta	infection			0.93	0.84	0.97	
				mixed			1-aOR					18-21
				variant	Delta	infection			0.92	0.86	0.95	
				mixed			1-aOR					22-25
				variant	Delta	infection			0.86	0.76	0.91	
				mixed			1-aOR					26-29
				variant	Delta	infection			0.84	0.74	0.9	
				mixed			1-aOR					30-34
				variant	Delta	infection			0.76	0.73	0.79	
				mixed	Omicron		1-aOR					NA
				variant	BA.1	infection			0.46	0.44	0.48	
				mixed	Omicron		1-aOR					4-8
				variant	BA.1	infection			0.73	0.66	0.79	
				mixed	Omicron		1-aOR					9-12
				variant	BA.1	infection			0.63	0.58	0.67	
				mixed	Omicron		1-aOR					13-17
				variant	BA.1	infection			0.57	0.52	0.62	10.01
				mixed	Omicron		1-aOR		0.55	0.46	0.60	18-21
				variant	BA.1	infection	4 00		0.55	0.46	0.62	22.25
				mixed	Omicron		1-aOR		0.53	0.40	0.6	22-25
				variant	BA.1	infection	4 00		0.53	0.43	0.6	26.20
				mixed	Omicron	infection	1-aOR		0.53	0.45	0.58	26-29
				variant	BA.1 Omicron	intection	1-aOR	-	0.52	0.45	0.58	30-34
Andeweg				mixed variant	BA.1	infection	1-aUK		0.34	0.31	0.38	30-34
S <sup>66</sup>				mixed	Omicron	miection	1-aOR	1	0.34	0.51	0.30	NA
3				variant	BA.2	infection	1 0010		0.47	0.44	0.5	11/11

	1	ı					
mixed	Omicron		1-aOR				4-8
variant	BA.2	infection		0.76	0.68	0.82	
mixed	Omicron		1-aOR				9-12
variant	BA.2	infection		0.56	0.48	0.62	
mixed	Omicron		1-aOR				13-17
variant	BA.2	infection		0.5	0.43	0.56	
mixed	Omicron		1-aOR				18-21
variant	BA.2	infection		0.57	0.49	0.64	
mixed	Omicron		1-aOR				22-25
variant	BA.2	infection		0.5	0.36	0.61	
mixed	Omicron		1-aOR				26-29
variant	BA.2	infection		0.53	0.42	0.62	
mixed	Omicron		1-aOR				30-34
variant	BA.2	infection		0.38	0.34	0.43	
mixed			1-aOR				NA
variant	Delta	infection		0.8	0.78	0.82	
mixed			1-aOR				4-8
variant	Delta	infection		0.7	0.48	0.83	
mixed			1-aOR				9-12
variant	Delta	infection		0.98	0.86	0.99	
mixed			1-aOR				13-17
variant	Delta	infection		0.94	0.83	0.98	
mixed			1-aOR				18-21
variant	Delta	infection		0.92	0.86	0.95	
mixed			1-aOR				22-25
variant	Delta	infection		0.84	0.73	0.9	
mixed			1-aOR				26-29
variant	Delta	infection		0.88	0.78	0.93	
mixed			1-aOR				30-34
variant	Delta	infection		0.77	0.74	0.8	
mixed	Omicron		1-aOR			_	NA
variant	BA.1	infection		0.47	0.44	0.49	
mixed	Omicron		1-aOR				4-8
variant	BA.1	infection		0.73	0.66	0.8	
mixed	Omicron		1-aOR			-	9-12
variant	BA.1	infection		0.62	0.57	0.67	

mixed	Omicron		1-aOR					13-17
		infaction	1-aUK		0.55	0.48	0.6	13-17
variant	BA.1	infection	4 00	_	0.55	0.48	0.6	10.21
mixed	Omicron		1-aOR					18-21
variant	BA.1	infection			0.51	0.41	0.6	
mixed	Omicron		1-aOR					22-25
variant	BA.1	infection			0.54	0.44	0.62	
mixed	Omicron		1-aOR					26-29
variant	BA.1	infection			0.53	0.45	0.59	
mixed	Omicron		1-aOR					30-34
variant	BA.1	infection			0.37	0.33	0.4	
mixed	Omicron		1-aOR					NA
variant	BA.2	infection			0.49	0.45	0.52	
mixed	Omicron		1-aOR					4-8
variant	BA.2	infection			0.76	0.69	0.82	
mixed	Omicron		1-aOR					9-12
variant	BA.2	infection			0.57	0.49	0.63	
mixed	Omicron		1-aOR					13-17
variant	BA.2	infection			0.5	0.43	0.56	
mixed	Omicron		1-aOR					18-21
variant	BA.2	infection			0.58	0.5	0.66	
mixed	Omicron		1-aOR					22-25
variant	BA.2	infection			0.55	0.41	0.65	
mixed	Omicron		1-aOR					26-29
variant	BA.2	infection			0.52	0.4	0.62	
mixed	Omicron		1-aOR					30-34
variant	BA.2	infection			0.4	0.35	0.44	

CI = Confidence Interval; NA = not available; \* indicates extracted data point is median age

Table S2 Protection against reinfection, symptomatic, and severe disease by time since infection

	Protection Protection against ancestral, Alpha, and Delta reinfection		ncestral,	Protection	n against C 1 reinfection	micron	Protectio	n against C 2 reinfectio	micron	Protectio	n against a ha, and De	ncestral,	Protec	tion agains tomatic dis			n against a and Delta s			ion against	
Week after infectio n	Estimat e	Lower boun d	Upper boun d	Estimat e	Lower boun d	Upper boun d	Estimat e	Lower boun d	Upper boun d	symp Estimat e	tomatic dis Lower boun d	ease Upper boun d	Estimat e	Lower boun d	Upper boun d	Estimat e	disease Lower boun d	Upper bound	Estimat e	Lower boun d	Upper boun d
0	85.2%	61.0%	96.0%	77.5%	66.1%	86.1%	96.9%	83.6%	99.0%	90.3%	80.4%	98.4%	89.2%	67.1%	95.8%	96.7%	90.9%	100.0	88.9%	86.9%	99.9%
0.1	85.2%	61.0%	96.0%	77.4%	66.0%	86.1%	96.8%	83.4%	98.9%	90.3%	80.4%	98.4%	89.0%	67.0%	95.7%	96.7%	90.9%	% 100.0	88.9%	86.9%	99.9%
0.2	85.2%	61.0%	96.0%	77.4%	65.9%	86.0%	96.6%	83.3%	98.9%	90.3%	80.4%	98.3%	88.8%	67.0%	95.6%	96.7%	91.1%	% 100.0	88.9%	86.9%	99.9%
0.3	85.2%	61.0%	96.0%	77.3%	65.8%	86.0%	96.5%	83.1%	98.8%	90.3%	80.4%	98.3%	88.6%	66.9%	95.5%	96.7%	91.1%	% 100.0	88.9%	86.9%	99.9%
0.4	85.2%	61.0%	96.0%	77.2%	65.7%	85.9%	96.3%	82.8%	98.7%	90.3%	80.4%	98.2%	88.4%	66.7%	95.4%	96.8%	91.1%	% 100.0	88.9%	86.9%	99.9%
0.5	85.2%	61.0%	96.0%	77.1%	65.6%	85.9%	96.1%	82.6%	98.6%	90.3%	80.3%	98.2%	88.2%	66.3%	95.2%	96.8%	91.1%	% 100.0	88.9%	86.9%	99.9%
0.6	85.2%	61.0%	96.0%	77.1%	65.5%	85.8%	96.0%	82.3%	98.5%	90.3%	80.3%	98.2%	88.0%	65.9%	95.1%	96.8%	91.1%	% 100.0	88.9%	86.9%	99.9%
																		%			
0.7	85.2%	61.0%	96.0%	76.9%	65.4%	85.8%	95.8%	82.1%	98.4%	90.3%	80.3%	98.1%	87.7%	65.9%	94.9%	96.9%	91.2%	100.0	88.9%	86.9%	99.9%
0.8	85.2%	61.0%	96.0%	76.8%	65.2%	85.7%	95.6%	81.8%	98.3%	90.3%	80.2%	98.1%	87.5%	65.8%	94.7%	96.9%	91.2%	100.0	88.9%	86.9%	99.9%
0.9	85.2%	60.9%	96.0%	76.8%	65.1%	85.6%	95.4%	81.6%	98.2%	90.3%	80.2%	98.1%	87.3%	65.6%	94.5%	96.9%	91.2%	100.0 %	88.9%	86.9%	99.8%
1	85.2%	60.9%	96.0%	76.7%	65.0%	85.6%	95.2%	81.3%	98.1%	90.3%	80.1%	98.0%	87.1%	65.5%	94.4%	96.9%	91.2%	100.0 %	88.9%	87.0%	99.8%
1.1	85.2%	60.9%	96.0%	76.6%	64.9%	85.5%	94.9%	81.0%	98.0%	90.3%	80.1%	98.0%	86.9%	65.4%	94.3%	97.0%	91.2%	100.0 %	88.9%	87.0%	99.8%
1.2	85.2%	60.9%	96.0%	76.5%	64.8%	85.5%	94.7%	80.8%	97.9%	90.3%	80.1%	97.9%	86.6%	65.3%	94.3%	97.0%	91.2%	100.0 %	88.9%	87.0%	99.8%
1.3	85.2%	60.9%	96.0%	76.4%	64.7%	85.4%	94.5%	80.5%	97.7%	90.3%	80.0%	97.9%	86.4%	65.2%	94.1%	97.0%	91.3%	100.0 %	88.9%	87.0%	99.8%
1.4	85.2%	60.8%	96.0%	76.3%	64.5%	85.4%	94.3%	80.3%	97.6%	90.3%	80.0%	97.9%	86.2%	65.2%	93.9%	97.0%	91.3%	100.0 %	88.9%	87.0%	99.8%
1.5	85.2%	60.8%	96.0%	76.3%	64.4%	85.3%	94.0%	80.0%	97.5%	90.3%	80.0%	97.8%	85.9%	65.1%	93.7%	97.1%	91.3%	100.0	88.9%	87.0%	99.8%
1.6	85.2%	60.8%	96.0%	76.2%	64.3%	85.3%	93.8%	79.7%	97.3%	90.3%	80.0%	97.8%	85.7%	65.0%	93.6%	97.1%	91.3%	100.0 %	88.9%	87.0%	99.8%
1.7	85.2%	60.8%	96.0%	76.1%	64.2%	85.2%	93.5%	79.5%	97.2%	90.3%	80.0%	97.7%	85.5%	65.0%	93.4%	97.1%	91.3%	100.0	88.9%	87.0%	99.8%
1.8	85.2%	60.8%	96.0%	76.0%	64.1%	85.2%	93.2%	79.2%	97.0%	90.3%	80.0%	97.7%	85.2%	64.9%	93.3%	97.1%	91.3%	100.0 %	88.9%	87.0%	99.8%
1.9	85.2%	60.8%	96.0%	75.9%	64.0%	85.1%	93.0%	78.9%	96.8%	90.3%	80.0%	97.7%	85.0%	64.8%	93.1%	97.2%	91.4%	100.0	88.9%	87.0%	99.8%
2	85.2%	60.8%	96.0%	75.8%	63.8%	85.0%	92.7%	78.7%	96.6%	90.3%	80.0%	97.7%	84.7%	64.7%	93.0%	97.2%	91.4%	% 100.0	88.9%	87.0%	99.8%
2.1	85.2%	60.8%	96.0%	75.7%	63.7%	85.0%	92.4%	78.4%	96.4%	90.3%	80.0%	97.7%	84.5%	64.7%	92.9%	97.2%	91.5%	% 100.0	88.9%	87.0%	99.8%
2.2	85.2%	60.8%	96.0%	75.6%	63.6%	84.9%	92.1%	78.2%	96.2%	90.3%	80.0%	97.7%	84.2%	64.6%	92.7%	97.2%	91.5%	% 100.0	88.9%	87.0%	99.7%
2.3	85.2%	60.8%	96.0%	75.6%	63.5%	84.9%	91.8%	78.0%	96.0%	90.3%	80.0%	97.7%	84.0%	64.2%	92.5%	97.2%	91.5%	% 100.0	88.9%	87.0%	99.7%
2.4	85.2%	60.8%	96.0%	75.5%	63.4%	84.8%	91.5%	77.8%	95.8%	90.3%	80.0%	97.7%	83.8%	63.9%	92.3%	97.3%	91.6%	% 100.0	88.9%	87.0%	99.7%
2.5	85.2%	60.8%	96.0%	75.4%	63.3%	84.8%	91.1%	77.5%	95.6%	90.3%	80.0%	97.6%	83.5%	63.5%	92.1%	97.3%	91.6%	% 100.0	88.9%	87.0%	99.7%

2.6	85.2%	60.8%	96.0%	75.3%	63.1%	84.7%	90.8%	77.2%	95.4%	90.3%	80.0%	97.6%	83.3%	63.2%	91.9%	97.3%	91.6%	100.0 %	88.9%	87.0%	99.7%
2.7	85.2%	60.8%	96.0%	75.2%	63.0%	84.6%	90.5%	77.0%	95.1%	90.3%	80.0%	97.5%	83.0%	63.1%	91.7%	97.3%	91.7%	70 100.0 %	88.9%	87.0%	99.7%
2.8	85.2%	60.8%	96.0%	75.1%	62.9%	84.6%	90.1%	76.8%	94.9%	90.3%	80.0%	97.5%	82.8%	63.0%	91.6%	97.3%	91.7%	% 100.0 %	88.9%	87.0%	99.7%
2.9	85.2%	60.8%	96.0%	75.0%	62.8%	84.5%	89.8%	76.7%	94.6%	90.3%	80.0%	97.5%	82.5%	62.8%	91.5%	97.3%	91.7%	% 100.0 %	88.9%	87.0%	99.7%
3	85.2%	60.8%	96.0%	74.9%	62.7%	84.5%	89.4%	76.4%	94.3%	90.3%	80.0%	97.4%	82.3%	62.7%	91.3%	97.4%	91.8%	70 100.0 %	88.9%	87.0%	99.6%
3.1	85.2%	60.8%	96.0%	74.8%	62.5%	84.4%	89.0%	76.1%	94.0%	90.3%	80.0%	97.4%	82.0%	62.5%	91.2%	97.4%	91.8%	% 100.0 %	88.9%	87.0%	99.6%
3.2	85.2%	60.8%	96.0%	74.8%	62.4%	84.4%	88.7%	75.9%	93.8%	90.3%	80.0%	97.4%	81.7%	62.5%	91.0%	97.4%	91.8%	70 100.0 %	88.9%	87.0%	99.6%
3.3	85.2%	60.8%	96.0%	74.7%	62.3%	84.3%	88.3%	75.7%	93.5%	90.3%	80.0%	97.4%	81.5%	62.4%	90.8%	97.4%	91.9%	100.0 %	88.9%	87.0%	99.6%
3.4	85.2%	60.8%	96.0%	74.6%	62.2%	84.2%	87.9%	75.5%	93.1%	90.3%	80.0%	97.4%	81.2%	62.3%	90.7%	97.4%	91.9%	% 100.0 %	88.9%	87.0%	99.6%
3.5	85.2%	60.8%	96.0%	74.5%	62.1%	84.2%	87.5%	75.3%	92.8%	90.3%	80.0%	97.4%	81.0%	62.1%	90.5%	97.4%	91.9%	% 100.0 %	88.9%	87.0%	99.6%
3.6	85.2%	60.8%	96.0%	74.4%	61.9%	84.1%	87.1%	74.9%	92.5%	90.3%	80.0%	97.3%	80.7%	61.9%	90.3%	97.4%	92.0%	100.0 %	88.9%	87.0%	99.5%
3.7	85.2%	60.8%	96.0%	74.3%	61.8%	84.1%	86.7%	74.7%	92.2%	90.3%	80.0%	97.3%	80.5%	61.7%	90.2%	97.5%	92.0%	100.0 %	88.9%	87.0%	99.5%
3.8	85.2%	60.8%	96.0%	74.2%	61.7%	84.0%	86.2%	74.6%	91.8%	90.3%	80.0%	97.3%	80.2%	61.5%	90.0%	97.5%	92.0%	100.0 %	88.9%	87.0%	99.5%
3.9	85.2%	60.8%	96.0%	74.1%	61.6%	84.0%	85.8%	74.2%	91.5%	90.3%	80.0%	97.3%	79.9%	61.3%	89.8%	97.5%	92.0%	100.0 %	88.9%	87.0%	99.5%
4	85.2%	60.8%	96.0%	74.0%	61.5%	83.9%	85.4%	74.0%	91.1%	90.3%	80.0%	97.2%	79.7%	61.0%	89.7%	97.5%	92.0%	100.0 %	88.9%	87.0%	99.5%
4.1	85.2%	60.8%	96.0%	73.9%	61.3%	83.8%	85.0%	73.7%	90.7%	90.3%	80.0%	97.2%	79.4%	60.7%	89.5%	97.5%	92.0%	100.0 %	88.9%	87.0%	99.5%
4.2	85.2%	60.8%	96.0%	73.8%	61.2%	83.8%	84.5%	73.4%	90.3%	90.3%	80.0%	97.1%	79.2%	60.5%	89.3%	97.5%	92.1%	100.0 %	88.9%	87.0%	99.4%
4.3	85.2%	60.8%	96.0%	73.8%	61.1%	83.7%	84.1%	73.2%	89.9%	90.3%	80.0%	97.1%	78.9%	60.2%	89.1%	97.5%	92.1%	99.9%	88.9%	87.0%	99.4%
4.4	85.2%	60.8%	95.9%	73.7%	61.0%	83.6%	83.6%	72.9%	89.5%	90.3%	80.0%	97.1%	78.6%	60.0%	88.9%	97.5%	92.1%	99.9%	88.9%	87.0%	99.4%
4.5	85.2%	60.8%	95.9%	73.6%	60.9%	83.5%	83.1%	72.6%	89.0%	90.3%	80.0%	97.1%	78.4%	59.7%	88.7%	97.6%	92.2%	99.9%	88.9%	87.0%	99.4%
4.6	85.2%	60.8%	95.9%	73.5%	60.8%	83.5%	82.7%	72.3%	88.6%	90.3%	79.9%	97.1%	78.1%	59.4%	88.5%	97.6%	92.2%	99.9%	88.9%	87.0%	99.4%
4.7	85.2%	60.8%	95.9%	73.4%	60.7%	83.4%	82.2%	71.9%	88.1%	90.3%	79.8%	97.1%	77.9%	59.1%	88.2%	97.6%	92.2%	99.9%	88.9%	87.0%	99.3%
4.8	85.2%	60.8%	95.9%	73.3%	60.6%	83.3%	81.7%	71.6%	87.6%	90.3%	79.7%	97.0%	77.6%	58.9%	88.0%	97.6%	92.2%	99.9%	88.9%	87.0%	99.3%
4.9	85.2%	60.8%	95.9%	73.2%	60.5%	83.2%	81.3%	71.2%	87.2%	90.3%	79.6%	97.0%	77.3%	58.9%	87.8%	97.6%	92.1%	99.9%	88.9%	87.0%	99.3%
5	85.2%	60.8%	95.9%	73.1%	60.4%	83.2%	80.8%	70.9%	86.7%	90.3%	79.6%	96.9%	77.1%	58.7%	87.7%	97.6%	92.1%	99.9%	88.9%	87.0%	99.3%
5.1	85.2%	60.8%	95.9%	73.0%	60.3%	83.1%	80.3%	70.6%	86.2%	90.3%	79.6%	96.9%	76.8%	58.3%	87.5%	97.6%	92.2%	99.9%	88.9%	87.0%	99.2%
5.2	85.2%	60.8%	95.9%	72.9%	60.2%	83.0%	79.8%	70.3%	85.8%	90.3%	79.6%	96.9%	76.6%	58.0%	87.3%	97.6%	92.2%	99.9%	88.9%	87.0%	99.2%
5.3	85.2%	60.8%	95.9%	72.8%	60.1%	82.9%	79.3%	69.9%	85.3%	90.3%	79.6%	96.9%	76.3%	57.9%	87.0%	97.6%	92.3%	99.9%	88.9%	87.0%	99.2%
5.4	85.2%	60.8%	95.9%	72.7%	60.0%	82.9%	78.8%	69.7%	84.8%	90.3%	79.6%	96.8%	76.0%	57.8%	86.9%	97.6%	92.3%	99.9%	88.9%	87.0%	99.1%
5.5	85.2%	60.8%	95.9%	72.6%	59.9%	82.8%	78.3%	69.4%	84.3%	90.3%	79.6%	96.8%	75.8%	57.5%	86.7%	97.6%	92.3%	99.9%	88.9%	87.0%	99.1%
5.6	85.2%	60.8%	95.9%	72.5%	59.8%	82.8%	77.8%	69.1%	83.8%	90.3%	79.6%	96.8%	75.5%	57.3%	86.5%	97.6%	92.3%	99.9%	88.9%	87.0%	99.1%
5.7	85.2%	60.8%	95.9%	72.4%	59.8%	82.7%	77.3%	68.8%	83.3%	90.3%	79.5%	96.8%	75.3%	57.1%	86.3%	97.7%	92.3%	99.9%	88.9%	87.0%	99.1%

5.8	85.2%	60.8%	95.9%	72.3%	59.7%	82.7%	76.8%	68.5%	82.8%	90.3%	79.3%	96.8%	75.0%	57.1%	86.0%	97.7%	92.3%	99.9%	88.9%	87.0%	99.0%
5.9	85.2%	60.8%	95.9%	72.3%	59.6%	82.6%	76.3%	68.1%	82.3%	90.3%	79.2%	96.8%	74.8%	56.7%	85.8%	97.7%	92.3%	99.9%	88.9%	87.0%	99.0%
6	85.2%	60.8%	95.9%	72.2%	59.5%	82.5%	75.8%	67.8%	81.8%	90.3%	79.1%	96.7%	74.5%	56.5%	85.7%	97.7%	92.3%	99.9%	88.9%	87.0%	99.0%
6.1	85.2%	60.8%	95.9%	72.1%	59.4%	82.5%	75.3%	67.5%	81.3%	90.3%	78.9%	96.7%	74.3%	56.2%	85.6%	97.7%	92.3%	99.9%	88.9%	87.0%	99.0%
6.2	85.2%	60.8%	95.9%	72.0%	59.3%	82.4%	74.8%	67.2%	80.7%	90.3%	78.8%	96.7%	74.0%	56.1%	85.4%	97.7%	92.3%	99.9%	88.9%	87.0%	98.9%
6.3	85.2%	60.8%	95.9%	71.9%	59.2%	82.4%	74.3%	66.9%	80.1%	90.3%	78.7%	96.7%	73.8%	55.9%	85.2%	97.7%	92.3%	99.9%	88.9%	87.0%	98.9%
6.4	85.2%	60.8%	95.9%	71.8%	59.1%	82.3%	73.8%	66.6%	79.6%	90.3%	78.7%	96.7%	73.5%	55.8%	85.0%	97.7%	92.4%	99.8%	88.9%	87.0%	98.9%
6.5	85.2%	60.8%	95.9%	71.7%	59.0%	82.2%	73.3%	66.2%	79.1%	90.3%	78.7%	96.7%	73.3%	55.6%	84.8%	97.7%	92.4%	99.8%	88.9%	87.0%	98.8%
6.6	85.2%	60.8%	95.9%	71.6%	58.9%	82.1%	72.8%	65.9%	78.6%	90.3%	78.7%	96.7%	73.0%	55.5%	84.6%	97.7%	92.4%	99.8%	88.9%	87.0%	98.8%
6.7	85.2%	60.8%	95.9%	71.5%	58.7%	82.1%	72.3%	65.5%	78.0%	90.3%	78.7%	96.6%	72.8%	55.3%	84.5%	97.7%	92.4%	99.8%	88.9%	87.0%	98.8%
6.8	85.2%	60.8%	95.9%	71.4%	58.6%	82.0%	71.8%	65.3%	77.4%	90.3%	78.6%	96.6%	72.5%	55.2%	84.3%	97.7%	92.4%	99.8%	88.9%	87.0%	98.7%
6.9	85.2%	60.8%	95.9%	71.3%	58.5%	81.9%	71.3%	65.0%	76.9%	90.3%	78.6%	96.6%	72.3%	55.0%	84.3%	97.7%	92.4%	99.8%	88.9%	87.0%	98.7%
7	85.2%	60.8%	95.9%	71.2%	58.4%	81.8%	70.8%	64.6%	76.3%	90.3%	78.6%	96.6%	72.0%	54.7%	84.1%	97.7%	92.4%	99.8%	88.9%	87.0%	98.7%
7.1	85.2%	60.8%	95.9%	71.1%	58.3%	81.8%	70.3%	64.3%	75.7%	90.3%	78.6%	96.5%	71.8%	54.3%	83.9%	97.7%	92.4%	99.8%	88.9%	87.0%	98.6%
7.2	85.2%	60.8%	95.9%	71.0%	58.1%	81.7%	69.8%	63.9%	75.1%	90.3%	78.6%	96.5%	71.5%	54.1%	83.8%	97.7%	92.4%	99.8%	88.9%	87.0%	98.6%
7.3	85.2%	60.8%	95.9%	70.9%	58.0%	81.6%	69.3%	63.6%	74.6%	90.3%	78.6%	96.5%	71.3%	54.0%	83.6%	97.7%	92.5%	99.8%	88.9%	87.0%	98.5%
7.4	85.2%	60.8%	95.9%	70.8%	57.9%	81.5%	68.9%	63.3%	74.0%	90.3%	78.5%	96.5%	71.1%	53.7%	83.4%	97.7%	92.5%	99.8%	88.9%	86.9%	98.5%
7.5	85.2%	60.8%	95.9%	70.7%	57.8%	81.4%	68.4%	62.9%	73.5%	90.3%	78.5%	96.5%	70.8%	53.4%	83.2%	97.7%	92.5%	99.8%	88.9%	86.9%	98.4%
7.6	85.2%	60.8%	95.9%	70.6%	57.7%	81.4%	67.9%	62.6%	73.0%	90.3%	78.5%	96.5%	70.6%	53.2%	83.0%	97.7%	92.5%	99.8%	88.9%	86.9%	98.4%
7.7	85.2%	60.8%	95.9%	70.5%	57.5%	81.3%	67.4%	62.3%	72.6%	90.3%	78.5%	96.5%	70.4%	53.0%	82.9%	97.7%	92.5%	99.8%	88.9%	86.9%	98.3%
7.8	85.2%	60.8%	95.9%	70.4%	57.4%	81.2%	67.0%	62.0%	72.1%	90.3%	78.5%	96.4%	70.1%	52.8%	82.8%	97.7%	92.5%	99.7%	88.9%	86.9%	98.3%
7.9	85.2%	60.8%	95.9%	70.3%	57.3%	81.1%	66.5%	61.6%	71.7%	90.3%	78.5%	96.4%	69.9%	52.6%	82.7%	97.7%	92.5%	99.7%	88.9%	86.9%	98.2%
8	85.2%	60.8%	95.9%	70.2%	57.1%	81.0%	66.1%	61.3%	71.2%	90.3%	78.4%	96.4%	69.7%	52.4%	82.6%	97.7%	92.5%	99.7%	88.9%	86.9%	98.2%
8.1	85.2%	60.8%	95.9%	70.1%	57.0%	81.0%	65.6%	61.0%	70.7%	90.3%	78.4%	96.4%	69.5%	52.3%	82.5%	97.7%	92.5%	99.7%	88.9%	86.9%	98.1%
8.2	85.2%	60.8%	95.9%	70.0%	56.9%	80.9%	65.2%	60.7%	70.3%	90.3%	78.4%	96.4%	69.2%	52.1%	82.2%	97.7%	92.4%	99.7%	88.9%	86.9%	98.1%
8.3	85.2%	60.8%	95.9%	69.9%	56.7%	80.8%	64.7%	60.4%	69.9%	90.3%	78.4%	96.4%	69.0%	51.9%	82.0%	97.7%	92.4%	99.7%	88.9%	86.9%	98.0%
8.4	85.2%	60.8%	95.9%	69.8%	56.6%	80.7%	64.3%	60.1%	69.5%	90.3%	78.4%	96.4%	68.8%	51.7%	81.8%	97.7%	92.4%	99.7%	88.9%	86.9%	98.0%
8.5	85.2%	60.8%	95.9%	69.7%	56.5%	80.7%	63.9%	59.7%	69.1%	90.3%	78.4%	96.4%	68.6%	51.6%	81.6%	97.7%	92.4%	99.7%	88.9%	86.9%	97.9%
8.6	85.2%	60.8%	95.9%	69.6%	56.3%	80.6%	63.5%	59.5%	68.7%	90.3%	78.4%	96.4%	68.4%	51.4%	81.4%	97.7%	92.4%	99.6%	88.9%	86.9%	97.9%
8.7	85.2%	60.8%	95.9%	69.5%	56.2%	80.5%	63.1%	59.2%	68.3%	90.3%	78.3%	96.4%	68.1%	51.2%	81.1%	97.7%	92.4%	99.6%	88.9%	86.9%	97.8%
8.8	85.2%	60.8%	95.9%	69.4%	56.1%	80.5%	62.6%	58.9%	68.0%	90.3%	78.3%	96.4%	67.9%	51.1%	81.0%	97.7%	92.3%	99.6%	88.9%	86.9%	97.8%
8.9	85.2%	60.8%	95.9%	69.3%	55.9%	80.4%	62.3%	58.7%	67.6%	90.3%	78.3%	96.3%	67.7%	50.9%	81.0%	97.7%	92.3%	99.6%	88.9%	86.9%	97.7%

9	85.2%	60.8%	95.9%	69.2%	55.8%	80.3%	61.9%	58.4%	67.2%	90.3%	78.3%	96.3%	67.5%	50.6%	80.9%	97.7%	92.2%	99.6%	88.9%	86.9%	97.7%
9.1	85.2%	60.8%	95.9%	69.1%	55.7%	80.2%	61.5%	58.1%	66.8%	90.3%	78.3%	96.3%	67.3%	50.4%	80.8%	97.7%	92.2%	99.6%	88.9%	86.9%	97.6%
9.2	85.2%	60.8%	95.9%	69.0%	55.5%	80.2%	61.1%	57.7%	66.5%	90.3%	78.3%	96.3%	67.1%	50.1%	80.6%	97.7%	92.1%	99.6%	88.9%	86.9%	97.6%
9.3	85.2%	60.8%	95.9%	68.9%	55.4%	80.1%	60.7%	57.4%	66.2%	90.3%	78.3%	96.3%	66.9%	49.9%	80.4%	97.7%	92.1%	99.6%	88.9%	86.9%	97.5%
9.4	85.2%	60.8%	95.8%	68.8%	55.3%	80.0%	60.4%	57.1%	65.9%	90.3%	78.3%	96.3%	66.7%	49.8%	80.3%	97.7%	92.1%	99.6%	88.9%	86.9%	97.4%
9.5	85.2%	60.8%	95.8%	68.7%	55.1%	79.9%	60.0%	56.8%	65.7%	90.3%	78.2%	96.3%	66.5%	49.8%	80.3%	97.7%	92.1%	99.6%	88.9%	86.9%	97.4%
9.6	85.2%	60.8%	95.8%	68.6%	55.0%	79.9%	59.7%	56.6%	65.4%	90.3%	78.2%	96.3%	66.3%	49.6%	80.2%	97.7%	92.1%	99.6%	88.9%	86.9%	97.3%
9.7	85.2%	60.8%	95.8%	68.5%	54.9%	79.8%	59.3%	56.3%	65.1%	90.3%	78.2%	96.3%	66.1%	49.4%	80.1%	97.7%	92.1%	99.5%	88.9%	86.9%	97.3%
9.8	85.2%	60.8%	95.8%	68.4%	54.7%	79.7%	59.0%	56.0%	64.8%	90.3%	78.2%	96.3%	66.0%	49.2%	79.9%	97.7%	92.0%	99.5%	88.9%	86.9%	97.2%
9.9	85.2%	60.7%	95.8%	68.3%	54.6%	79.6%	58.7%	55.7%	64.6%	90.3%	78.2%	96.3%	65.8%	49.0%	79.8%	97.7%	91.9%	99.5%	88.9%	86.9%	97.2%
10	85.2%	60.7%	95.8%	68.2%	54.5%	79.6%	58.4%	55.5%	64.4%	90.3%	78.2%	96.3%	65.6%	48.8%	79.7%	97.7%	91.9%	99.5%	88.9%	86.9%	97.1%
10.1	85.2%	60.7%	95.8%	68.1%	54.3%	79.5%	58.1%	55.1%	64.1%	90.3%	78.2%	96.3%	65.4%	48.6%	79.6%	97.7%	91.8%	99.5%	88.9%	86.9%	97.0%
10.2	85.2%	60.7%	95.8%	68.0%	54.2%	79.4%	57.8%	54.8%	63.9%	90.3%	78.2%	96.3%	65.2%	48.4%	79.4%	97.7%	91.8%	99.5%	88.9%	86.9%	97.0%
10.3	85.2%	60.7%	95.8%	67.9%	54.1%	79.4%	57.5%	54.6%	63.7%	90.3%	78.2%	96.3%	65.1%	48.2%	79.3%	97.7%	91.8%	99.5%	88.9%	86.8%	96.9%
10.4	85.2%	60.7%	95.8%	67.8%	53.9%	79.3%	57.2%	54.3%	63.5%	90.3%	78.1%	96.3%	64.9%	48.0%	79.1%	97.6%	91.7%	99.5%	88.9%	86.8%	96.8%
10.5	85.2%	60.7%	95.8%	67.7%	53.8%	79.2%	56.9%	54.0%	63.2%	90.3%	78.1%	96.3%	64.7%	47.8%	79.0%	97.6%	91.7%	99.5%	88.9%	86.8%	96.8%
10.6	85.2%	60.7%	95.8%	67.6%	53.7%	79.1%	56.7%	53.7%	63.0%	90.3%	78.1%	96.3%	64.5%	47.7%	78.9%	97.6%	91.7%	99.5%	88.9%	86.8%	96.7%
10.7	85.2%	60.7%	95.8%	67.5%	53.5%	79.1%	56.4%	53.4%	62.8%	90.3%	78.1%	96.2%	64.4%	47.6%	78.8%	97.6%	91.7%	99.5%	88.9%	86.8%	96.6%
10.8	85.2%	60.7%	95.8%	67.3%	53.4%	79.0%	56.2%	53.2%	62.6%	90.3%	78.1%	96.2%	64.2%	47.3%	78.7%	97.6%	91.6%	99.5%	88.9%	86.8%	96.6%
10.9	85.2%	60.7%	95.8%	67.2%	53.3%	78.9%	55.9%	52.9%	62.3%	90.3%	78.1%	96.2%	64.1%	47.2%	78.6%	97.6%	91.5%	99.5%	88.9%	86.8%	96.5%
11	85.2%	60.7%	95.8%	67.1%	53.1%	78.8%	55.7%	52.7%	62.1%	90.3%	78.1%	96.2%	63.9%	47.0%	78.5%	97.6%	91.4%	99.5%	88.9%	86.8%	96.4%
11.1	85.2%	60.7%	95.8%	67.0%	53.0%	78.8%	55.5%	52.5%	61.9%	90.3%	78.1%	96.2%	63.8%	46.9%	78.4%	97.6%	91.3%	99.5%	88.9%	86.8%	96.4%
11.2	85.2%	60.7%	95.8%	66.9%	52.9%	78.7%	55.3%	52.3%	61.6%	90.3%	78.1%	96.1%	63.6%	46.8%	78.3%	97.6%	91.2%	99.5%	88.9%	86.8%	96.4%
11.3	85.2%	60.7%	95.8%	66.8%	52.7%	78.6%	55.1%	52.0%	61.5%	90.3%	78.1%	96.1%	63.5%	46.6%	78.2%	97.6%	91.1%	99.5%	88.9%	86.8%	96.3%
11.4	85.2%	60.7%	95.8%	66.7%	52.6%	78.5%	54.9%	51.7%	61.3%	90.3%	78.1%	96.0%	63.3%	46.5%	78.1%	97.6%	91.1%	99.5%	88.9%	86.8%	96.2%
11.5	85.2%	60.7%	95.8%	66.6%	52.5%	78.4%	54.7%	51.5%	61.1%	90.3%	78.1%	96.0%	63.2%	46.4%	78.1%	97.6%	91.0%	99.4%	88.9%	86.8%	96.1%
11.6	85.2%	60.7%	95.8%	66.5%	52.4%	78.4%	54.6%	51.4%	60.9%	90.3%	78.0%	96.0%	63.0%	46.2%	78.0%	97.5%	91.0%	99.4%	88.9%	86.8%	96.1%
11.7	85.2%	60.7%	95.8%	66.4%	52.3%	78.3%	54.4%	51.2%	60.7%	90.3%	78.0%	96.0%	62.9%	46.1%	77.9%	97.5%	90.9%	99.4%	88.9%	86.8%	96.0%
11.8	85.2%	60.7%	95.8%	66.3%	52.2%	78.2%	54.2%	51.1%	60.5%	90.3%	78.0%	96.0%	62.8%	46.0%	77.8%	97.5%	90.9%	99.4%	88.9%	86.8%	95.9%
11.9	85.2%	60.7%	95.8%	66.2%	52.1%	78.1%	54.1%	50.9%	60.4%	90.3%	78.0%	96.0%	62.6%	45.7%	77.8%	97.5%	90.8%	99.4%	88.9%	86.8%	95.8%
12	85.2%	60.7%	95.8%	66.1%	52.0%	78.1%	54.0%	50.7%	60.2%	90.3%	78.0%	96.0%	62.5%	45.5%	77.7%	97.5%	90.7%	99.4%	88.9%	86.8%	95.8%
12.1	85.2%	60.7%	95.8%	66.0%	51.9%	78.0%	53.8%	50.6%	60.1%	90.3%	78.0%	96.0%	62.4%	45.4%	77.6%	97.5%	90.7%	99.4%	88.9%	86.8%	95.7%

12.2	85.2%	60.7%	95.8%	65.9%	51.8%	77.9%	53.7%	50.5%	59.9%	90.3%	78.0%	96.0%	62.3%	45.3%	77.5%	97.5%	90.6%	99.4%	88.9%	86.8%	95.6%
12.3	85.2%	60.7%	95.8%	65.8%	51.7%	77.8%	53.6%	50.3%	59.6%	90.3%	78.0%	96.0%	62.1%	45.2%	77.5%	97.5%	90.5%	99.4%	88.9%	86.8%	95.5%
12.4	85.2%	60.7%	95.8%	65.7%	51.6%	77.7%	53.5%	50.2%	59.5%	90.3%	78.0%	96.0%	62.0%	45.1%	77.4%	97.4%	90.5%	99.4%	88.9%	86.8%	95.4%
12.5	85.2%	60.7%	95.8%	65.5%	51.5%	77.7%	53.4%	50.1%	59.3%	90.3%	78.0%	95.9%	61.9%	45.0%	77.3%	97.4%	90.4%	99.3%	88.9%	86.8%	95.3%
12.6	85.2%	60.7%	95.8%	65.4%	51.4%	77.6%	53.3%	50.0%	59.2%	90.3%	78.0%	95.9%	61.8%	44.9%	77.3%	97.4%	90.3%	99.3%	88.9%	86.8%	95.3%
12.7	85.2%	60.7%	95.8%	65.3%	51.3%	77.5%	53.3%	49.9%	59.1%	90.3%	78.0%	95.9%	61.7%	44.8%	77.2%	97.4%	90.3%	99.3%	88.9%	86.8%	95.2%
12.8	85.2%	60.7%	95.8%	65.2%	51.1%	77.4%	53.2%	49.8%	59.0%	90.3%	78.0%	95.9%	61.6%	44.7%	77.2%	97.4%	90.3%	99.3%	88.9%	86.8%	95.1%
12.9	85.2%	60.7%	95.8%	65.1%	51.0%	77.3%	53.1%	49.8%	58.8%	90.3%	77.9%	95.9%	61.5%	44.5%	77.1%	97.4%	90.3%	99.3%	88.9%	86.8%	95.0%
13	85.2%	60.7%	95.8%	65.0%	50.9%	77.3%	53.1%	49.7%	58.6%	90.3%	77.8%	95.9%	61.4%	44.4%	77.0%	97.4%	90.2%	99.3%	88.9%	86.8%	95.0%
13.1	85.2%	60.7%	95.8%	64.9%	50.7%	77.2%	53.1%	49.7%	58.5%	90.3%	77.8%	95.9%	61.3%	44.3%	76.9%	97.3%	90.2%	99.3%	88.9%	86.8%	94.9%
13.2	85.2%	60.7%	95.8%	64.8%	50.6%	77.1%	53.0%	49.6%	58.4%	90.3%	77.7%	95.9%	61.2%	44.1%	76.8%	97.3%	90.1%	99.3%	88.9%	86.8%	94.8%
13.3	85.2%	60.7%	95.8%	64.7%	50.5%	77.0%	53.0%	49.6%	58.3%	90.3%	77.6%	95.9%	61.1%	44.0%	76.7%	97.3%	90.1%	99.3%	88.9%	86.8%	94.7%
13.4	85.2%	60.7%	95.8%	64.6%	50.3%	76.9%	53.0%	49.6%	58.2%	90.3%	77.6%	95.9%	61.0%	43.9%	76.5%	97.3%	90.0%	99.3%	88.9%	86.8%	94.6%
13.5	85.2%	60.7%	95.8%	64.5%	50.2%	76.9%	53.0%	49.6%	58.1%	90.3%	77.5%	95.9%	61.0%	43.8%	76.4%	97.3%	89.9%	99.3%	88.9%	86.8%	94.6%
13.6	85.2%	60.7%	95.8%	64.4%	50.1%	76.8%	53.0%	49.6%	58.0%	90.3%	77.5%	95.9%	60.9%	43.7%	76.3%	97.3%	89.8%	99.3%	88.9%	86.8%	94.5%
13.7	85.2%	60.7%	95.8%	64.2%	50.0%	76.7%	53.0%	49.6%	58.0%	90.3%	77.5%	95.9%	60.8%	43.6%	76.2%	97.2%	89.7%	99.3%	88.9%	86.8%	94.4%
13.8	85.2%	60.7%	95.8%	64.1%	49.9%	76.6%	53.0%	49.6%	57.9%	90.3%	77.5%	95.9%	60.7%	43.5%	76.1%	97.2%	89.6%	99.3%	88.9%	86.8%	94.3%
13.9	85.2%	60.7%	95.8%	64.0%	49.8%	76.5%	53.0%	49.6%	57.9%	90.3%	77.5%	95.9%	60.7%	43.4%	76.0%	97.2%	89.5%	99.3%	88.9%	86.8%	94.3%
14	85.2%	60.7%	95.8%	63.9%	49.6%	76.5%	53.0%	49.6%	57.9%	90.3%	77.5%	95.9%	60.6%	43.3%	75.9%	97.2%	89.4%	99.3%	88.9%	86.8%	94.2%
14.1	85.2%	60.7%	95.8%	63.8%	49.5%	76.4%	53.0%	49.5%	57.9%	90.3%	77.5%	95.9%	60.5%	43.3%	75.8%	97.2%	89.3%	99.3%	88.9%	86.8%	94.1%
14.2	85.2%	60.7%	95.8%	63.7%	49.4%	76.3%	53.0%	49.5%	57.9%	90.3%	77.5%	95.9%	60.5%	43.2%	75.7%	97.1%	89.2%	99.3%	88.9%	86.8%	94.1%
14.3	85.2%	60.7%	95.8%	63.6%	49.2%	76.2%	53.0%	49.5%	57.8%	90.3%	77.4%	95.9%	60.4%	43.1%	75.6%	97.1%	89.1%	99.3%	88.9%	86.8%	94.0%
14.4	85.2%	60.7%	95.8%	63.5%	49.1%	76.1%	53.0%	49.5%	57.8%	90.3%	77.4%	95.9%	60.4%	43.0%	75.5%	97.1%	89.0%	99.2%	88.9%	86.8%	94.0%
14.5	85.2%	60.7%	95.8%	63.4%	49.0%	76.0%	53.0%	49.5%	57.8%	90.3%	77.4%	95.9%	60.3%	43.0%	75.5%	97.1%	88.9%	99.2%	88.9%	86.8%	93.9%
14.6	85.2%	60.7%	95.8%	63.3%	48.9%	76.0%	53.0%	49.5%	57.7%	90.3%	77.4%	95.9%	60.3%	42.9%	75.4%	97.0%	88.8%	99.2%	88.9%	86.8%	93.8%
14.7	85.2%	60.7%	95.8%	63.1%	48.7%	75.9%	53.0%	49.5%	57.7%	90.3%	77.4%	95.9%	60.2%	42.9%	75.4%	97.0%	88.8%	99.2%	88.9%	86.8%	93.7%
14.8	85.2%	60.7%	95.8%	63.0%	48.6%	75.8%	53.0%	49.5%	57.6%	90.3%	77.4%	95.9%	60.2%	42.8%	75.4%	97.0%	88.7%	99.2%	88.9%	86.8%	93.7%
14.9	85.2%	60.7%	95.8%	62.9%	48.5%	75.7%	53.0%	49.5%	57.6%	90.3%	77.4%	95.9%	60.2%	42.8%	75.3%	97.0%	88.6%	99.2%	88.9%	86.8%	93.6%
15	85.2%	60.7%	95.8%	62.8%	48.3%	75.6%	53.0%	49.5%	57.6%	90.3%	77.4%	95.9%	60.1%	42.7%	75.3%	96.9%	88.5%	99.2%	88.9%	86.8%	93.6%
15.1	85.2%	60.7%	95.8%	62.7%	48.2%	75.5%	53.0%	49.5%	57.6%	90.3%	77.4%	95.9%	60.1%	42.7%	75.3%	96.9%	88.4%	99.2%	88.9%	86.7%	93.6%
15.2	85.2%	60.7%	95.8%	62.6%	48.1%	75.5%	53.0%	49.4%	57.5%	90.3%	77.4%	95.9%	60.1%	42.7%	75.3%	96.9%	88.3%	99.2%	88.9%	86.7%	93.6%
15.3	85.2%	60.7%	95.8%	62.5%	48.0%	75.4%	53.0%	49.3%	57.5%	90.3%	77.4%	95.9%	60.0%	42.7%	75.2%	96.9%	88.2%	99.2%	88.9%	86.7%	93.6%

15.4	85.2%	60.7%	95.8%	62.4%	47.8%	75.3%	53.0%	49.2%	57.5%	90.3%	77.4%	95.9%	60.0%	42.6%	75.2%	96.8%	88.2%	99.2%	88.9%	86.7%	93.5%
15.5	85.2%	60.7%	95.8%	62.3%	47.7%	75.2%	53.0%	49.2%	57.3%	90.3%	77.4%	95.9%	60.0%	42.6%	75.2%	96.8%	88.1%	99.2%	88.9%	86.7%	93.5%
15.6	85.2%	60.7%	95.8%	62.1%	47.6%	75.1%	53.0%	49.1%	57.3%	90.3%	77.4%	95.9%	60.0%	42.6%	75.2%	96.8%	88.0%	99.2%	88.9%	86.7%	93.5%
15.7	85.2%	60.7%	95.8%	62.0%	47.4%	75.0%	53.0%	49.0%	57.3%	90.3%	77.4%	95.9%	60.0%	42.6%	75.1%	96.7%	88.0%	99.2%	88.9%	86.7%	93.5%
15.8	85.2%	60.7%	95.8%	61.9%	47.3%	74.9%	53.0%	49.0%	57.3%	90.3%	77.4%	95.9%	60.0%	42.6%	75.0%	96.7%	87.9%	99.2%	88.9%	86.7%	93.5%
15.9	85.2%	60.7%	95.8%	61.8%	47.2%	74.9%	53.0%	49.0%	57.2%	90.3%	77.4%	95.9%	60.0%	42.6%	75.0%	96.7%	87.8%	99.1%	88.9%	86.7%	93.4%
16	85.2%	60.7%	95.8%	61.7%	47.0%	74.8%	53.0%	48.9%	57.2%	90.3%	77.4%	95.9%	60.0%	42.6%	74.9%	96.7%	87.7%	99.1%	88.9%	86.7%	93.4%
16.1	85.2%	60.7%	95.8%	61.6%	46.9%	74.7%	53.0%	48.9%	57.2%	90.3%	77.4%	95.9%	60.0%	42.6%	74.9%	96.6%	87.6%	99.1%	88.9%	86.7%	93.3%
16.2	85.2%	60.7%	95.8%	61.5%	46.8%	74.6%	53.0%	48.9%	57.1%	90.3%	77.4%	95.9%	60.0%	42.5%	74.8%	96.6%	87.5%	99.1%	88.9%	86.7%	93.3%
16.3	85.2%	60.7%	95.8%	61.4%	46.7%	74.5%	53.0%	48.8%	57.1%	90.3%	77.4%	95.9%	60.0%	42.5%	74.8%	96.6%	87.4%	99.1%	88.9%	86.7%	93.3%
16.4	85.2%	60.7%	95.8%	61.2%	46.5%	74.4%	53.0%	48.8%	57.0%	90.3%	77.4%	95.9%	60.0%	42.5%	74.8%	96.5%	87.2%	99.1%	88.9%	86.7%	93.2%
16.5	85.2%	60.7%	95.8%	61.1%	46.4%	74.3%	53.0%	48.8%	57.0%	90.3%	77.4%	95.9%	60.0%	42.5%	74.8%	96.5%	87.2%	99.1%	88.9%	86.7%	93.2%
16.6	85.2%	60.7%	95.8%	61.0%	46.3%	74.2%	53.0%	48.7%	57.0%	90.3%	77.4%	95.9%	60.0%	42.5%	74.8%	96.4%	87.1%	99.1%	88.9%	86.7%	93.2%
16.7	85.2%	60.7%	95.8%	60.9%	46.2%	74.2%	53.0%	48.6%	57.0%	90.3%	77.4%	95.9%	60.0%	42.5%	74.7%	96.4%	87.1%	99.1%	88.9%	86.7%	93.1%
16.8	85.2%	60.7%	95.8%	60.8%	46.0%	74.1%	53.0%	48.6%	57.0%	90.3%	77.4%	95.9%	60.0%	42.5%	74.7%	96.4%	87.0%	99.1%	88.9%	86.7%	93.1%
16.9	85.2%	60.7%	95.8%	60.7%	45.9%	74.0%	53.0%	48.6%	57.0%	90.3%	77.3%	95.9%	60.0%	42.5%	74.6%	96.3%	86.9%	99.1%	88.9%	86.7%	93.1%
17	85.2%	60.7%	95.8%	60.6%	45.8%	73.9%	53.0%	48.5%	56.9%	90.3%	77.2%	95.9%	60.0%	42.5%	74.6%	96.3%	86.8%	99.1%	88.9%	86.7%	93.1%
17.1	85.2%	60.7%	95.8%	60.4%	45.6%	73.8%	53.0%	48.5%	56.9%	90.3%	77.2%	95.9%	60.0%	42.4%	74.6%	96.3%	86.7%	99.1%	88.9%	86.7%	93.1%
17.2	85.2%	60.7%	95.8%	60.3%	45.5%	73.7%	53.0%	48.4%	56.9%	90.3%	77.1%	95.9%	60.0%	42.4%	74.6%	96.2%	86.6%	99.1%	88.9%	86.7%	93.1%
17.3	85.2%	60.7%	95.8%	60.2%	45.4%	73.6%	53.0%	48.4%	56.8%	90.3%	77.1%	95.9%	60.0%	42.3%	74.6%	96.2%	86.5%	99.1%	88.9%	86.7%	93.1%
17.4	85.2%	60.7%	95.8%	60.1%	45.3%	73.5%	53.0%	48.3%	56.7%	90.3%	77.1%	95.9%	60.0%	42.3%	74.6%	96.1%	86.4%	99.0%	88.9%	86.7%	93.1%
17.5	85.2%	60.7%	95.8%	60.0%	45.1%	73.5%	53.0%	48.3%	56.7%	90.2%	77.1%	95.9%	60.0%	42.2%	74.5%	96.1%	86.3%	99.0%	88.9%	86.7%	93.1%
17.6	85.2%	60.7%	95.8%	59.9%	45.0%	73.4%	53.0%	48.2%	56.7%	90.2%	77.1%	95.9%	60.0%	42.2%	74.5%	96.0%	86.2%	99.0%	88.9%	86.7%	93.1%
17.7	85.2%	60.7%	95.8%	59.8%	44.9%	73.3%	53.0%	48.1%	56.7%	90.2%	77.1%	95.9%	60.0%	42.2%	74.5%	96.0%	86.1%	99.0%	88.9%	86.7%	93.1%
17.8	85.2%	60.7%	95.8%	59.6%	44.7%	73.2%	53.0%	48.1%	56.6%	90.2%	77.0%	95.9%	59.9%	42.1%	74.4%	95.9%	86.0%	99.0%	88.9%	86.7%	93.1%
17.9	85.2%	60.7%	95.8%	59.5%	44.6%	73.1%	53.0%	48.0%	56.6%	90.2%	77.0%	95.9%	59.9%	42.1%	74.4%	95.9%	85.9%	99.0%	88.9%	86.7%	93.1%
18	85.2%	60.7%	95.8%	59.4%	44.5%	73.0%	53.0%	48.0%	56.6%	90.2%	77.0%	95.9%	59.9%	42.1%	74.3%	95.9%	85.8%	99.0%	88.9%	86.7%	93.1%
18.1	85.2%	60.7%	95.8%	59.3%	44.4%	72.9%	53.0%	47.9%	56.6%	90.2%	77.0%	95.9%	59.9%	42.1%	74.3%	95.8%	85.7%	99.0%	88.9%	86.6%	93.1%
18.2	85.2%	60.7%	95.8%	59.2%	44.2%	72.8%	53.0%	47.9%	56.6%	90.2%	77.0%	95.9%	59.8%	42.0%	74.3%	95.8%	85.6%	99.0%	88.9%	86.6%	93.1%
18.3	85.2%	60.7%	95.8%	59.1%	44.1%	72.7%	53.0%	47.9%	56.6%	90.2%	77.0%	95.9%	59.8%	41.9%	74.2%	95.7%	85.5%	99.0%	88.9%	86.6%	93.1%
18.4	85.2%	60.7%	95.8%	58.9%	44.0%	72.6%	53.0%	47.8%	56.6%	90.2%	77.0%	95.9%	59.8%	41.7%	74.2%	95.7%	85.4%	99.0%	88.9%	86.6%	93.1%
18.5	85.2%	60.7%	95.8%	58.8%	43.9%	72.5%	53.0%	47.8%	56.6%	90.2%	77.0%	95.9%	59.7%	41.7%	74.2%	95.6%	85.3%	99.0%	88.9%	86.6%	93.0%

18.6	85.2%	60.7%	95.8%	58.7%	43.7%	72.4%	53.0%	47.8%	56.5%	90.2%	77.0%	95.9%	59.7%	41.7%	74.1%	95.6%	85.2%	99.0%	88.9%	86.5%	93.0%
18.7	85.2%	60.7%	95.8%	58.6%	43.6%	72.4%	53.0%	47.8%	56.5%	90.2%	77.0%	95.9%	59.7%	41.6%	74.1%	95.5%	85.1%	98.9%	88.9%	86.5%	93.0%
18.8	85.2%	60.7%	95.8%	58.5%	43.5%	72.3%	53.0%	47.7%	56.4%	90.1%	77.0%	95.9%	59.6%	41.6%	74.1%	95.5%	85.0%	98.9%	88.9%	86.5%	93.0%
18.9	85.2%	60.7%	95.8%	58.3%	43.3%	72.2%	53.0%	47.7%	56.4%	90.1%	77.0%	95.9%	59.6%	41.5%	74.0%	95.4%	84.9%	98.9%	88.9%	86.5%	93.0%
19	85.2%	60.7%	95.8%	58.2%	43.2%	72.1%	53.0%	47.7%	56.4%	90.1%	76.9%	95.8%	59.5%	41.5%	74.0%	95.4%	84.8%	98.9%	88.9%	86.5%	93.0%
19.1	85.2%	60.7%	95.8%	58.1%	43.1%	72.0%	53.0%	47.7%	56.3%	90.1%	76.9%	95.8%	59.5%	41.5%	73.9%	95.3%	84.6%	98.9%	88.9%	86.5%	93.0%
19.2	85.2%	60.7%	95.8%	58.0%	43.0%	71.9%	53.0%	47.6%	56.3%	90.1%	76.9%	95.8%	59.4%	41.4%	73.9%	95.3%	84.5%	98.9%	88.9%	86.5%	93.0%
19.3	85.2%	60.7%	95.8%	57.9%	42.8%	71.8%	53.0%	47.6%	56.3%	90.1%	76.9%	95.8%	59.4%	41.4%	73.8%	95.2%	84.4%	98.9%	88.9%	86.4%	93.0%
19.4	85.2%	60.7%	95.8%	57.7%	42.7%	71.7%	53.0%	47.6%	56.3%	90.1%	76.9%	95.8%	59.3%	41.3%	73.8%	95.2%	84.2%	98.9%	88.9%	86.4%	93.0%
19.5	85.2%	60.7%	95.8%	57.6%	42.6%	71.6%	53.0%	47.5%	56.3%	90.1%	76.9%	95.8%	59.3%	41.2%	73.7%	95.1%	84.1%	98.9%	88.9%	86.4%	93.0%
19.6	85.2%	60.7%	95.8%	57.5%	42.4%	71.5%	53.0%	47.5%	56.3%	90.0%	76.8%	95.8%	59.2%	41.1%	73.7%	95.1%	83.9%	98.9%	88.9%	86.3%	93.0%
19.7	85.2%	60.7%	95.8%	57.4%	42.3%	71.4%	53.0%	47.5%	56.3%	90.0%	76.8%	95.8%	59.2%	40.9%	73.6%	95.0%	83.8%	98.9%	88.9%	86.3%	93.0%
19.8	85.2%	60.7%	95.8%	57.2%	42.2%	71.3%	53.0%	47.4%	56.3%	90.0%	76.7%	95.8%	59.1%	40.8%	73.5%	95.0%	83.6%	98.9%	88.9%	86.2%	93.0%
19.9	85.2%	60.7%	95.8%	57.1%	42.1%	71.2%	53.0%	47.4%	56.2%	90.0%	76.6%	95.8%	59.0%	40.8%	73.5%	94.9%	83.5%	98.9%	88.9%	86.2%	93.0%
20	85.2%	60.7%	95.8%	57.0%	41.9%	71.1%	53.0%	47.3%	56.2%	90.0%	76.5%	95.8%	59.0%	40.7%	73.4%	94.9%	83.3%	98.9%	88.9%	86.2%	93.0%
20.1	85.2%	60.7%	95.8%	56.9%	41.8%	71.0%	53.0%	47.3%	56.1%	90.0%	76.5%	95.8%	58.9%	40.6%	73.3%	94.8%	83.2%	98.9%	88.9%	86.2%	93.0%
20.2	85.2%	60.7%	95.8%	56.7%	41.7%	70.8%	53.0%	47.2%	56.1%	89.9%	76.4%	95.7%	58.8%	40.5%	73.2%	94.8%	83.0%	98.9%	88.9%	86.2%	93.0%
20.3	85.2%	60.7%	95.8%	56.6%	41.6%	70.7%	53.0%	47.2%	56.1%	89.9%	76.3%	95.7%	58.7%	40.5%	73.1%	94.8%	82.9%	98.9%	88.9%	86.1%	93.0%
20.4	85.2%	60.7%	95.8%	56.5%	41.4%	70.6%	53.0%	47.1%	56.1%	89.9%	76.2%	95.7%	58.7%	40.4%	73.0%	94.7%	82.7%	98.9%	88.9%	86.1%	93.0%
20.5	85.2%	60.7%	95.8%	56.4%	41.3%	70.5%	53.0%	47.1%	56.1%	89.9%	76.2%	95.7%	58.6%	40.3%	72.9%	94.7%	82.6%	98.8%	88.9%	86.0%	93.0%
20.6	85.2%	60.7%	95.8%	56.2%	41.2%	70.4%	53.0%	47.1%	56.1%	89.9%	76.2%	95.7%	58.5%	40.2%	72.8%	94.6%	82.4%	98.8%	88.9%	86.0%	93.0%
20.7	85.2%	60.7%	95.8%	56.1%	41.0%	70.3%	53.0%	47.0%	56.1%	89.9%	76.1%	95.7%	58.4%	40.2%	72.7%	94.6%	82.3%	98.8%	88.9%	86.0%	93.0%
20.8	85.2%	60.7%	95.8%	56.0%	40.9%	70.2%	53.0%	46.9%	56.1%	89.8%	76.1%	95.7%	58.3%	40.1%	72.7%	94.5%	82.2%	98.8%	88.9%	86.0%	93.0%
20.9	85.2%	60.7%	95.8%	55.8%	40.8%	70.1%	53.0%	46.8%	56.1%	89.8%	76.0%	95.7%	58.2%	40.0%	72.6%	94.5%	82.2%	98.8%	88.9%	86.0%	93.0%
21	85.2%	60.7%	95.8%	55.7%	40.7%	70.0%	53.0%	46.8%	56.1%	89.8%	75.9%	95.7%	58.1%	39.9%	72.5%	94.4%	82.1%	98.8%	88.9%	86.0%	93.0%
21.1	85.2%	60.7%	95.8%	55.6%	40.5%	69.9%	53.0%	46.7%	56.1%	89.8%	75.9%	95.7%	58.0%	39.8%	72.5%	94.4%	82.1%	98.8%	88.9%	86.0%	93.0%
21.2	85.2%	60.7%	95.8%	55.5%	40.4%	69.8%	53.0%	46.5%	56.0%	89.8%	75.8%	95.6%	57.9%	39.7%	72.4%	94.4%	82.1%	98.8%	88.9%	86.0%	93.0%
21.3	85.2%	60.7%	95.8%	55.3%	40.3%	69.7%	53.0%	46.4%	56.0%	89.7%	75.7%	95.6%	57.8%	39.6%	72.3%	94.3%	82.0%	98.8%	88.9%	86.0%	93.0%
21.4	85.2%	60.7%	95.8%	55.2%	40.2%	69.5%	53.0%	46.3%	56.0%	89.7%	75.7%	95.6%	57.7%	39.5%	72.3%	94.3%	82.0%	98.8%	88.9%	86.0%	93.0%
21.5	85.2%	60.7%	95.8%	55.1%	40.0%	69.4%	53.0%	46.1%	56.0%	89.7%	75.6%	95.6%	57.6%	39.4%	72.2%	94.2%	81.9%	98.8%	88.9%	86.0%	93.0%
21.6	85.2%	60.7%	95.8%	54.9%	39.9%	69.3%	52.9%	46.0%	56.0%	89.7%	75.6%	95.6%	57.5%	39.3%	72.1%	94.2%	81.9%	98.7%	88.9%	86.0%	93.0%
21.7	85.2%	60.7%	95.8%	54.8%	39.8%	69.2%	52.9%	45.9%	55.9%	89.6%	75.5%	95.6%	57.4%	39.2%	72.0%	94.2%	81.8%	98.7%	88.9%	86.0%	93.0%

21.8	85.2%	60.7%	95.8%	54.7%	39.6%	69.1%	52.9%	45.7%	55.9%	89.6%	75.4%	95.6%	57.3%	39.0%	72.0%	94.1%	81.7%	98.7%	88.9%	86.0%	93.0%
21.9	85.2%	60.7%	95.8%	54.5%	39.5%	69.0%	52.9%	45.7%	55.9%	89.6%	75.4%	95.6%	57.2%	38.9%	71.9%	94.1%	81.7%	98.7%	88.9%	86.0%	93.0%
22	85.2%	60.7%	95.8%	54.4%	39.4%	68.9%	52.8%	45.6%	55.9%	89.6%	75.3%	95.6%	57.1%	38.7%	71.8%	94.0%	81.6%	98.7%	88.9%	86.0%	93.0%
22.1	85.2%	60.7%	95.8%	54.3%	39.3%	68.7%	52.8%	45.4%	55.8%	89.5%	75.2%	95.5%	57.0%	38.6%	71.7%	94.0%	81.6%	98.7%	88.9%	86.0%	93.0%
22.2	85.2%	60.7%	95.8%	54.1%	39.2%	68.6%	52.8%	45.3%	55.8%	89.5%	75.2%	95.5%	56.8%	38.4%	71.6%	94.0%	81.5%	98.7%	88.9%	86.0%	93.0%
22.3	85.2%	60.7%	95.8%	54.0%	39.0%	68.5%	52.7%	45.2%	55.7%	89.5%	75.1%	95.5%	56.7%	38.3%	71.5%	93.9%	81.4%	98.7%	88.9%	86.0%	93.0%
22.4	85.2%	60.7%	95.8%	53.9%	38.9%	68.4%	52.7%	45.1%	55.7%	89.5%	75.0%	95.5%	56.6%	38.2%	71.4%	93.9%	81.3%	98.7%	88.9%	86.0%	93.0%
22.5	85.2%	60.7%	95.8%	53.7%	38.8%	68.3%	52.6%	45.0%	55.6%	89.4%	75.0%	95.5%	56.5%	38.0%	71.3%	93.8%	81.2%	98.7%	88.9%	86.0%	93.0%
22.6	85.2%	60.7%	95.8%	53.6%	38.7%	68.2%	52.6%	44.9%	55.5%	89.4%	74.9%	95.5%	56.3%	37.9%	71.2%	93.8%	81.1%	98.7%	88.9%	86.0%	92.9%
22.7	85.2%	60.7%	95.8%	53.5%	38.6%	68.0%	52.5%	44.8%	55.5%	89.4%	74.8%	95.5%	56.2%	37.7%	71.1%	93.8%	81.0%	98.7%	88.9%	86.0%	92.9%
22.8	85.2%	60.7%	95.8%	53.3%	38.5%	67.9%	52.5%	44.6%	55.4%	89.3%	74.8%	95.5%	56.1%	37.6%	70.9%	93.7%	80.9%	98.7%	88.9%	86.0%	92.9%
22.9	85.2%	60.7%	95.8%	53.2%	38.4%	67.8%	52.4%	44.5%	55.4%	89.3%	74.7%	95.5%	55.9%	37.4%	70.8%	93.7%	80.8%	98.7%	88.9%	86.0%	92.9%
23	85.2%	60.7%	95.8%	53.0%	38.2%	67.7%	52.3%	44.4%	55.3%	89.3%	74.6%	95.4%	55.8%	37.3%	70.7%	93.7%	80.7%	98.7%	88.9%	86.0%	92.9%
23.1	85.2%	60.7%	95.8%	52.9%	38.1%	67.5%	52.3%	44.2%	55.2%	89.3%	74.5%	95.4%	55.7%	37.1%	70.6%	93.6%	80.6%	98.7%	88.9%	86.0%	92.9%
23.2	85.2%	60.7%	95.8%	52.8%	38.0%	67.4%	52.2%	44.1%	55.2%	89.2%	74.5%	95.4%	55.5%	37.0%	70.5%	93.6%	80.5%	98.6%	88.9%	86.0%	92.9%
23.3	85.2%	60.7%	95.8%	52.6%	37.9%	67.3%	52.1%	44.0%	55.1%	89.2%	74.4%	95.4%	55.4%	36.8%	70.4%	93.6%	80.5%	98.6%	88.9%	86.0%	92.9%
23.4	85.2%	60.7%	95.8%	52.5%	37.8%	67.2%	52.1%	43.9%	55.0%	89.2%	74.3%	95.4%	55.2%	36.7%	70.3%	93.5%	80.4%	98.6%	88.9%	86.0%	92.9%
23.5	85.2%	60.7%	95.8%	52.3%	37.6%	67.1%	52.0%	43.7%	54.9%	89.1%	74.3%	95.4%	55.1%	36.6%	70.2%	93.5%	80.3%	98.6%	88.9%	86.0%	92.9%
23.6	85.2%	60.7%	95.8%	52.2%	37.5%	66.9%	51.9%	43.7%	54.8%	89.1%	74.2%	95.4%	54.9%	36.4%	70.1%	93.5%	80.2%	98.6%	88.9%	86.0%	92.9%
23.7	85.2%	60.7%	95.8%	52.1%	37.4%	66.8%	51.8%	43.6%	54.6%	89.1%	74.1%	95.4%	54.7%	36.3%	70.0%	93.5%	80.1%	98.6%	88.9%	86.0%	92.9%
23.8	85.2%	60.7%	95.8%	51.9%	37.3%	66.7%	51.7%	43.6%	54.5%	89.0%	74.1%	95.3%	54.6%	36.2%	69.8%	93.4%	80.0%	98.6%	88.9%	86.0%	92.9%
23.9	85.2%	60.7%	95.8%	51.8%	37.2%	66.5%	51.7%	43.5%	54.4%	89.0%	74.0%	95.3%	54.4%	36.0%	69.7%	93.4%	79.9%	98.6%	88.9%	86.0%	92.9%
24	85.2%	60.7%	95.8%	51.6%	37.0%	66.4%	51.6%	43.4%	54.3%	89.0%	73.9%	95.3%	54.3%	35.9%	69.6%	93.4%	79.9%	98.6%	88.9%	86.0%	92.9%
24.1	85.2%	60.7%	95.8%	51.5%	36.9%	66.3%	51.5%	43.2%	54.2%	88.9%	73.8%	95.3%	54.1%	35.8%	69.4%	93.3%	79.8%	98.6%	88.9%	86.0%	92.9%
24.2	85.2%	60.7%	95.8%	51.4%	36.8%	66.2%	51.4%	43.1%	54.1%	88.9%	73.8%	95.3%	53.9%	35.6%	69.3%	93.3%	79.7%	98.6%	88.9%	86.0%	92.9%
24.3	85.2%	60.7%	95.8%	51.2%	36.7%	66.0%	51.3%	43.1%	54.0%	88.8%	73.7%	95.3%	53.8%	35.5%	69.1%	93.3%	79.6%	98.6%	88.9%	86.0%	92.9%
24.4	85.2%	60.7%	95.8%	51.1%	36.6%	65.9%	51.2%	43.0%	53.9%	88.8%	73.6%	95.3%	53.6%	35.4%	69.0%	93.3%	79.6%	98.6%	88.9%	86.0%	92.9%
24.5	85.2%	60.7%	95.8%	50.9%	36.4%	65.8%	51.1%	42.9%	53.8%	88.8%	73.6%	95.3%	53.4%	35.2%	68.8%	93.2%	79.5%	98.6%	88.9%	86.0%	92.9%
24.6	85.2%	60.7%	95.8%	50.8%	36.3%	65.6%	50.9%	42.8%	53.7%	88.7%	73.5%	95.2%	53.2%	35.1%	68.7%	93.2%	79.4%	98.6%	88.9%	86.0%	92.9%
24.7	85.2%	60.7%	95.8%	50.6%	36.2%	65.5%	50.8%	42.7%	53.5%	88.7%	73.4%	95.2%	53.0%	34.9%	68.5%	93.2%	79.3%	98.6%	88.9%	86.0%	92.9%
24.8	85.2%	60.7%	95.8%	50.5%	36.1%	65.4%	50.7%	42.6%	53.4%	88.6%	73.3%	95.2%	52.9%	34.8%	68.3%	93.2%	79.2%	98.5%	88.9%	86.0%	92.8%
24.9	85.2%	60.7%	95.8%	50.4%	36.0%	65.2%	50.6%	42.5%	53.2%	88.6%	73.2%	95.2%	52.7%	34.7%	68.2%	93.2%	79.0%	98.5%	88.9%	86.0%	92.8%

25	85.2%	60.7%	95.8%	50.2%	35.8%	65.1%	50.5%	42.4%	53.1%	88.6%	73.2%	95.2%	52.5%	34.5%	68.0%	93.1%	79.0%	98.5%	88.9%	86.0%	92.8%
25.1	85.2%	60.7%	95.8%	50.1%	35.7%	65.0%	50.4%	42.4%	52.9%	88.5%	73.1%	95.2%	52.3%	34.3%	67.8%	93.1%	79.0%	98.5%	88.9%	86.0%	92.8%
25.2	85.2%	60.7%	95.8%	49.9%	35.6%	64.8%	50.2%	42.3%	52.8%	88.5%	73.0%	95.1%	52.1%	34.1%	67.6%	93.1%	78.9%	98.5%	88.9%	86.0%	92.8%
25.3	85.2%	60.7%	95.8%	49.8%	35.5%	64.7%	50.1%	42.2%	52.7%	88.4%	72.9%	95.1%	51.9%	33.9%	67.5%	93.1%	78.8%	98.5%	88.9%	85.9%	92.8%
25.4	85.2%	60.7%	95.8%	49.6%	35.3%	64.5%	50.0%	42.1%	52.5%	88.4%	72.8%	95.1%	51.7%	33.7%	67.3%	93.1%	78.8%	98.5%	88.9%	85.9%	92.8%
25.5	85.2%	60.7%	95.8%	49.5%	35.2%	64.4%	49.8%	42.0%	52.3%	88.3%	72.7%	95.1%	51.5%	33.5%	67.1%	93.1%	78.7%	98.5%	88.9%	85.9%	92.8%
25.6	85.2%	60.7%	95.8%	49.3%	35.1%	64.3%	49.7%	41.9%	52.2%	88.3%	72.6%	95.1%	51.3%	33.3%	66.9%	93.0%	78.7%	98.5%	88.9%	85.9%	92.8%
25.7	85.2%	60.7%	95.8%	49.2%	35.0%	64.1%	49.6%	41.8%	52.0%	88.3%	72.5%	95.0%	51.1%	33.2%	66.7%	93.0%	78.6%	98.5%	88.9%	85.9%	92.8%
25.8	85.2%	60.7%	95.7%	49.0%	34.8%	64.0%	49.4%	41.7%	51.8%	88.2%	72.4%	95.0%	50.9%	33.0%	66.5%	93.0%	78.5%	98.5%	88.9%	85.9%	92.8%
25.9	85.2%	60.6%	95.7%	48.9%	34.7%	63.8%	49.3%	41.6%	51.7%	88.2%	72.3%	95.0%	50.7%	32.8%	66.3%	93.0%	78.5%	98.4%	88.9%	85.9%	92.8%
26	85.2%	60.6%	95.7%	48.7%	34.6%	63.7%	49.1%	41.6%	51.5%	88.1%	72.2%	95.0%	50.5%	32.7%	66.1%	93.0%	78.5%	98.4%	88.9%	85.9%	92.8%
26.1	85.2%	60.6%	95.7%	48.6%	34.5%	63.6%	49.0%	41.5%	51.3%	88.1%	72.1%	95.0%	50.2%	32.5%	66.0%	93.0%	78.5%	98.4%	88.9%	85.9%	92.8%
26.2	85.1%	60.6%	95.7%	48.4%	34.3%	63.4%	48.8%	41.4%	51.2%	88.0%	72.0%	95.0%	50.0%	32.4%	65.8%	93.0%	78.5%	98.4%	88.9%	85.9%	92.8%
26.3	85.1%	60.6%	95.7%	48.3%	34.2%	63.3%	48.6%	41.4%	51.0%	88.0%	72.0%	94.9%	49.8%	32.2%	65.6%	93.0%	78.4%	98.4%	88.9%	85.9%	92.8%
26.4	85.1%	60.5%	95.7%	48.1%	34.1%	63.1%	48.5%	41.3%	50.9%	87.9%	71.9%	94.9%	49.6%	32.1%	65.4%	92.9%	78.3%	98.4%	88.9%	85.9%	92.8%
26.5	85.1%	60.5%	95.7%	48.0%	34.0%	63.0%	48.3%	41.3%	50.7%	87.9%	71.9%	94.9%	49.4%	31.9%	65.2%	92.9%	78.2%	98.4%	88.9%	85.9%	92.8%
26.6	85.1%	60.5%	95.7%	47.8%	33.8%	62.8%	48.1%	41.2%	50.6%	87.8%	71.8%	94.9%	49.1%	31.7%	65.0%	92.9%	78.2%	98.4%	88.9%	85.9%	92.8%
26.7	85.1%	60.5%	95.7%	47.7%	33.7%	62.7%	48.0%	41.1%	50.4%	87.8%	71.7%	94.9%	48.9%	31.6%	64.8%	92.9%	78.1%	98.4%	88.9%	85.9%	92.8%
26.8	85.1%	60.5%	95.7%	47.5%	33.6%	62.5%	47.8%	41.1%	50.3%	87.7%	71.6%	94.8%	48.7%	31.4%	64.7%	92.9%	78.1%	98.4%	88.9%	85.9%	92.8%
26.9	85.1%	60.4%	95.7%	47.4%	33.4%	62.4%	47.6%	41.0%	50.1%	87.7%	71.5%	94.8%	48.4%	31.3%	64.5%	92.9%	78.1%	98.4%	88.9%	85.9%	92.8%
27	85.1%	60.4%	95.7%	47.2%	33.3%	62.3%	47.4%	41.0%	49.9%	87.6%	71.4%	94.8%	48.2%	31.1%	64.3%	92.9%	78.1%	98.4%	88.9%	85.9%	92.8%
27.1	85.1%	60.4%	95.7%	47.1%	33.2%	62.1%	47.3%	40.9%	49.9%	87.6%	71.3%	94.8%	48.0%	30.9%	64.2%	92.9%	78.0%	98.4%	88.9%	85.9%	92.8%
27.2	85.0%	60.3%	95.7%	46.9%	33.1%	62.0%	47.1%	40.9%	49.6%	87.5%	71.2%	94.8%	47.8%	30.7%	64.0%	92.9%	78.0%	98.4%	88.9%	85.9%	92.8%
27.3	85.0%	60.3%	95.7%	46.8%	32.9%	61.8%	46.9%	40.8%	49.5%	87.5%	71.2%	94.8%	47.5%	30.6%	63.8%	92.9%	78.0%	98.4%	88.9%	85.9%	92.7%
27.4	85.0%	60.3%	95.7%	46.6%	32.8%	61.7%	46.7%	40.7%	49.4%	87.4%	71.1%	94.7%	47.3%	30.4%	63.7%	92.9%	78.0%	98.4%	88.9%	85.9%	92.7%
27.5	85.0%	60.3%	95.7%	46.5%	32.7%	61.5%	46.5%	40.6%	49.2%	87.3%	71.0%	94.7%	47.1%	30.2%	63.5%	92.9%	78.0%	98.4%	88.9%	85.9%	92.7%
27.6	85.0%	60.2%	95.7%	46.3%	32.5%	61.3%	46.3%	40.5%	49.1%	87.3%	70.9%	94.7%	46.9%	30.0%	63.4%	92.9%	78.0%	98.4%	88.9%	85.9%	92.7%
27.7	85.0%	60.2%	95.7%	46.2%	32.4%	61.2%	46.1%	40.5%	49.0%	87.2%	70.8%	94.7%	46.7%	29.9%	63.2%	92.9%	78.0%	98.4%	88.9%	85.9%	92.7%
27.8	85.0%	60.2%	95.7%	46.0%	32.3%	61.0%	45.9%	40.4%	48.8%	87.2%	70.6%	94.7%	46.5%	29.7%	63.1%	92.9%	78.0%	98.4%	88.9%	85.9%	92.7%
27.9	84.9%	60.1%	95.7%	45.9%	32.2%	60.9%	45.7%	40.3%	48.6%	87.1%	70.6%	94.6%	46.3%	29.6%	62.9%	92.9%	78.0%	98.4%	88.9%	85.9%	92.7%
28	84.9%	60.1%	95.7%	45.7%	32.0%	60.7%	45.5%	40.3%	48.4%	87.1%	70.5%	94.6%	46.1%	29.5%	62.8%	92.9%	78.0%	98.4%	88.9%	85.9%	92.7%
28.1	84.9%	60.0%	95.7%	45.6%	31.9%	60.6%	45.3%	40.2%	48.2%	87.0%	70.4%	94.6%	45.9%	29.3%	62.6%	92.9%	78.0%	98.4%	88.9%	85.9%	92.7%

28.2	84.9%	60.0%	95.7%	45.4%	31.8%	60.4%	45.1%	40.1%	48.1%	87.0%	70.3%	94.5%	45.7%	29.2%	62.4%	92.9%	78.0%	98.4%	88.9%	85.9%	92.7%
28.3	84.9%	60.0%	95.7%	45.2%	31.6%	60.3%	44.8%	40.0%	47.9%	86.9%	70.2%	94.5%	45.5%	29.1%	62.2%	92.9%	77.9%	98.4%	88.9%	85.9%	92.6%
28.4	84.9%	59.9%	95.7%	45.1%	31.5%	60.1%	44.6%	39.9%	47.7%	86.8%	70.1%	94.5%	45.3%	29.0%	62.0%	92.9%	77.9%	98.4%	88.9%	85.9%	92.6%
28.5	84.8%	59.9%	95.6%	44.9%	31.4%	59.9%	44.4%	39.8%	47.6%	86.8%	70.0%	94.5%	45.1%	28.9%	61.9%	92.9%	77.9%	98.4%	88.9%	85.9%	92.5%
28.6	84.8%	59.9%	95.6%	44.8%	31.2%	59.8%	44.2%	39.8%	47.5%	86.7%	69.9%	94.4%	44.9%	28.8%	61.7%	92.9%	77.8%	98.4%	88.9%	85.9%	92.5%
28.7	84.8%	59.8%	95.6%	44.6%	31.1%	59.6%	44.0%	39.6%	47.3%	86.7%	69.8%	94.4%	44.7%	28.7%	61.5%	92.9%	77.8%	98.4%	88.9%	85.9%	92.5%
28.8	84.8%	59.8%	95.6%	44.5%	31.0%	59.5%	43.8%	39.6%	47.1%	86.6%	69.7%	94.4%	44.5%	28.5%	61.3%	92.9%	77.8%	98.4%	88.9%	85.9%	92.5%
28.9	84.8%	59.8%	95.6%	44.3%	30.9%	59.3%	43.6%	39.4%	47.0%	86.6%	69.6%	94.4%	44.3%	28.4%	61.2%	92.9%	77.8%	98.4%	88.9%	85.9%	92.5%
29	84.7%	59.7%	95.6%	44.2%	30.7%	59.1%	43.4%	39.2%	46.8%	86.5%	69.5%	94.3%	44.2%	28.2%	61.0%	92.9%	77.8%	98.4%	88.9%	85.9%	92.5%
29.1	84.7%	59.7%	95.6%	44.0%	30.6%	59.0%	43.2%	39.2%	46.7%	86.4%	69.5%	94.3%	44.0%	28.1%	60.8%	92.9%	77.8%	98.4%	88.9%	85.9%	92.5%
29.2	84.7%	59.6%	95.6%	43.8%	30.5%	58.8%	43.0%	39.0%	46.6%	86.4%	69.4%	94.3%	43.8%	28.0%	60.7%	92.9%	77.8%	98.4%	88.9%	85.9%	92.4%
29.3	84.7%	59.6%	95.6%	43.7%	30.4%	58.7%	42.8%	38.8%	46.5%	86.3%	69.3%	94.2%	43.6%	27.8%	60.5%	92.9%	77.8%	98.4%	88.9%	85.9%	92.4%
29.4	84.6%	59.6%	95.6%	43.5%	30.3%	58.5%	42.7%	38.6%	46.3%	86.3%	69.2%	94.2%	43.5%	27.7%	60.4%	92.9%	77.8%	98.4%	88.9%	85.9%	92.4%
29.5	84.6%	59.5%	95.6%	43.4%	30.2%	58.4%	42.5%	38.6%	46.2%	86.2%	69.1%	94.2%	43.3%	27.6%	60.2%	92.9%	77.8%	98.4%	88.9%	85.9%	92.4%
29.6	84.6%	59.5%	95.6%	43.3%	30.1%	58.3%	42.3%	38.4%	46.0%	86.1%	69.0%	94.2%	43.1%	27.4%	60.1%	92.9%	77.8%	98.4%	88.9%	85.9%	92.4%
29.7	84.6%	59.4%	95.6%	43.1%	29.9%	58.1%	42.1%	38.2%	45.9%	86.1%	68.9%	94.1%	43.0%	27.3%	59.9%	92.9%	77.8%	98.4%	88.9%	85.9%	92.4%
29.8	84.5%	59.4%	95.6%	43.0%	29.8%	58.0%	41.9%	38.1%	45.8%	86.0%	68.8%	94.1%	42.8%	27.2%	59.7%	92.9%	77.7%	98.4%	88.9%	85.9%	92.3%
29.9	84.5%	59.3%	95.5%	42.8%	29.7%	57.9%	41.8%	37.9%	45.7%	86.0%	68.7%	94.1%	42.7%	27.1%	59.6%	92.9%	77.5%	98.3%	88.9%	85.9%	92.3%
30	84.5%	59.3%	95.5%	42.7%	29.6%	57.8%	41.6%	37.7%	45.6%	85.9%	68.7%	94.1%	42.5%	27.0%	59.5%	92.9%	77.4%	98.3%	88.9%	85.9%	92.3%
30.1	84.4%	59.2%	95.5%	42.6%	29.5%	57.6%	41.4%	37.6%	45.4%	85.8%	68.6%	94.0%	42.3%	26.8%	59.3%	92.9%	77.4%	98.3%	88.9%	85.9%	92.3%
30.2	84.4%	59.2%	95.5%	42.4%	29.4%	57.5%	41.3%	37.4%	45.4%	85.8%	68.5%	94.0%	42.2%	26.7%	59.2%	92.9%	77.3%	98.3%	88.9%	85.9%	92.3%
30.3	84.4%	59.1%	95.5%	42.3%	29.3%	57.4%	41.1%	37.3%	45.3%	85.7%	68.4%	94.0%	42.1%	26.6%	59.0%	92.9%	77.2%	98.3%	88.9%	85.9%	92.3%
30.4	84.4%	59.1%	95.5%	42.1%	29.2%	57.3%	41.0%	37.2%	45.1%	85.7%	68.3%	93.9%	41.9%	26.5%	58.9%	92.9%	77.1%	98.3%	88.9%	85.9%	92.2%
30.5	84.3%	59.0%	95.5%	42.0%	29.1%	57.1%	40.8%	37.0%	45.0%	85.6%	68.2%	93.9%	41.8%	26.4%	58.8%	92.9%	77.0%	98.3%	88.9%	85.9%	92.2%
30.6	84.3%	59.0%	95.5%	41.9%	29.0%	57.0%	40.7%	36.9%	44.9%	85.5%	68.1%	93.9%	41.6%	26.3%	58.6%	92.9%	76.9%	98.3%	88.9%	85.9%	92.2%
30.7	84.3%	58.9%	95.5%	41.8%	28.9%	56.9%	40.5%	36.7%	44.9%	85.5%	67.9%	93.9%	41.5%	26.2%	58.5%	92.9%	76.8%	98.3%	88.9%	85.9%	92.1%
30.8	84.2%	58.8%	95.5%	41.6%	28.8%	56.8%	40.4%	36.6%	44.8%	85.4%	67.8%	93.8%	41.4%	26.1%	58.3%	92.9%	76.7%	98.3%	88.9%	85.9%	92.1%
30.9	84.2%	58.8%	95.5%	41.5%	28.7%	56.7%	40.3%	36.5%	44.6%	85.3%	67.7%	93.8%	41.2%	26.0%	58.2%	92.9%	76.6%	98.3%	88.9%	85.9%	92.1%
31	84.2%	58.7%	95.4%	41.4%	28.6%	56.6%	40.1%	36.3%	44.5%	85.3%	67.6%	93.8%	41.1%	25.9%	58.1%	92.8%	76.6%	98.3%	88.9%	85.9%	92.1%
31.1	84.1%	58.7%	95.4%	41.3%	28.6%	56.5%	40.0%	36.1%	44.4%	85.2%	67.5%	93.7%	41.0%	25.8%	57.9%	92.8%	76.6%	98.3%	88.9%	85.9%	92.1%
31.2	84.1%	58.6%	95.4%	41.1%	28.5%	56.3%	39.9%	36.0%	44.3%	85.2%	67.4%	93.7%	40.8%	25.7%	57.8%	92.8%	76.5%	98.3%	88.9%	85.9%	92.1%
31.3	84.1%	58.5%	95.4%	41.0%	28.4%	56.2%	39.7%	35.8%	44.2%	85.1%	67.3%	93.7%	40.7%	25.6%	57.7%	92.8%	76.4%	98.3%	88.9%	85.9%	92.1%

31.4	84.0%	58.5%	95.4%	40.9%	28.3%	56.1%	39.6%	35.7%	44.1%	85.0%	67.1%	93.7%	40.6%	25.5%	57.5%	92.8%	76.3%	98.3%	88.9%	85.9%	92.1%
31.5	84.0%	58.4%	95.4%	40.8%	28.2%	56.0%	39.5%	35.6%	44.0%	85.0%	67.0%	93.6%	40.5%	25.4%	57.4%	92.8%	76.1%	98.3%	88.9%	85.9%	92.1%
31.6	84.0%	58.4%	95.4%	40.7%	28.1%	55.9%	39.4%	35.5%	43.9%	84.9%	66.9%	93.6%	40.4%	25.4%	57.3%	92.8%	76.0%	98.3%	88.9%	85.9%	92.0%
31.7	83.9%	58.3%	95.4%	40.6%	28.0%	55.8%	39.3%	35.4%	43.9%	84.8%	66.8%	93.6%	40.3%	25.3%	57.2%	92.8%	75.9%	98.2%	88.9%	85.9%	92.0%
31.8	83.9%	58.2%	95.4%	40.4%	27.9%	55.7%	39.1%	35.2%	43.8%	84.8%	66.7%	93.6%	40.1%	25.2%	57.1%	92.8%	75.8%	98.2%	88.9%	85.9%	92.0%
31.9	83.8%	58.2%	95.3%	40.3%	27.9%	55.6%	39.0%	35.1%	43.7%	84.7%	66.6%	93.6%	40.0%	25.1%	57.0%	92.8%	75.7%	98.2%	88.9%	85.9%	92.0%
32	83.8%	58.1%	95.3%	40.2%	27.8%	55.5%	38.9%	35.0%	43.7%	84.6%	66.4%	93.5%	39.9%	25.0%	56.9%	92.7%	75.6%	98.2%	88.9%	85.9%	91.9%
32.1	83.8%	58.0%	95.3%	40.1%	27.7%	55.4%	38.8%	34.8%	43.6%	84.6%	66.3%	93.5%	39.8%	25.0%	56.8%	92.7%	75.5%	98.2%	88.9%	85.9%	91.9%
32.2	83.7%	57.9%	95.3%	40.0%	27.6%	55.3%	38.7%	34.7%	43.5%	84.5%	66.2%	93.5%	39.7%	24.9%	56.7%	92.7%	75.4%	98.2%	88.9%	85.9%	91.9%
32.3	83.7%	57.9%	95.3%	39.9%	27.5%	55.2%	38.6%	34.6%	43.5%	84.4%	66.1%	93.4%	39.6%	24.8%	56.6%	92.7%	75.3%	98.2%	88.9%	85.9%	91.9%
32.4	83.6%	57.8%	95.3%	39.8%	27.5%	55.1%	38.5%	34.5%	43.4%	84.3%	66.0%	93.4%	39.5%	24.7%	56.5%	92.7%	75.2%	98.2%	88.9%	85.9%	91.9%
32.5	83.6%	57.7%	95.3%	39.7%	27.4%	55.0%	38.4%	34.4%	43.3%	84.3%	65.9%	93.4%	39.4%	24.7%	56.4%	92.7%	75.1%	98.1%	88.9%	85.8%	91.9%
32.6	83.5%	57.7%	95.3%	39.6%	27.3%	54.9%	38.4%	34.3%	43.3%	84.2%	65.7%	93.4%	39.4%	24.6%	56.3%	92.7%	75.1%	98.1%	88.9%	85.8%	91.9%
32.7	83.5%	57.6%	95.2%	39.5%	27.2%	54.8%	38.3%	34.1%	43.2%	84.1%	65.6%	93.3%	39.3%	24.5%	56.2%	92.6%	75.0%	98.1%	88.9%	85.8%	91.9%
32.8	83.5%	57.5%	95.2%	39.4%	27.2%	54.7%	38.2%	33.9%	43.2%	84.1%	65.5%	93.3%	39.2%	24.5%	56.1%	92.6%	74.9%	98.1%	88.9%	85.8%	91.9%
32.9	83.4%	57.4%	95.2%	39.3%	27.1%	54.6%	38.1%	33.8%	43.2%	84.0%	65.3%	93.2%	39.1%	24.4%	56.0%	92.6%	74.8%	98.1%	88.9%	85.8%	91.9%
33	83.4%	57.3%	95.2%	39.2%	27.0%	54.5%	38.0%	33.8%	43.1%	83.9%	65.2%	93.2%	39.0%	24.3%	55.9%	92.6%	74.8%	98.1%	88.9%	85.8%	91.9%
33.1	83.3%	57.3%	95.2%	39.1%	27.0%	54.5%	38.0%	33.7%	43.1%	83.9%	65.1%	93.2%	38.9%	24.3%	55.8%	92.6%	74.7%	98.1%	88.9%	85.8%	91.8%
33.2	83.3%	57.2%	95.2%	39.0%	26.9%	54.4%	37.9%	33.5%	43.1%	83.8%	64.9%	93.1%	38.9%	24.2%	55.8%	92.5%	74.6%	98.1%	88.9%	85.8%	91.8%
33.3	83.2%	57.1%	95.2%	38.9%	26.8%	54.3%	37.8%	33.4%	43.0%	83.7%	64.8%	93.1%	38.8%	24.2%	55.7%	92.5%	74.5%	98.1%	88.9%	85.8%	91.8%
33.4	83.2%	57.0%	95.1%	38.9%	26.7%	54.2%	37.7%	33.2%	43.0%	83.6%	64.6%	93.1%	38.7%	24.1%	55.6%	92.5%	74.5%	98.1%	88.9%	85.8%	91.8%
33.5	83.1%	56.9%	95.1%	38.8%	26.7%	54.1%	37.7%	33.1%	42.9%	83.6%	64.5%	93.0%	38.6%	24.1%	55.5%	92.5%	74.4%	98.1%	88.9%	85.8%	91.8%
33.6	83.1%	56.8%	95.1%	38.7%	26.6%	54.0%	37.6%	33.0%	42.9%	83.5%	64.4%	93.0%	38.6%	24.0%	55.5%	92.5%	74.3%	98.1%	88.9%	85.8%	91.8%
33.7	83.0%	56.8%	95.1%	38.6%	26.6%	53.9%	37.6%	32.8%	42.8%	83.4%	64.2%	93.0%	38.5%	24.0%	55.4%	92.4%	74.3%	98.1%	88.9%	85.8%	91.8%
33.8	83.0%	56.7%	95.1%	38.5%	26.5%	53.8%	37.5%	32.7%	42.7%	83.3%	64.1%	92.9%	38.4%	23.9%	55.3%	92.4%	74.2%	98.1%	88.9%	85.8%	91.8%
33.9	82.9%	56.6%	95.1%	38.4%	26.4%	53.8%	37.5%	32.6%	42.7%	83.3%	63.9%	92.9%	38.4%	23.9%	55.2%	92.4%	74.2%	98.1%	88.9%	85.8%	91.8%
34	82.9%	56.5%	95.0%	38.4%	26.4%	53.7%	37.4%	32.5%	42.7%	83.2%	63.8%	92.9%	38.3%	23.8%	55.2%	92.4%	74.1%	98.0%	88.9%	85.8%	91.7%
34.1	82.8%	56.4%	95.0%	38.3%	26.3%	53.6%	37.4%	32.5%	42.7%	83.1%	63.6%	92.8%	38.3%	23.8%	55.1%	92.4%	74.0%	98.0%	88.9%	85.8%	91.7%
34.2	82.7%	56.3%	95.0%	38.2%	26.3%	53.5%	37.3%	32.3%	42.6%	83.0%	63.5%	92.8%	38.2%	23.8%	55.1%	92.3%	74.0%	98.0%	88.9%	85.8%	91.7%
34.3	82.7%	56.2%	95.0%	38.1%	26.2%	53.4%	37.3%	32.2%	42.6%	83.0%	63.3%	92.7%	38.2%	23.7%	55.0%	92.3%	73.9%	98.0%	88.9%	85.8%	91.7%
34.4	82.6%	56.1%	95.0%	38.0%	26.1%	53.3%	37.2%	32.1%	42.6%	82.9%	63.2%	92.7%	38.1%	23.7%	54.9%	92.3%	73.9%	98.0%	88.9%	85.8%	91.7%
34.5	82.6%	56.0%	95.0%	38.0%	26.1%	53.2%	37.2%	32.0%	42.6%	82.8%	63.1%	92.7%	38.1%	23.7%	54.9%	92.3%	73.8%	98.0%	88.9%	85.8%	91.7%

34.6	82.5%	55.9%	94.9%	37.9%	26.0%	53.2%	37.2%	31.9%	42.6%	82.7%	62.9%	92.6%	38.0%	23.6%	54.8%	92.2%	73.8%	98.0%	88.9%	85.8%	91.7%
34.7	82.5%	55.8%	94.9%	37.8%	26.0%	53.1%	37.2%	31.8%	42.6%	82.7%	62.8%	92.6%	38.0%	23.6%	54.8%	92.2%	73.7%	98.0%	88.9%	85.8%	91.6%
34.8	82.4%	55.8%	94.9%	37.8%	25.9%	53.0%	37.1%	31.6%	42.6%	82.6%	62.6%	92.6%	37.9%	23.6%	54.7%	92.2%	73.7%	98.0%	88.9%	85.8%	91.6%
34.9	82.3%	55.6%	94.9%	37.7%	25.9%	52.9%	37.1%	31.5%	42.6%	82.5%	62.5%	92.5%	37.9%	23.5%	54.7%	92.2%	73.6%	98.0%	88.9%	85.8%	91.6%
35	82.3%	55.5%	94.9%	37.6%	25.8%	52.8%	37.1%	31.3%	42.5%	82.4%	62.3%	92.5%	37.9%	23.5%	54.6%	92.1%	73.6%	98.0%	88.9%	85.8%	91.6%
35.1	82.2%	55.4%	94.9%	37.6%	25.8%	52.8%	37.1%	31.1%	42.5%	82.4%	62.2%	92.4%	37.8%	23.5%	54.6%	92.1%	73.5%	97.9%	88.9%	85.8%	91.6%
35.2	82.2%	55.3%	94.8%	37.5%	25.7%	52.7%	37.0%	30.9%	42.5%	82.3%	62.0%	92.4%	37.8%	23.5%	54.6%	92.1%	73.5%	97.9%	88.9%	85.8%	91.5%
35.3	82.1%	55.2%	94.8%	37.5%	25.7%	52.6%	37.0%	30.7%	42.5%	82.2%	61.9%	92.4%	37.8%	23.4%	54.5%	92.0%	73.5%	97.9%	88.9%	85.8%	91.5%
35.4	82.0%	55.1%	94.8%	37.4%	25.6%	52.6%	37.0%	30.6%	42.5%	82.1%	61.7%	92.3%	37.7%	23.4%	54.5%	92.0%	73.4%	97.9%	88.9%	85.8%	91.5%
35.5	82.0%	55.0%	94.8%	37.3%	25.6%	52.5%	37.0%	30.4%	42.5%	82.0%	61.6%	92.3%	37.7%	23.3%	54.5%	92.0%	73.4%	97.9%	88.9%	85.8%	91.5%
35.6	81.9%	54.9%	94.8%	37.3%	25.5%	52.4%	37.0%	30.2%	42.5%	82.0%	61.4%	92.2%	37.7%	23.3%	54.4%	92.0%	73.4%	97.9%	88.9%	85.8%	91.4%
35.7	81.8%	54.8%	94.7%	37.2%	25.5%	52.4%	37.0%	30.0%	42.4%	81.9%	61.3%	92.2%	37.7%	23.3%	54.4%	91.9%	73.3%	97.9%	88.9%	85.8%	91.4%
35.8	81.8%	54.7%	94.7%	37.2%	25.5%	52.3%	37.0%	29.9%	42.5%	81.8%	61.1%	92.1%	37.7%	23.2%	54.4%	91.9%	73.3%	97.9%	88.9%	85.7%	91.4%
35.9	81.7%	54.6%	94.7%	37.1%	25.4%	52.3%	37.0%	29.7%	42.5%	81.7%	61.0%	92.1%	37.6%	23.2%	54.4%	91.9%	73.3%	97.9%	88.9%	85.7%	91.4%
36	81.6%	54.4%	94.7%	37.1%	25.4%	52.2%	37.0%	29.5%	42.5%	81.6%	60.8%	92.1%	37.6%	23.2%	54.3%	91.8%	73.2%	97.9%	88.9%	85.7%	91.3%
36.1	81.6%	54.3%	94.6%	37.0%	25.3%	52.2%	37.0%	29.2%	42.5%	81.5%	60.6%	92.0%	37.6%	23.2%	54.3%	91.8%	73.2%	97.9%	88.9%	85.7%	91.3%
36.2	81.5%	54.2%	94.6%	37.0%	25.3%	52.1%	37.0%	29.0%	42.5%	81.5%	60.5%	92.0%	37.6%	23.2%	54.3%	91.8%	73.1%	97.9%	88.9%	85.6%	91.3%
36.3	81.4%	54.1%	94.6%	36.9%	25.2%	52.1%	37.0%	28.8%	42.5%	81.4%	60.3%	91.9%	37.6%	23.2%	54.3%	91.7%	73.1%	97.9%	88.9%	85.6%	91.3%
36.4	81.4%	54.0%	94.6%	36.9%	25.2%	52.1%	37.0%	28.6%	42.5%	81.3%	60.2%	91.9%	37.6%	23.2%	54.3%	91.7%	73.0%	97.8%	88.9%	85.6%	91.3%
36.5	81.3%	53.9%	94.5%	36.8%	25.2%	52.0%	37.0%	28.5%	42.4%	81.2%	60.1%	91.8%	37.6%	23.2%	54.2%	91.6%	73.0%	97.8%	88.9%	85.6%	91.2%
36.6	81.2%	53.8%	94.5%	36.8%	25.1%	52.0%	37.0%	28.3%	42.4%	81.1%	60.0%	91.8%	37.6%	23.2%	54.2%	91.6%	72.9%	97.8%	88.9%	85.6%	91.2%
36.7	81.2%	53.7%	94.5%	36.7%	25.1%	51.9%	37.0%	28.1%	42.4%	81.0%	59.9%	91.8%	37.6%	23.3%	54.2%	91.6%	72.9%	97.8%	88.9%	85.6%	91.2%
36.8	81.1%	53.6%	94.5%	36.7%	25.0%	51.9%	37.0%	27.9%	42.4%	81.0%	59.8%	91.7%	37.6%	23.3%	54.1%	91.5%	72.8%	97.8%	88.9%	85.6%	91.2%
36.9	81.0%	53.5%	94.5%	36.7%	25.0%	51.8%	37.0%	27.7%	42.4%	80.9%	59.6%	91.7%	37.6%	23.3%	54.1%	91.5%	72.7%	97.8%	88.9%	85.6%	91.2%
37	80.9%	53.4%	94.4%	36.6%	25.0%	51.8%	37.0%	27.5%	42.4%	80.8%	59.5%	91.6%	37.6%	23.3%	54.1%	91.5%	72.7%	97.7%	88.9%	85.6%	91.1%
37.1	80.9%	53.3%	94.4%	36.6%	24.9%	51.8%	37.0%	27.3%	42.4%	80.7%	59.4%	91.6%	37.6%	23.3%	54.1%	91.4%	72.6%	97.7%	88.9%	85.6%	91.1%
37.2	80.8%	53.1%	94.4%	36.6%	24.9%	51.7%	37.0%	27.2%	42.4%	80.6%	59.3%	91.5%	37.7%	23.2%	54.1%	91.4%	72.6%	97.7%	88.9%	85.6%	91.1%
37.3	80.7%	53.0%	94.4%	36.5%	24.9%	51.7%	37.0%	27.0%	42.4%	80.5%	59.2%	91.5%	37.7%	23.2%	54.1%	91.3%	72.6%	97.7%	88.9%	85.5%	91.1%
37.4	80.7%	52.9%	94.3%	36.5%	24.8%	51.7%	37.0%	26.8%	42.4%	80.5%	59.1%	91.5%	37.7%	23.2%	54.1%	91.3%	72.5%	97.7%	88.9%	85.5%	91.1%
37.5	80.6%	52.8%	94.3%	36.5%	24.8%	51.7%	37.0%	26.7%	42.4%	80.4%	59.0%	91.5%	37.7%	23.2%	54.1%	91.3%	72.5%	97.7%	88.9%	85.5%	91.1%
37.6	80.5%	52.7%	94.3%	36.4%	24.8%	51.6%	37.0%	26.5%	42.4%	80.3%	58.9%	91.4%	37.7%	23.2%	54.1%	91.2%	72.4%	97.7%	88.9%	85.5%	91.1%
37.7	80.4%	52.6%	94.3%	36.4%	24.8%	51.6%	37.0%	26.4%	42.4%	80.2%	58.8%	91.4%	37.7%	23.2%	54.2%	91.2%	72.4%	97.7%	88.9%	85.5%	91.1%

37.8	80.4%	52.5%	94.2%	36.4%	24.7%	51.6%	37.0%	26.2%	42.4%	80.1%	58.7%	91.3%	37.7%	23.2%	54.2%	91.1%	72.3%	97.7%	88.9%	85.5%	91.0%
37.9	80.3%	52.3%	94.2%	36.4%	24.7%	51.5%	37.0%	26.1%	42.3%	80.0%	58.5%	91.3%	37.7%	23.2%	54.2%	91.1%	72.2%	97.7%	88.9%	85.5%	91.0%
38	80.2%	52.2%	94.2%	36.3%	24.7%	51.5%	37.0%	25.9%	42.3%	80.0%	58.4%	91.3%	37.7%	23.2%	54.2%	91.0%	72.2%	97.7%	88.9%	85.4%	91.0%
38.1	80.1%	52.1%	94.2%	36.3%	24.7%	51.5%	37.0%	25.8%	42.3%	79.9%	58.3%	91.2%	37.7%	23.2%	54.2%	91.0%	72.2%	97.7%	88.9%	85.4%	91.0%
38.2	80.1%	52.0%	94.1%	36.3%	24.6%	51.5%	37.0%	25.6%	42.3%	79.8%	58.2%	91.2%	37.8%	23.2%	54.2%	90.9%	72.1%	97.7%	88.9%	85.4%	91.0%
38.3	80.0%	51.9%	94.1%	36.3%	24.6%	51.5%	37.0%	25.4%	42.3%	79.7%	58.0%	91.1%	37.8%	23.1%	54.2%	90.9%	72.0%	97.7%	88.9%	85.4%	91.0%
38.4	79.9%	51.8%	94.1%	36.3%	24.6%	51.4%	37.0%	25.3%	42.3%	79.6%	57.8%	91.1%	37.8%	23.1%	54.2%	90.9%	72.0%	97.6%	88.9%	85.3%	91.0%
38.5	79.8%	51.6%	94.0%	36.2%	24.6%	51.4%	37.0%	25.2%	42.3%	79.6%	57.7%	91.0%	37.8%	23.1%	54.2%	90.8%	71.9%	97.6%	88.9%	85.3%	91.0%
38.6	79.7%	51.5%	94.0%	36.2%	24.6%	51.4%	37.0%	25.1%	42.3%	79.5%	57.6%	90.9%	37.8%	23.1%	54.2%	90.8%	71.9%	97.6%	88.9%	85.3%	91.0%
38.7	79.7%	51.4%	94.0%	36.2%	24.5%	51.4%	37.0%	24.9%	42.3%	79.4%	57.5%	90.9%	37.8%	23.1%	54.2%	90.7%	71.8%	97.6%	88.9%	85.3%	91.0%
38.8	79.6%	51.3%	94.0%	36.2%	24.5%	51.4%	37.0%	24.8%	42.2%	79.3%	57.4%	90.8%	37.8%	23.1%	54.2%	90.7%	71.7%	97.6%	88.9%	85.3%	91.0%
38.9	79.5%	51.1%	93.9%	36.2%	24.5%	51.4%	37.0%	24.7%	42.2%	79.3%	57.3%	90.8%	37.8%	23.0%	54.2%	90.7%	71.7%	97.6%	88.9%	85.2%	91.0%
39	79.4%	51.0%	93.9%	36.2%	24.5%	51.4%	37.0%	24.6%	42.2%	79.2%	57.2%	90.8%	37.8%	23.0%	54.2%	90.6%	71.6%	97.6%	88.9%	85.2%	91.0%
39.1	79.3%	50.9%	93.9%	36.2%	24.5%	51.4%	37.0%	24.5%	42.2%	79.1%	57.1%	90.7%	37.8%	23.0%	54.2%	90.6%	71.4%	97.6%	88.9%	85.1%	91.0%
39.2	79.3%	50.8%	93.9%	36.2%	24.5%	51.3%	37.0%	24.4%	42.2%	79.0%	57.0%	90.7%	37.8%	23.0%	54.2%	90.5%	71.1%	97.6%	88.9%	85.1%	91.0%
39.3	79.2%	50.7%	93.8%	36.2%	24.5%	51.3%	37.0%	24.3%	42.2%	78.9%	56.9%	90.7%	37.8%	22.9%	54.2%	90.5%	70.9%	97.6%	88.9%	85.0%	91.0%
39.4	79.1%	50.5%	93.8%	36.1%	24.4%	51.3%	37.0%	24.2%	42.2%	78.9%	56.8%	90.7%	37.8%	22.9%	54.2%	90.4%	70.7%	97.6%	88.9%	84.9%	91.0%
39.5	79.0%	50.4%	93.8%	36.1%	24.4%	51.3%	37.0%	24.1%	42.2%	78.8%	56.7%	90.6%	37.8%	22.9%	54.2%	90.4%	70.5%	97.5%	88.9%	84.9%	91.0%
39.6	78.9%	50.3%	93.7%	36.1%	24.4%	51.3%	37.0%	24.0%	42.2%	78.7%	56.6%	90.6%	37.7%	22.8%	54.2%	90.4%	70.3%	97.5%	88.9%	84.9%	91.0%
39.7	78.9%	50.2%	93.7%	36.1%	24.4%	51.3%	37.0%	23.9%	42.2%	78.6%	56.5%	90.6%	37.7%	22.8%	54.2%	90.3%	70.1%	97.5%	88.9%	84.8%	90.9%
39.8	78.8%	50.0%	93.7%	36.1%	24.4%	51.3%	37.0%	23.7%	42.2%	78.6%	56.3%	90.5%	37.7%	22.8%	54.1%	90.3%	69.9%	97.5%	88.9%	84.8%	90.9%
39.9	78.7%	49.9%	93.7%	36.1%	24.4%	51.3%	37.0%	23.6%	42.2%	78.5%	56.2%	90.5%	37.7%	22.8%	54.1%	90.3%	69.7%	97.5%	88.9%	84.7%	90.9%
40	78.6%	49.8%	93.6%	36.1%	24.4%	51.3%	37.0%	23.5%	42.2%	78.4%	56.1%	90.5%	37.7%	22.8%	54.1%	90.2%	69.7%	97.5%	88.9%	84.7%	90.9%
40.1	78.5%	49.6%	93.6%	36.2%	24.4%	51.3%	37.0%	23.4%	42.2%	78.4%	55.9%	90.4%	37.7%	22.8%	54.1%	90.2%	69.7%	97.5%	88.9%	84.6%	90.9%
40.2	78.4%	49.5%	93.6%	36.2%	24.4%	51.3%	37.0%	23.3%	42.2%	78.3%	55.8%	90.4%	37.7%	22.7%	54.1%	90.1%	69.7%	97.5%	88.9%	84.6%	90.9%
40.3	78.3%	49.4%	93.5%	36.2%	24.4%	51.4%	37.0%	23.2%	42.2%	78.2%	55.7%	90.4%	37.7%	22.7%	54.0%	90.1%	69.7%	97.4%	88.9%	84.6%	90.9%
40.4	78.3%	49.2%	93.5%	36.2%	24.4%	51.4%	37.0%	23.1%	42.2%	78.1%	55.6%	90.3%	37.7%	22.7%	54.0%	90.1%	69.6%	97.4%	88.9%	84.5%	90.9%
40.5	78.2%	49.1%	93.5%	36.2%	24.4%	51.4%	37.0%	22.9%	42.2%	78.1%	55.4%	90.3%	37.6%	22.7%	54.0%	90.0%	69.4%	97.4%	88.9%	84.4%	90.9%
40.6	78.1%	49.0%	93.4%	36.2%	24.4%	51.4%	37.0%	22.8%	42.2%	78.0%	55.3%	90.3%	37.6%	22.6%	54.0%	90.0%	69.4%	97.4%	88.9%	84.3%	90.9%
40.7	78.0%	48.9%	93.4%	36.2%	24.4%	51.4%	37.0%	22.7%	42.2%	77.9%	55.2%	90.2%	37.6%	22.6%	54.0%	90.0%	69.3%	97.4%	88.9%	84.2%	90.9%
40.8	77.9%	48.7%	93.4%	36.2%	24.4%	51.4%	37.0%	22.6%	42.2%	77.9%	55.1%	90.2%	37.6%	22.6%	53.9%	89.9%	69.3%	97.4%	88.9%	84.2%	90.9%
40.9	77.8%	48.6%	93.3%	36.2%	24.4%	51.4%	37.0%	22.6%	42.2%	77.8%	54.9%	90.1%	37.6%	22.6%	53.9%	89.9%	69.2%	97.4%	88.9%	84.0%	90.9%

41	77.7%	48.5%	93.3%	36.2%	24.4%	51.4%	37.0%	22.5%	42.2%	77.7%	54.8%	90.1%	37.6%	22.5%	53.9%	89.9%	69.2%	97.4%	88.9%	84.0%	90.9%
41.1	77.6%	48.3%	93.3%	36.2%	24.4%	51.3%	37.0%	22.4%	42.2%	77.6%	54.7%	90.1%	37.5%	22.5%	53.9%	89.8%	69.1%	97.4%	88.9%	83.9%	90.9%
41.2	77.5%	48.2%	93.2%	36.2%	24.4%	51.3%	37.0%	22.4%	42.2%	77.6%	54.6%	90.0%	37.5%	22.5%	53.8%	89.8%	69.1%	97.4%	88.9%	83.8%	90.9%
41.3	77.4%	48.0%	93.2%	36.2%	24.4%	51.3%	37.0%	22.3%	42.2%	77.5%	54.5%	90.0%	37.5%	22.4%	53.8%	89.8%	69.0%	97.4%	88.9%	83.7%	90.9%
41.4	77.3%	47.9%	93.2%	36.2%	24.4%	51.3%	37.0%	22.3%	42.2%	77.4%	54.4%	90.0%	37.5%	22.4%	53.8%	89.7%	68.9%	97.4%	88.9%	83.5%	90.8%
41.5	77.3%	47.8%	93.2%	36.2%	24.4%	51.3%	37.0%	22.2%	42.2%	77.4%	54.3%	89.9%	37.5%	22.4%	53.8%	89.7%	68.6%	97.4%	88.9%	83.5%	90.8%
41.6	77.2%	47.6%	93.1%	36.3%	24.4%	51.3%	37.0%	22.2%	42.2%	77.3%	54.2%	89.9%	37.4%	22.3%	53.7%	89.7%	68.6%	97.4%	88.9%	83.4%	90.8%
41.7	77.1%	47.5%	93.1%	36.3%	24.4%	51.3%	37.0%	22.1%	42.2%	77.2%	54.1%	89.9%	37.4%	22.3%	53.7%	89.6%	68.6%	97.3%	88.9%	83.3%	90.8%
41.8	77.0%	47.4%	93.1%	36.3%	24.4%	51.3%	37.0%	22.1%	42.2%	77.2%	54.0%	89.8%	37.4%	22.3%	53.7%	89.6%	68.5%	97.3%	88.9%	83.1%	90.8%
41.9	76.9%	47.2%	93.0%	36.3%	24.4%	51.3%	37.0%	22.0%	42.2%	77.1%	53.9%	89.8%	37.3%	22.3%	53.7%	89.6%	68.5%	97.3%	88.8%	83.0%	90.8%
42	76.8%	47.1%	93.0%	36.3%	24.4%	51.3%	37.0%	22.0%	42.2%	77.1%	53.9%	89.8%	37.3%	22.2%	53.6%	89.6%	68.5%	97.2%	88.8%	82.9%	90.8%
42.1	76.7%	46.9%	92.9%	36.3%	24.4%	51.3%	37.0%	22.0%	42.2%	77.0%	53.8%	89.7%	37.3%	22.2%	53.6%	89.5%	68.4%	97.2%	88.8%	82.8%	90.8%
42.2	76.6%	46.8%	92.9%	36.3%	24.4%	51.3%	37.0%	21.9%	42.2%	76.9%	53.7%	89.7%	37.3%	22.2%	53.5%	89.5%	68.4%	97.2%	88.8%	82.7%	90.8%
42.3	76.5%	46.7%	92.9%	36.3%	24.4%	51.3%	37.0%	21.9%	42.2%	76.9%	53.6%	89.7%	37.2%	22.1%	53.5%	89.5%	68.3%	97.2%	88.8%	82.6%	90.8%
42.4	76.4%	46.5%	92.8%	36.3%	24.4%	51.3%	37.0%	21.9%	42.2%	76.8%	53.5%	89.6%	37.2%	22.1%	53.4%	89.4%	68.3%	97.2%	88.8%	82.5%	90.8%
42.5	76.3%	46.4%	92.8%	36.3%	24.4%	51.3%	37.0%	21.9%	42.2%	76.7%	53.4%	89.6%	37.2%	22.1%	53.4%	89.4%	68.2%	97.2%	88.8%	82.4%	90.7%
42.6	76.2%	46.2%	92.8%	36.3%	24.4%	51.3%	37.0%	21.9%	42.2%	76.7%	53.3%	89.6%	37.1%	22.0%	53.3%	89.4%	68.1%	97.2%	88.8%	82.3%	90.7%
42.7	76.1%	46.1%	92.7%	36.3%	24.4%	51.3%	37.0%	21.8%	42.2%	76.6%	53.3%	89.5%	37.1%	22.0%	53.3%	89.4%	68.0%	97.2%	88.7%	82.2%	90.7%
42.8	76.0%	45.9%	92.7%	36.3%	24.4%	51.3%	37.0%	21.8%	42.2%	76.6%	53.2%	89.5%	37.1%	22.0%	53.2%	89.3%	67.9%	97.2%	88.7%	82.1%	90.7%
42.9	75.9%	45.8%	92.7%	36.3%	24.4%	51.3%	37.0%	21.8%	42.2%	76.5%	53.1%	89.5%	37.0%	21.9%	53.2%	89.3%	67.7%	97.2%	88.7%	82.1%	90.7%
43	75.8%	45.7%	92.6%	36.3%	24.4%	51.3%	37.0%	21.8%	42.2%	76.4%	53.0%	89.4%	37.0%	21.9%	53.1%	89.3%	67.6%	97.1%	88.7%	82.0%	90.6%
43.1	75.7%	45.5%	92.6%	36.3%	24.4%	51.3%	37.0%	21.8%	42.2%	76.4%	52.9%	89.4%	36.9%	21.9%	53.1%	89.3%	67.5%	97.1%	88.7%	81.9%	90.6%
43.2	75.6%	45.4%	92.6%	36.3%	24.4%	51.3%	37.0%	21.8%	42.2%	76.3%	52.8%	89.4%	36.9%	21.8%	53.0%	89.2%	67.2%	97.1%	88.7%	81.8%	90.6%
43.3	75.5%	45.2%	92.5%	36.3%	24.4%	51.3%	37.0%	21.8%	42.2%	76.3%	52.7%	89.3%	36.9%	21.8%	53.0%	89.2%	66.9%	97.1%	88.6%	81.7%	90.6%
43.4	75.4%	45.1%	92.5%	36.3%	24.4%	51.3%	37.0%	21.8%	42.2%	76.2%	52.6%	89.3%	36.8%	21.7%	52.9%	89.2%	66.7%	97.1%	88.6%	81.6%	90.6%
43.5	75.3%	44.9%	92.4%	36.3%	24.4%	51.3%	37.0%	21.8%	42.2%	76.1%	52.5%	89.3%	36.8%	21.7%	52.9%	89.2%	66.6%	97.1%	88.6%	81.5%	90.5%
43.6	75.2%	44.8%	92.4%	36.3%	24.4%	51.3%	37.0%	21.8%	42.2%	76.1%	52.4%	89.3%	36.7%	21.7%	52.8%	89.1%	66.6%	97.1%	88.6%	81.4%	90.5%
43.7	75.1%	44.6%	92.4%	36.3%	24.4%	51.3%	37.0%	21.8%	42.2%	76.0%	52.3%	89.2%	36.7%	21.7%	52.8%	89.1%	66.5%	97.1%	88.6%	81.4%	90.5%
43.8	75.0%	44.5%	92.3%	36.3%	24.4%	51.3%	37.0%	21.8%	42.2%	76.0%	52.3%	89.2%	36.6%	21.6%	52.7%	89.1%	66.5%	97.1%	88.5%	81.3%	90.4%
43.9	74.8%	44.3%	92.3%	36.3%	24.4%	51.3%	37.0%	21.8%	42.2%	75.9%	52.2%	89.2%	36.6%	21.6%	52.7%	89.1%	66.2%	97.1%	88.5%	81.2%	90.4%
44	74.7%	44.2%	92.2%	36.3%	24.4%	51.3%	37.0%	21.8%	42.2%	75.9%	52.2%	89.1%	36.6%	21.5%	52.6%	89.1%	66.0%	97.1%	88.5%	81.1%	90.4%
44.1	74.6%	44.1%	92.2%	36.3%	24.4%	51.3%	37.0%	21.8%	42.2%	75.8%	52.1%	89.1%	36.5%	21.5%	52.5%	89.0%	66.0%	97.1%	88.5%	81.0%	90.4%

44.2	74.5%	44.0%	92.2%	36.3%	24.4%	51.2%	37.0%	21.8%	42.2%	75.8%	52.1%	89.1%	36.5%	21.5%	52.5%	89.0%	65.9%	97.1%	88.4%	81.0%	90.3%
44.3	74.4%	43.8%	92.1%	36.3%	24.4%	51.2%	37.0%	21.8%	42.2%	75.7%	52.0%	89.1%	36.4%	21.4%	52.4%	89.0%	65.9%	97.1%	88.4%	80.9%	90.3%
44.4	74.3%	43.7%	92.1%	36.3%	24.4%	51.2%	37.0%	21.8%	42.2%	75.7%	51.9%	89.0%	36.4%	21.4%	52.4%	89.0%	65.8%	97.1%	88.4%	80.8%	90.3%
44.5	74.2%	43.5%	92.0%	36.3%	24.4%	51.2%	37.0%	21.7%	42.2%	75.6%	51.8%	89.0%	36.3%	21.4%	52.3%	89.0%	65.8%	97.1%	88.4%	80.7%	90.2%
44.6	74.1%	43.4%	92.0%	36.3%	24.4%	51.2%	37.0%	21.7%	42.2%	75.6%	51.8%	89.0%	36.3%	21.3%	52.2%	89.0%	65.7%	97.1%	88.3%	80.6%	90.2%
44.7	74.0%	43.2%	91.9%	36.3%	24.4%	51.2%	37.0%	21.7%	42.1%	75.5%	51.7%	89.0%	36.2%	21.3%	52.2%	88.9%	65.7%	97.1%	88.3%	80.5%	90.2%
44.8	73.9%	43.1%	91.9%	36.3%	24.4%	51.2%	37.0%	21.6%	42.1%	75.5%	51.6%	88.9%	36.2%	21.2%	52.1%	88.9%	65.5%	97.1%	88.3%	80.5%	90.2%
44.9	73.7%	42.9%	91.8%	36.3%	24.4%	51.2%	37.0%	21.6%	42.1%	75.4%	51.6%	88.9%	36.1%	21.2%	52.1%	88.9%	65.1%	97.1%	88.3%	80.4%	90.1%
45	73.6%	42.8%	91.8%	36.3%	24.4%	51.2%	37.0%	21.6%	42.1%	75.4%	51.5%	88.9%	36.0%	21.2%	52.0%	88.9%	65.1%	97.1%	88.2%	80.3%	90.1%
45.1	73.5%	42.6%	91.7%	36.3%	24.4%	51.2%	37.0%	21.6%	42.1%	75.3%	51.4%	88.9%	36.0%	21.1%	51.9%	88.9%	65.1%	97.1%	88.2%	80.2%	90.1%
45.2	73.4%	42.5%	91.7%	36.3%	24.4%	51.1%	37.0%	21.6%	42.1%	75.3%	51.4%	88.8%	35.9%	21.1%	51.9%	88.9%	64.6%	97.1%	88.2%	80.1%	90.0%
45.3	73.3%	42.3%	91.6%	36.3%	24.4%	51.1%	37.0%	21.6%	42.1%	75.2%	51.3%	88.8%	35.9%	21.0%	51.8%	88.9%	64.0%	97.1%	88.1%	80.0%	90.0%
45.4	73.2%	42.2%	91.6%	36.3%	24.4%	51.1%	37.0%	21.6%	42.1%	75.2%	51.2%	88.8%	35.8%	21.0%	51.8%	88.8%	63.5%	97.0%	88.1%	80.0%	90.0%
45.5	73.0%	42.0%	91.5%	36.3%	24.4%	51.1%	37.0%	21.6%	42.1%	75.1%	51.2%	88.8%	35.8%	21.0%	51.7%	88.8%	62.9%	97.0%	88.1%	79.9%	89.9%
45.6	72.9%	41.9%	91.5%	36.3%	24.4%	51.1%	37.0%	21.6%	42.1%	75.1%	51.1%	88.7%	35.7%	20.9%	51.6%	88.8%	62.3%	97.0%	88.0%	79.8%	89.9%
45.7	72.8%	41.7%	91.4%	36.3%	24.3%	51.1%	37.0%	21.5%	42.1%	75.1%	51.1%	88.7%	35.6%	20.9%	51.6%	88.8%	61.6%	97.0%	88.0%	79.7%	89.9%
45.8	72.7%	41.6%	91.3%	36.3%	24.3%	51.1%	37.0%	21.4%	42.1%	75.0%	51.0%	88.6%	35.6%	20.8%	51.5%	88.8%	61.5%	97.0%	88.0%	79.7%	89.8%
45.9	72.6%	41.5%	91.3%	36.3%	24.3%	51.0%	37.0%	21.3%	42.1%	75.0%	51.0%	88.6%	35.5%	20.8%	51.4%	88.8%	61.5%	97.0%	87.9%	79.6%	89.8%
46	72.5%	41.3%	91.2%	36.3%	24.3%	51.0%	37.0%	21.2%	42.1%	74.9%	50.9%	88.6%	35.4%	20.8%	51.4%	88.8%	61.4%	97.0%	87.9%	79.6%	89.8%
46.1	72.3%	41.2%	91.2%	36.3%	24.3%	51.0%	37.0%	21.2%	42.1%	74.9%	50.9%	88.6%	35.4%	20.7%	51.3%	88.8%	61.3%	97.0%	87.9%	79.5%	89.7%
46.2	72.2%	41.1%	91.1%	36.3%	24.3%	51.0%	37.0%	21.2%	42.1%	74.8%	50.8%	88.6%	35.3%	20.7%	51.2%	88.8%	61.1%	97.0%	87.8%	79.4%	89.7%
46.3	72.1%	41.0%	91.1%	36.2%	24.3%	51.0%	37.0%	21.2%	42.1%	74.8%	50.8%	88.6%	35.2%	20.6%	51.2%	88.8%	61.1%	97.0%	87.8%	79.4%	89.6%
46.4	72.0%	40.9%	91.0%	36.2%	24.3%	51.0%	37.0%	21.2%	42.0%	74.8%	50.7%	88.5%	35.2%	20.5%	51.1%	88.7%	61.0%	97.0%	87.8%	79.3%	89.6%
46.5	71.8%	40.7%	91.0%	36.2%	24.3%	50.9%	37.0%	21.1%	42.0%	74.7%	50.7%	88.5%	35.1%	20.4%	51.0%	88.7%	60.9%	97.0%	87.7%	79.3%	89.6%
46.6	71.7%	40.6%	90.9%	36.2%	24.3%	50.9%	37.0%	21.0%	42.0%	74.7%	50.6%	88.5%	35.0%	20.4%	51.0%	88.7%	60.7%	97.0%	87.7%	79.2%	89.6%
46.7	71.6%	40.5%	90.8%	36.2%	24.3%	50.9%	37.0%	20.9%	42.0%	74.7%	50.6%	88.5%	35.0%	20.4%	50.9%	88.7%	60.5%	97.0%	87.6%	79.2%	89.6%
46.8	71.5%	40.4%	90.8%	36.2%	24.3%	50.9%	37.0%	20.9%	42.0%	74.6%	50.5%	88.5%	34.9%	20.3%	50.8%	88.7%	59.8%	97.0%	87.6%	79.1%	89.5%
46.9	71.4%	40.3%	90.7%	36.2%	24.3%	50.9%	37.0%	20.9%	42.0%	74.6%	50.5%	88.5%	34.8%	20.3%	50.8%	88.7%	59.5%	97.0%	87.6%	79.1%	89.5%
47	71.2%	40.2%	90.7%	36.2%	24.2%	50.9%	37.0%	20.9%	42.0%	74.5%	50.4%	88.4%	34.8%	20.3%	50.7%	88.7%	59.4%	96.9%	87.5%	79.1%	89.4%
47.1	71.1%	40.0%	90.6%	36.2%	24.2%	50.9%	37.0%	20.9%	42.0%	74.5%	50.4%	88.4%	34.7%	20.2%	50.6%	88.7%	58.8%	96.9%	87.5%	79.0%	89.4%
47.2	71.0%	39.9%	90.6%	36.2%	24.2%	50.9%	37.0%	20.9%	42.0%	74.5%	50.4%	88.4%	34.6%	20.2%	50.5%	88.7%	58.3%	96.9%	87.4%	79.0%	89.3%
47.3	70.9%	39.8%	90.5%	36.2%	24.2%	50.9%	37.0%	20.9%	42.0%	74.4%	50.3%	88.4%	34.5%	20.1%	50.5%	88.7%	58.1%	96.9%	87.4%	79.0%	89.3%

47.4	70.8%	39.7%	90.5%	36.2%	24.2%	50.9%	37.0%	20.9%	42.0%	74.4%	50.3%	88.4%	34.5%	20.1%	50.4%	88.7%	57.9%	96.9%	87.3%	78.9%	89.3%
47.5	70.6%	39.6%	90.4%	36.2%	24.2%	50.9%	37.0%	20.9%	42.0%	74.4%	50.2%	88.3%	34.4%	20.1%	50.3%	88.7%	57.4%	96.9%	87.3%	78.9%	89.2%
47.6	70.5%	39.5%	90.4%	36.2%	24.2%	50.9%	37.0%	20.9%	42.0%	74.3%	50.2%	88.3%	34.3%	20.0%	50.2%	88.7%	56.8%	96.9%	87.2%	78.9%	89.2%
47.7	70.4%	39.3%	90.3%	36.1%	24.2%	50.9%	37.0%	20.8%	42.0%	74.3%	50.1%	88.3%	34.2%	20.0%	50.1%	88.7%	56.6%	96.9%	87.2%	78.9%	89.1%
47.8	70.3%	39.2%	90.3%	36.1%	24.2%	50.9%	37.0%	20.8%	42.0%	74.2%	50.1%	88.3%	34.2%	20.0%	50.0%	88.7%	55.9%	96.9%	87.1%	78.8%	89.1%
47.9	70.2%	39.1%	90.2%	36.1%	24.2%	50.9%	37.0%	20.8%	42.0%	74.2%	50.0%	88.3%	34.1%	19.9%	49.9%	88.7%	55.5%	96.9%	87.1%	78.8%	89.0%
48	70.1%	39.0%	90.2%	36.1%	24.2%	50.9%	37.0%	20.8%	42.0%	74.2%	50.0%	88.2%	34.0%	19.9%	49.8%	88.7%	55.1%	96.9%	87.0%	78.8%	89.0%
48.1	69.9%	38.9%	90.1%	36.1%	24.2%	50.9%	37.0%	20.8%	42.0%	74.1%	49.9%	88.2%	33.9%	19.8%	49.8%	88.7%	54.7%	96.9%	87.0%	78.7%	88.9%
48.2	69.8%	38.8%	90.1%	36.1%	24.2%	50.9%	37.0%	20.8%	42.0%	74.1%	49.9%	88.2%	33.8%	19.8%	49.7%	88.7%	53.9%	96.9%	86.9%	78.7%	88.9%
48.3	69.7%	38.6%	90.0%	36.1%	24.2%	50.9%	37.0%	20.8%	42.0%	74.1%	49.8%	88.2%	33.8%	19.8%	49.6%	88.7%	52.9%	96.8%	86.9%	78.7%	88.8%
48.4	69.6%	38.5%	90.0%	36.1%	24.2%	50.9%	37.0%	20.8%	42.0%	74.0%	49.8%	88.2%	33.7%	19.7%	49.5%	88.7%	52.0%	96.8%	86.8%	78.7%	88.8%
48.5	69.5%	38.4%	89.9%	36.1%	24.2%	50.9%	37.0%	20.8%	42.0%	74.0%	49.7%	88.1%	33.6%	19.7%	49.5%	88.7%	51.0%	96.8%	86.8%	78.7%	88.7%
48.6	69.3%	38.3%	89.9%	36.1%	24.1%	50.9%	37.0%	20.8%	42.0%	74.0%	49.6%	88.1%	33.5%	19.6%	49.4%	88.7%	50.3%	96.8%	86.7%	78.7%	88.7%
48.7	69.2%	38.2%	89.8%	36.1%	24.1%	50.9%	37.0%	20.8%	42.0%	73.9%	49.5%	88.1%	33.5%	19.6%	49.3%	88.7%	50.3%	96.8%	86.7%	78.7%	88.6%
48.8	69.1%	38.0%	89.8%	36.0%	24.1%	50.9%	37.0%	20.8%	42.0%	73.9%	49.5%	88.1%	33.4%	19.5%	49.2%	88.7%	50.2%	96.7%	86.6%	78.6%	88.5%
48.9	69.0%	37.9%	89.8%	36.0%	24.1%	50.9%	37.0%	20.8%	42.0%	73.8%	49.4%	88.1%	33.3%	19.5%	49.2%	88.7%	50.2%	96.7%	86.6%	78.6%	88.5%
49	68.9%	37.8%	89.7%	36.0%	24.1%	50.9%	37.0%	20.8%	42.0%	73.8%	49.3%	88.0%	33.2%	19.4%	49.1%	88.7%	49.8%	96.7%	86.5%	78.6%	88.4%
49.1	68.8%	37.6%	89.7%	36.0%	24.1%	50.9%	37.0%	20.8%	42.0%	73.8%	49.2%	88.0%	33.2%	19.4%	49.0%	88.7%	49.1%	96.7%	86.4%	78.6%	88.4%
49.2	68.6%	37.5%	89.6%	36.0%	24.1%	50.9%	37.0%	20.8%	42.0%	73.7%	49.1%	88.0%	33.1%	19.4%	48.9%	88.7%	48.5%	96.6%	86.4%	78.6%	88.3%
49.3	68.5%	37.4%	89.6%	36.0%	24.1%	50.9%	37.0%	20.8%	42.0%	73.7%	49.0%	88.0%	33.0%	19.3%	48.8%	88.7%	48.3%	96.6%	86.3%	78.6%	88.2%
49.4	68.4%	37.3%	89.5%	36.0%	24.1%	50.9%	37.0%	20.8%	42.0%	73.7%	48.9%	87.9%	32.9%	19.3%	48.8%	88.7%	48.3%	96.6%	86.3%	78.6%	88.2%
49.5	68.3%	37.1%	89.5%	36.0%	24.1%	50.9%	37.0%	20.8%	42.0%	73.6%	48.9%	87.9%	32.9%	19.2%	48.7%	88.7%	47.9%	96.6%	86.2%	78.6%	88.1%
49.6	68.2%	37.0%	89.4%	35.9%	24.1%	50.8%	37.0%	20.7%	42.0%	73.6%	48.8%	87.9%	32.8%	19.2%	48.6%	88.7%	47.9%	96.6%	86.1%	78.6%	88.1%
49.7	68.1%	36.9%	89.4%	35.9%	24.0%	50.8%	37.0%	20.7%	42.0%	73.5%	48.7%	87.9%	32.7%	19.1%	48.5%	88.7%	47.7%	96.6%	86.1%	78.6%	88.0%
49.8	67.9%	36.8%	89.3%	35.9%	24.0%	50.8%	37.0%	20.7%	42.0%	73.5%	48.6%	87.9%	32.6%	19.1%	48.5%	88.7%	47.0%	96.6%	86.0%	78.6%	88.0%
49.9	67.8%	36.6%	89.3%	35.9%	24.0%	50.8%	37.0%	20.7%	42.0%	73.5%	48.5%	87.9%	32.6%	19.0%	48.4%	88.7%	46.3%	96.6%	85.9%	78.5%	87.9%
50	67.7%	36.5%	89.2%	35.9%	24.0%	50.8%	37.0%	20.7%	42.0%	73.4%	48.4%	87.8%	32.5%	18.9%	48.3%	88.7%	45.7%	96.6%	85.9%	78.5%	87.9%
50.1	67.6%	36.4%	89.2%	35.9%	23.9%	50.7%	37.0%	20.7%	42.0%	73.4%	48.3%	87.8%	32.4%	18.9%	48.2%	88.7%	45.0%	96.6%	85.8%	78.5%	87.8%
50.2	67.5%	36.3%	89.1%	35.9%	23.9%	50.7%	37.0%	20.7%	42.0%	73.4%	48.3%	87.8%	32.3%	18.8%	48.1%	88.7%	44.5%	96.6%	85.8%	78.5%	87.8%
50.3	67.4%	36.2%	89.1%	35.9%	23.9%	50.7%	37.0%	20.7%	42.0%	73.3%	48.2%	87.8%	32.3%	18.8%	48.1%	88.7%	43.6%	96.6%	85.7%	78.5%	87.7%
50.4	67.2%	36.0%	89.0%	35.8%	23.9%	50.7%	37.0%	20.7%	42.0%	73.3%	48.1%	87.8%	32.2%	18.8%	48.0%	88.7%	43.0%	96.5%	85.6%	78.5%	87.6%
50.5	67.1%	35.9%	89.0%	35.8%	23.8%	50.7%	37.0%	20.7%	42.0%	73.2%	48.0%	87.7%	32.1%	18.8%	47.9%	88.7%	42.3%	96.5%	85.6%	78.5%	87.6%

50.6	67.0%	35.8%	88.9%	35.8%	23.8%	50.6%	37.0%	20.7%	42.0%	73.2%	47.9%	87.7%	32.0%	18.7%	47.8%	88.7%	41.6%	96.5%	85.5%	78.4%	87.6%
50.7	66.9%	35.7%	88.9%	35.8%	23.8%	50.6%	37.0%	20.7%	42.0%	73.2%	47.9%	87.6%	32.0%	18.7%	47.8%	88.7%	41.0%	96.5%	85.5%	78.4%	87.5%
50.8	66.8%	35.5%	88.8%	35.8%	23.8%	50.6%	37.0%	20.7%	42.0%	73.1%	47.8%	87.6%	31.9%	18.6%	47.7%	88.7%	40.5%	96.5%	85.4%	78.4%	87.5%
50.9	66.7%	35.4%	88.8%	35.8%	23.7%	50.6%	37.0%	20.7%	41.9%	73.1%	47.7%	87.6%	31.8%	18.6%	47.6%	88.7%	40.2%	96.5%	85.3%	78.4%	87.4%
51	66.6%	35.3%	88.7%	35.7%	23.7%	50.6%	37.0%	20.7%	41.9%	73.1%	47.7%	87.5%	31.7%	18.5%	47.5%	88.7%	39.8%	96.5%	85.3%	78.4%	87.3%
51.1	66.5%	35.2%	88.7%	35.7%	23.7%	50.5%	37.0%	20.7%	41.9%	73.0%	47.6%	87.5%	31.7%	18.5%	47.4%	88.7%	39.5%	96.5%	85.2%	78.4%	87.3%
51.2	66.3%	35.1%	88.6%	35.7%	23.7%	50.5%	37.0%	20.7%	41.9%	73.0%	47.5%	87.5%	31.6%	18.4%	47.4%	88.7%	39.0%	96.5%	85.1%	78.4%	87.2%
51.3	66.2%	35.0%	88.6%	35.7%	23.6%	50.5%	37.0%	20.7%	41.9%	72.9%	47.5%	87.4%	31.5%	18.4%	47.3%	88.7%	38.6%	96.5%	85.1%	78.4%	87.2%
51.4	66.1%	34.9%	88.5%	35.7%	23.6%	50.5%	37.0%	20.7%	41.9%	72.9%	47.4%	87.4%	31.4%	18.3%	47.2%	88.7%	37.9%	96.5%	85.0%	78.4%	87.1%
51.5	66.0%	34.7%	88.5%	35.7%	23.6%	50.4%	37.0%	20.7%	41.9%	72.9%	47.4%	87.3%	31.4%	18.3%	47.1%	88.7%	37.3%	96.5%	84.9%	78.4%	87.1%
51.6	65.9%	34.6%	88.4%	35.6%	23.5%	50.4%	37.0%	20.7%	41.9%	72.8%	47.3%	87.3%	31.3%	18.2%	47.1%	88.7%	36.7%	96.5%	84.9%	78.3%	87.0%
51.7	65.8%	34.5%	88.4%	35.6%	23.5%	50.4%	37.0%	20.7%	41.9%	72.8%	47.2%	87.3%	31.2%	18.1%	47.0%	88.7%	36.1%	96.5%	84.8%	78.3%	87.0%
51.8	65.7%	34.4%	88.3%	35.6%	23.5%	50.4%	37.0%	20.7%	41.9%	72.8%	47.2%	87.2%	31.1%	18.1%	46.9%	88.7%	35.4%	96.5%	84.7%	78.3%	86.9%
51.9	65.6%	34.3%	88.3%	35.6%	23.4%	50.3%	37.0%	20.7%	41.9%	72.7%	47.2%	87.2%	31.1%	18.0%	46.8%	88.7%	34.8%	96.5%	84.7%	78.2%	86.9%
52	65.4%	34.2%	88.2%	35.6%	23.4%	50.3%	37.0%	20.7%	41.9%	72.7%	47.2%	87.2%	31.0%	17.9%	46.7%	88.7%	34.2%	96.5%	84.6%	78.2%	86.9%
52.1	65.3%	34.1%	88.2%	35.6%	23.4%	50.3%	37.0%	20.7%	41.9%	72.6%	47.2%	87.2%	30.9%	17.9%	46.7%	88.7%	33.5%	96.5%	84.5%	78.1%	86.8%
52.2	65.2%	34.0%	88.1%	35.5%	23.4%	50.3%	37.0%	20.7%	41.9%	72.6%	47.1%	87.1%	30.8%	17.8%	46.6%	88.7%	32.6%	96.5%	84.5%	78.1%	86.8%
52.3	65.1%	33.9%	88.1%	35.5%	23.4%	50.2%	37.0%	20.7%	41.9%	72.6%	47.1%	87.1%	30.8%	17.7%	46.5%	88.7%	31.7%	96.5%	84.4%	78.1%	86.8%
52.4	65.0%	33.8%	88.0%	35.5%	23.4%	50.2%	37.0%	20.7%	41.9%	72.5%	47.1%	87.1%	30.7%	17.6%	46.4%	88.7%	30.9%	96.4%	84.3%	78.1%	86.7%
52.5	64.9%	33.7%	88.0%	35.5%	23.4%	50.2%	37.0%	20.7%	41.9%	72.5%	47.1%	87.1%	30.6%	17.6%	46.4%	88.7%	30.5%	96.4%	84.3%	78.1%	86.7%
52.6	64.8%	33.6%	87.9%	35.5%	23.4%	50.2%	37.0%	20.7%	41.9%	72.4%	47.1%	87.1%	30.6%	17.5%	46.3%	88.7%	29.8%	96.4%	84.2%	78.1%	86.7%
52.7	64.7%	33.5%	87.9%	35.5%	23.4%	50.2%	37.0%	20.7%	41.9%	72.4%	47.1%	87.0%	30.5%	17.4%	46.2%	88.7%	29.1%	96.4%	84.1%	78.1%	86.6%
52.8	64.6%	33.4%	87.8%	35.4%	23.4%	50.1%	37.0%	20.7%	41.9%	72.4%	47.0%	87.0%	30.4%	17.4%	46.1%	88.7%	28.6%	96.4%	84.1%	78.1%	86.6%
52.9	64.5%	33.3%	87.8%	35.4%	23.4%	50.1%	37.0%	20.7%	41.9%	72.3%	47.0%	87.0%	30.3%	17.4%	46.1%	88.7%	28.2%	96.4%	84.0%	78.0%	86.5%
53	64.4%	33.2%	87.7%	35.4%	23.4%	50.1%	37.0%	20.7%	41.9%	72.3%	47.0%	87.0%	30.3%	17.3%	46.0%	88.7%	27.7%	96.4%	83.9%	78.0%	86.5%
53.1	64.3%	33.1%	87.7%	35.4%	23.4%	50.1%	37.0%	20.7%	41.9%	72.3%	47.0%	86.9%	30.2%	17.3%	45.9%	88.7%	27.1%	96.4%	83.9%	78.0%	86.5%
53.2	64.1%	33.0%	87.6%	35.4%	23.4%	50.1%	37.0%	20.7%	41.9%	72.2%	47.0%	86.9%	30.1%	17.2%	45.8%	88.7%	26.5%	96.4%	83.8%	78.0%	86.4%
53.3	64.0%	32.9%	87.6%	35.4%	23.4%	50.0%	37.0%	20.7%	41.9%	72.2%	47.0%	86.9%	30.0%	17.2%	45.7%	88.7%	25.9%	96.4%	83.7%	77.9%	86.4%
53.4	63.9%	32.8%	87.5%	35.4%	23.3%	50.0%	37.0%	20.7%	41.9%	72.1%	46.9%	86.9%	30.0%	17.1%	45.6%	88.7%	25.2%	96.4%	83.7%	77.9%	86.4%
53.5	63.8%	32.7%	87.5%	35.3%	23.3%	50.0%	37.0%	20.7%	41.9%	72.1%	46.9%	86.9%	29.9%	17.1%	45.5%	88.7%	24.6%	96.4%	83.6%	77.9%	86.3%
53.6	63.7%	32.6%	87.4%	35.3%	23.3%	50.0%	37.0%	20.7%	41.9%	72.1%	46.9%	86.9%	29.8%	17.0%	45.4%	88.7%	24.0%	96.4%	83.5%	77.9%	86.3%
53.7	63.6%	32.5%	87.4%	35.3%	23.3%	50.0%	37.0%	20.6%	41.9%	72.0%	46.9%	86.8%	29.8%	17.0%	45.3%	88.7%	23.4%	96.4%	83.5%	77.8%	86.2%

53.8         63.5%         32.4%         87.3%         35.3%         23.3%         49.9%         37.0%         20.5%         41.9%         72.0%         46.9%         86.8%         29.7%         16.9%         45.2%           53.9         63.4%         32.3%         87.3%         35.3%         23.3%         49.9%         37.0%         20.5%         41.9%         71.9%         46.9%         86.8%         29.6%         16.8%         45.2%           54         63.3%         32.2%         87.2%         35.3%         23.3%         49.9%         37.0%         20.5%         41.9%         71.9%         46.8%         86.8%         29.5%         16.8%         45.1%           54.1         63.2%         32.2%         87.2%         35.3%         23.3%         49.9%         37.0%         20.5%         41.9%         71.9%         46.8%         86.8%         29.5%         16.7%         45.0%           54.2         63.1%         32.1%         87.1%         35.3%         23.3%         49.9%         37.0%         20.5%         41.9%         71.8%         46.8%         86.8%         29.4%         16.7%         44.9%           54.3         63.0%         32.0%         87.1%         35.2	88.7%     22.9%     96.4%     83.4%     77.8%     86.2%       88.7%     22.4%     96.4%     83.3%     77.7%     86.2%       88.7%     21.9%     96.4%     83.2%     77.6%     86.1%       88.7%     21.5%     96.4%     83.2%     77.6%     86.1%       88.7%     21.0%     96.4%     83.1%     77.6%     86.0%       88.7%     20.5%     96.4%     83.0%     77.6%     86.0%       88.7%     20.1%     96.4%     83.0%     77.6%     86.0%
54     63.3%     32.2%     87.2%     35.3%     23.3%     49.9%     37.0%     20.5%     41.9%     71.9%     46.8%     86.8%     29.5%     16.8%     45.1%       54.1     63.2%     32.2%     87.2%     35.3%     23.3%     49.9%     37.0%     20.5%     41.9%     71.9%     46.8%     86.8%     29.5%     16.7%     45.0%       54.2     63.1%     32.1%     87.1%     35.3%     23.3%     49.9%     37.0%     20.5%     41.9%     71.8%     46.8%     86.8%     29.4%     16.7%     44.9%       54.3     63.0%     32.0%     87.1%     35.2%     23.3%     49.8%     37.0%     20.5%     41.9%     71.8%     46.8%     86.8%     29.3%     16.6%     44.8%	88.7%       21.9%       96.4%       83.2%       77.6%       86.1%         88.7%       21.5%       96.4%       83.2%       77.6%       86.1%         88.7%       21.0%       96.4%       83.1%       77.6%       86.0%         88.7%       20.5%       96.4%       83.0%       77.6%       86.0%
54.1     63.2%     32.2%     87.2%     35.3%     23.3%     49.9%     37.0%     20.5%     41.9%     71.9%     46.8%     86.8%     29.5%     16.7%     45.0%       54.2     63.1%     32.1%     87.1%     35.3%     23.3%     49.9%     37.0%     20.5%     41.9%     71.8%     46.8%     86.8%     29.4%     16.7%     44.9%       54.3     63.0%     32.0%     87.1%     35.2%     23.3%     49.8%     37.0%     20.5%     41.9%     71.8%     46.8%     86.8%     29.3%     16.6%     44.8%	88.7%       21.5%       96.4%       83.2%       77.6%       86.1%         88.7%       21.0%       96.4%       83.1%       77.6%       86.0%         88.7%       20.5%       96.4%       83.0%       77.6%       86.0%
54.2     63.1%     32.1%     87.1%     35.3%     23.3%     49.9%     37.0%     20.5%     41.9%     71.8%     46.8%     86.8%     29.4%     16.7%     44.9%       54.3     63.0%     32.0%     87.1%     35.2%     23.3%     49.8%     37.0%     20.5%     41.9%     71.8%     46.8%     86.8%     29.3%     16.6%     44.8%	88.7%       21.0%       96.4%       83.1%       77.6%       86.0%         88.7%       20.5%       96.4%       83.0%       77.6%       86.0%
54.3 63.0% 32.0% 87.1% 35.2% 23.3% 49.8% 37.0% 20.5% 41.9% 71.8% 46.8% 86.8% 29.3% 16.6% 44.8%	88.7% 20.5% 96.4% 83.0% 77.6% 86.0%
54.4 62.9% 31.9% 87.0% 35.2% 23.3% 49.8% 37.0% 20.5% 41.9% 71.8% 46.8% 86.7% 29.3% 16.6% 44.7%	88.7% 20.1% 96.4% 83.0% 77.6% 86.0%
54.5 62.8% 31.8% 87.0% 35.2% 23.3% 49.8% 37.0% 20.5% 41.9% 71.7% 46.8% 86.7% 29.2% 16.5% 44.6%	88.7% 19.7% 96.4% 82.9% 77.6% 85.9%
54.6 62.7% 31.7% 86.9% 35.2% 23.3% 49.8% 37.0% 20.4% 41.9% 71.7% 46.7% 86.7% 29.1% 16.4% 44.5%	88.7% 19.3% 96.4% 82.8% 77.5% 85.8%
54.7 62.6% 31.6% 86.9% 35.2% 23.3% 49.8% 37.0% 20.3% 41.9% 71.6% 46.7% 86.7% 29.0% 16.4% 44.4%	88.7% 18.8% 96.4% 82.7% 77.4% 85.8%
54.8 62.5% 31.5% 86.8% 35.2% 23.3% 49.8% 37.0% 20.3% 41.9% 71.6% 46.6% 86.7% 29.0% 16.3% 44.3%	88.7% 18.4% 96.4% 82.7% 77.4% 85.8%
54.9 62.4% 31.4% 86.8% 35.2% 23.3% 49.7% 37.0% 20.3% 41.9% 71.6% 46.6% 86.7% 28.9% 16.3% 44.3%	88.7% 18.0% 96.4% 82.6% 77.3% 85.8%
55 62.3% 31.3% 86.7% 35.2% 23.2% 49.7% 37.0% 20.3% 41.9% 71.5% 46.5% 86.6% 28.8% 16.2% 44.2%	88.7% 17.6% 96.4% 82.5% 77.3% 85.7%
55.1 62.2% 31.2% 86.7% 35.1% 23.2% 49.7% 37.0% 20.3% 41.9% 71.5% 46.4% 86.6% 28.8% 16.2% 44.1%	88.7% 17.2% 96.4% 82.5% 77.2% 85.7%
55.2 62.1% 31.1% 86.7% 35.1% 23.2% 49.7% 37.0% 20.3% 41.9% 71.4% 46.3% 86.5% 28.7% 16.1% 44.0%	88.7% 16.8% 96.4% 82.4% 77.2% 85.7%
55.3 62.0% 31.0% 86.6% 35.1% 23.2% 49.7% 37.0% 20.2% 41.9% 71.4% 46.3% 86.5% 28.6% 16.1% 43.9%	88.7% 16.4% 96.4% 82.3% 77.2% 85.6%
55.4 61.9% 30.9% 86.6% 35.1% 23.2% 49.7% 37.0% 20.2% 41.9% 71.4% 46.2% 86.5% 28.6% 16.0% 43.8%	88.7% 16.1% 96.4% 82.2% 77.1% 85.6%
55.5 61.8% 30.8% 86.5% 35.1% 23.2% 49.7% 37.0% 20.1% 41.9% 71.3% 46.1% 86.4% 28.5% 15.9% 43.7%	88.7% 15.6% 96.4% 82.2% 77.0% 85.6%
55.6 61.7% 30.7% 86.5% 35.1% 23.2% 49.6% 37.0% 20.0% 41.9% 71.3% 46.1% 86.4% 28.4% 15.9% 43.6%	88.7% 15.2% 96.4% 82.1% 76.9% 85.6%
55.7 61.6% 30.5% 86.4% 35.1% 23.2% 49.6% 37.0% 19.9% 41.9% 71.2% 46.0% 86.4% 28.3% 15.8% 43.5%	88.7% 14.8% 96.4% 82.0% 76.9% 85.5%
55.8 61.5% 30.4% 86.4% 35.1% 23.2% 49.6% 37.0% 19.8% 41.9% 71.2% 45.9% 86.3% 28.3% 15.8% 43.4%	88.7% 14.4% 96.4% 81.9% 76.9% 85.5%
55.9 61.4% 30.3% 86.3% 35.1% 23.2% 49.6% 37.0% 19.8% 41.9% 71.2% 45.8% 86.3% 28.2% 15.7% 43.4%	88.7% 14.0% 96.4% 81.9% 76.8% 85.4%
56 61.3% 30.2% 86.3% 35.1% 23.2% 49.6% 37.0% 19.8% 41.9% 71.1% 45.8% 86.3% 28.1% 15.7% 43.3%	88.7% 13.6% 96.4% 81.8% 76.7% 85.4%
56.1 61.2% 30.1% 86.2% 35.0% 23.1% 49.6% 37.0% 19.8% 41.9% 71.1% 45.7% 86.3% 28.1% 15.6% 43.2%	88.7% 13.2% 96.4% 81.7% 76.6% 85.4%
56.2 61.1% 30.0% 86.2% 35.0% 23.1% 49.6% 37.0% 19.7% 41.9% 71.0% 45.6% 86.3% 28.0% 15.6% 43.1%	88.7% 12.9% 96.4% 81.6% 76.5% 85.4%
56.3 61.0% 29.9% 86.1% 35.0% 23.1% 49.5% 37.0% 19.7% 41.9% 71.0% 45.5% 86.3% 27.9% 15.5% 43.0%	88.7% 12.5% 96.4% 81.6% 76.4% 85.3%
56.4 60.9% 29.8% 86.1% 35.0% 23.1% 49.5% 37.0% 19.7% 41.9% 71.0% 45.5% 86.3% 27.9% 15.5% 43.0%	88.7% 12.2% 96.4% 81.5% 76.4% 85.3%
56.5 60.8% 29.7% 86.0% 35.0% 23.1% 49.5% 37.0% 19.7% 41.9% 70.9% 45.4% 86.2% 27.8% 15.4% 42.9%	88.7% 12.0% 96.4% 81.4% 76.3% 85.3%
56.6 60.7% 29.6% 86.0% 35.0% 23.1% 49.5% 37.0% 19.7% 41.9% 70.9% 45.3% 86.2% 27.7% 15.4% 42.8%	88.7% 11.7% 96.4% 81.3% 76.2% 85.2%
56.7 60.6% 29.5% 85.9% 35.0% 23.1% 49.5% 37.0% 19.7% 41.9% 70.8% 45.3% 86.2% 27.7% 15.4% 42.8%	88.7% 11.4% 96.4% 81.2% 76.1% 85.2%
56.8 60.5% 29.4% 85.9% 35.0% 23.1% 49.5% 37.0% 19.7% 41.9% 70.8% 45.2% 86.2% 27.6% 15.3% 42.7%	88.7% 11.1% 96.4% 81.2% 76.0% 85.2%
56.9 60.4% 29.3% 85.8% 35.0% 23.1% 49.5% 37.0% 19.7% 41.9% 70.8% 45.1% 86.2% 27.5% 15.3% 42.6%	88.7% 10.8% 96.4% 81.1% 76.0% 85.2%

57	60.3%	29.2%	85.8%	35.0%	23.1%	49.5%	37.0%	19.7%	41.9%	70.7%	45.0%	86.2%	27.4%	15.2%	42.5%	88.7%	10.5%	96.4%	81.0%	75.9%	85.1%
57.1	60.2%	29.1%	85.7%	35.0%	23.1%	49.5%	37.0%	19.7%	41.9%				27.4%	15.2%	42.4%	88.7%	10.2%	96.4%	80.9%	75.8%	85.1%
57.2	60.2%	29.0%	85.7%	35.0%	23.1%	49.4%	37.0%	19.7%	41.9%				27.3%	15.1%	42.3%	88.7%	10.0%	96.4%	80.9%	75.7%	85.0%
57.3	60.1%	28.9%	85.6%	35.0%	23.1%	49.4%	37.0%	19.7%	41.8%				27.2%	15.1%	42.2%	88.7%	9.7%	96.4%	80.8%	75.6%	85.0%
57.4	60.0%	28.8%	85.6%	34.9%	23.1%	49.4%	37.0%	19.7%	41.8%				27.2%	15.0%	42.1%	88.7%	9.5%	96.4%	80.7%	75.5%	85.0%
57.5	59.9%	28.7%	85.5%	34.9%	23.1%	49.4%	37.0%	19.7%	41.8%				27.1%	14.9%	42.0%	88.7%	9.2%	96.4%	80.6%	75.3%	84.9%
57.6	59.8%	28.6%	85.5%	34.9%	23.1%	49.4%	37.0%	19.7%	41.8%				27.0%	14.9%	41.9%	88.7%	8.9%	96.4%	80.5%	75.2%	84.9%
57.7	59.7%	28.5%	85.4%	34.9%	23.1%	49.4%	37.0%	19.7%	41.8%				27.0%	14.8%	41.8%	88.7%	8.7%	96.4%	80.5%	75.1%	84.8%
57.8	59.6%	28.4%	85.4%	34.9%	23.1%	49.4%	37.0%	19.7%	41.8%				26.9%	14.8%	41.7%	88.7%	8.4%	96.4%	80.4%	75.0%	84.8%
57.9	59.5%	28.3%	85.4%	34.9%	23.1%	49.4%	37.0%	19.7%	41.8%				26.8%	14.7%	41.6%	88.7%	8.2%	96.4%	80.3%	74.8%	84.8%
58	59.5%	28.3%	85.3%	34.9%	23.1%	49.4%	37.0%	19.7%	41.8%				26.8%	14.7%	41.5%	88.7%	8.0%	96.4%	80.2%	74.7%	84.8%
58.1	59.4%	28.2%	85.3%	34.9%	23.1%	49.4%															
58.2	59.3%	28.1%	85.2%	34.9%	23.1%	49.4%															
58.3	59.2%	28.1%	85.2%	34.9%	23.1%	49.3%															
58.4	59.1%	28.0%	85.1%	34.9%	23.1%	49.3%															
58.5	59.0%	27.9%	85.1%	34.9%	23.1%	49.3%															
58.6	59.0%	27.9%	85.0%	34.9%	23.1%	49.3%															
58.7	58.9%	27.8%	85.0%	34.9%	23.1%	49.3%															
58.8	58.8%	27.7%	85.0%	34.9%	23.1%	49.3%															
58.9	58.7%	27.6%	84.9%	34.9%	23.1%	49.3%															
59	58.7%	27.5%	84.9%	34.9%	23.1%	49.3%															
59.1	58.6%	27.5%	84.8%	34.9%	23.1%	49.3%															
59.2	58.5%	27.4%	84.8%	34.9%	23.1%	49.3%															
59.3	58.4%	27.3%	84.7%	34.9%	23.1%	49.3%															
59.4	58.4%	27.3%	84.7%	34.9%	23.1%	49.3%															
59.5	58.3%	27.2%	84.6%	34.9%	23.1%	49.3%															
59.6	58.2%	27.1%	84.6%	34.9%	23.1%	49.3%															
59.7	58.2%	27.0%	84.6%	34.9%	23.1%	49.3%															
59.8	58.1%	27.0%	84.5%	34.8%	23.1%	49.3%															
59.9	58.0%	26.9%	84.5%	34.8%	23.0%	49.3%															
60	58.0%	26.8%	84.4%	34.8%	23.0%	49.3%															
60.1	57.9%	26.7%	84.4%	34.8%	23.0%	49.2%															

60.2	57.8%	26.7%	84.4%	34.8%	23.0%	49.2%
60.3	57.8%	26.6%	84.3%	34.8%	23.0%	49.1%
60.4	57.7%	26.5%	84.3%	34.8%	22.9%	49.1%
60.5	57.6%	26.4%	84.2%	34.8%	22.9%	49.0%
60.6	57.6%	26.3%	84.2%	34.8%	22.9%	49.0%
60.7	57.5%	26.3%	84.2%	34.8%	22.8%	49.0%
60.8	57.4%	26.2%	84.1%	34.8%	22.8%	49.0%
60.9	57.4%	26.2%	84.1%	34.8%	22.7%	49.0%
61	57.3%	26.1%	84.0%	34.8%	22.7%	49.0%
61.1	57.3%	26.1%	84.0%	34.8%	22.7%	49.0%
61.2	57.2%	26.0%	84.0%	34.8%	22.6%	49.0%
61.3	57.2%	26.0%	83.9%	34.8%	22.6%	49.0%
61.4	57.1%	25.9%	83.9%	34.8%	22.6%	49.0%
61.5	57.1%	25.8%	83.8%	34.8%	22.6%	48.9%
61.6	57.0%	25.8%	83.8%	34.8%	22.6%	48.9%
61.7	56.9%	25.7%	83.8%	34.8%	22.6%	48.8%
61.8	56.9%	25.7%	83.7%	34.9%	22.6%	48.8%
61.9	56.8%	25.6%	83.7%	34.9%	22.6%	48.8%
62	56.8%	25.6%	83.6%	34.9%	22.6%	48.8%
62.1	56.7%	25.6%	83.6%	34.9%	22.6%	48.8%
62.2	56.7%	25.5%	83.6%	34.9%	22.6%	48.8%
62.3	56.7%	25.5%	83.5%	34.9%	22.6%	48.8%
62.4	56.6%	25.4%	83.5%	34.9%	22.6%	48.8%
62.5	56.6%	25.4%	83.5%	34.9%	22.6%	48.8%
62.6	56.5%	25.4%	83.4%	34.9%	22.6%	48.8%
62.7	56.5%	25.3%	83.4%	34.9%	22.6%	48.8%
62.8	56.4%	25.3%	83.4%	34.9%	22.6%	48.7%
62.9	56.4%	25.3%	83.3%	34.9%	22.6%	48.7%
63	56.4%	25.3%	83.3%	34.9%	22.6%	48.7%
63.1	56.3%	25.2%	83.3%	34.9%	22.6%	48.7%
63.2	56.3%	25.2%	83.2%	34.9%	22.6%	48.7%
63.3	56.2%	25.2%	83.2%	34.9%	22.6%	48.7%

63.4	56.2%	25.1%	83.2%	34.9%	22.6%	48.79
63.5	56.2%	25.1%	83.1%	34.9%	22.6%	48.79
63.6	56.1%	25.1%	83.1%	34.9%	22.6%	48.69
63.7	56.1%	25.1%	83.1%	34.9%	22.6%	48.69
63.8	56.1%	25.0%	83.0%	34.9%	22.6%	48.6%
63.9	56.0%	25.0%	83.0%	34.9%	22.6%	48.5%
64	56.0%	25.0%	83.0%	34.9%	22.6%	48.5%
64.1	56.0%	25.0%	83.0%	34.9%	22.6%	48.59
64.2	55.9%	25.0%	83.0%	34.9%	22.6%	48.5%
64.3	55.9%	24.9%	82.9%	34.9%	22.6%	48.59
64.4	55.9%	24.9%	82.9%	34.9%	22.6%	48.59
64.5	55.9%	24.9%	82.9%	34.9%	22.6%	48.49
64.6	55.8%	24.8%	82.9%	34.9%	22.6%	48.49
64.7	55.8%	24.8%	82.9%	34.9%	22.6%	48.39
64.8	55.8%	24.7%	82.9%	34.9%	22.5%	48.29
64.9	55.8%	24.6%	82.8%	34.9%	22.5%	48.29
65	55.7%	24.6%	82.8%	34.9%	22.5%	48.29
65.1	55.7%	24.5%	82.8%	34.9%	22.5%	48.29
65.2	55.7%	24.5%	82.8%	34.9%	22.5%	48.29
65.3	55.7%	24.4%	82.8%	34.9%	22.5%	48.29
65.4	55.7%	24.3%	82.8%	34.9%	22.5%	48.29
65.5	55.6%	24.3%	82.8%	34.8%	22.5%	48.29
65.6	55.6%	24.2%	82.8%	34.8%	22.5%	48.29
65.7	55.6%	24.2%	82.7%	34.8%	22.4%	48.29
65.8	55.6%	24.2%	82.7%	34.8%	22.4%	48.29
65.9	55.6%	24.2%	82.7%	34.8%	22.4%	48.29
66	55.6%	24.2%	82.7%	34.8%	22.4%	48.29
66.1	55.6%	24.2%	82.7%	34.8%	22.4%	48.29
66.2	55.5%	24.2%	82.7%	34.8%	22.4%	48.29
66.3	55.5%	24.2%	82.7%	34.8%	22.4%	48.19
66.4	55.5%	24.2%	82.7%	34.7%	22.3%	48.19
66.5	55.5%	24.1%	82.7%	34.7%	22.3%	48.19

66.6	55.5%	24.0%	82.7%	34.7%	22.3%	48.1%
66.7	55.5%	24.0%	82.7%	34.7%	22.3%	48.0%
66.8	55.5%	23.9%	82.7%	34.7%	22.3%	48.0%
66.9	55.5%	23.8%	82.7%	34.7%	22.2%	48.0%
67	55.5%	23.8%	82.7%	34.7%	22.2%	47.9%
67.1	55.5%	23.7%	82.7%	34.6%	22.1%	47.9%
67.2	55.5%	23.7%	82.7%	34.6%	22.1%	47.8%
67.3	55.5%	23.7%	82.7%	34.6%	22.1%	47.8%
67.4	55.5%	23.7%	82.7%	34.6%	22.1%	47.8%
67.5	55.5%	23.7%	82.7%	34.6%	22.1%	47.7%
67.6	55.5%	23.6%	82.7%	34.5%	22.1%	47.7%
67.7	55.5%	23.6%	82.7%	34.5%	22.1%	47.6%
67.8	55.5%	23.6%	82.7%	34.5%	22.0%	47.6%
67.9	55.5%	23.6%	82.7%	34.5%	22.0%	47.5%
68	55.5%	23.5%	82.7%	34.5%	22.0%	47.5%
68.1	55.5%	23.5%	82.7%	34.4%	22.0%	47.5%
68.2	55.5%	23.5%	82.6%	34.4%	22.0%	47.4%
68.3	55.5%	23.5%	82.6%	34.4%	22.0%	47.4%
68.4	55.5%	23.5%	82.6%	34.4%	22.0%	47.4%
68.5	55.5%	23.4%	82.6%	34.3%	22.0%	47.4%
68.6	55.5%	23.4%	82.6%	34.3%	22.0%	47.4%
68.7	55.5%	23.4%	82.6%	34.3%	22.0%	47.4%
68.8	55.5%	23.4%	82.6%	34.3%	22.0%	47.4%
68.9	55.5%	23.4%	82.5%	34.2%	22.0%	47.4%
69	55.5%	23.3%	82.5%	34.2%	22.0%	47.4%
69.1	55.5%	23.3%	82.5%	34.2%	22.0%	47.4%
69.2	55.5%	23.3%	82.5%	34.1%	22.0%	47.4%
69.3	55.5%	23.3%	82.5%	34.1%	21.9%	47.4%
69.4	55.5%	23.3%	82.5%	34.1%	21.9%	47.4%
69.5	55.5%	23.2%	82.5%	34.1%	21.8%	47.4%
69.6	55.5%	23.2%	82.4%	34.0%	21.7%	47.4%
69.7	55.5%	23.2%	82.4%	34.0%	21.7%	47.3%

69.8	55.5%	23.2%	82.4%	34.0%	21.6%	47.3%
69.9	55.5%	23.2%	82.4%	33.9%	21.6%	47.2%
70	55.5%	23.1%	82.4%	33.9%	21.5%	47.1%
70.1	55.5%	23.1%	82.4%	33.9%	21.4%	47.0%
70.2	55.5%	23.1%	82.4%	33.8%	21.4%	47.0%
70.3	55.5%	23.1%	82.3%	33.8%	21.3%	47.0%
70.4	55.5%	23.1%	82.3%	33.7%	21.3%	47.0%
70.5	55.5%	23.0%	82.3%	33.7%	21.2%	46.9%
70.6	55.5%	23.0%	82.3%	33.7%	21.1%	46.9%
70.7	55.5%	23.0%	82.3%	33.6%	21.1%	46.8%
70.8	55.5%	22.9%	82.3%	33.6%	21.0%	46.8%
70.9	55.5%	22.8%	82.3%	33.6%	21.0%	46.7%
71	55.5%	22.8%	82.2%	33.5%	20.9%	46.7%
71.1	55.5%	22.7%	82.2%	33.5%	20.9%	46.6%
71.2	55.5%	22.6%	82.2%	33.4%	20.9%	46.6%
71.3	55.5%	22.6%	82.2%	33.4%	20.8%	46.6%
71.4	55.5%	22.5%	82.2%	33.4%	20.8%	46.6%
71.5	55.5%	22.4%	82.2%	33.3%	20.8%	46.6%
71.6	55.5%	22.4%	82.2%	33.3%	20.7%	46.5%
71.7	55.5%	22.4%	82.1%	33.2%	20.7%	46.4%
71.8	55.5%	22.4%	82.1%	33.2%	20.6%	46.3%
71.9	55.5%	22.4%	82.1%	33.2%	20.6%	46.2%
72	55.5%	22.4%	82.1%	33.1%	20.6%	46.1%
72.1	55.5%	22.4%	82.1%	33.1%	20.5%	46.1%
72.2	55.5%	22.4%	82.1%	33.0%	20.5%	46.1%
72.3	55.5%	22.4%	82.1%	33.0%	20.4%	46.1%
72.4	55.5%	22.3%	82.0%	32.9%	20.4%	46.1%
72.5	55.5%	22.3%	82.0%	32.9%	20.3%	46.0%
72.6	55.5%	22.3%	82.0%	32.8%	20.3%	46.0%
72.7	55.5%	22.2%	82.0%	32.8%	20.2%	46.0%
72.8	55.5%	22.2%	82.0%	32.7%	20.2%	46.0%
72.9	55.5%	22.2%	82.0%	32.7%	20.1%	46.0%

73	55.5%	22.2%	82.0%	32.6%	20.1%	46.0%
73.1	55.5%	22.2%	82.0%	32.6%	20.0%	46.0%
73.2	55.5%	22.1%	82.0%	32.5%	20.0%	46.0%
73.3	55.5%	22.1%	81.9%	32.5%	19.9%	46.0%
73.4	55.5%	22.0%	81.9%	32.4%	19.9%	46.0%
73.5	55.5%	21.9%	81.9%	32.4%	19.8%	46.0%
73.6	55.5%	21.9%	81.9%	32.3%	19.8%	45.9%
73.7	55.5%	21.8%	81.9%	32.3%	19.7%	45.9%
73.8	55.5%	21.8%	81.8%	32.2%	19.7%	45.8%
73.9	55.5%	21.8%	81.8%	32.2%	19.6%	45.8%
74	55.5%	21.7%	81.8%	32.1%	19.6%	45.7%
74.1	55.5%	21.7%	81.8%	32.1%	19.5%	45.6%
74.2	55.5%	21.7%	81.8%	32.0%	19.5%	45.5%
74.3	55.5%	21.6%	81.8%	32.0%	19.4%	45.4%
74.4	55.5%	21.6%	81.8%	31.9%	19.4%	45.3%
74.5	55.5%	21.5%	81.8%	31.8%	19.3%	45.3%
74.6	55.5%	21.5%	81.8%	31.8%	19.2%	45.2%
74.7	55.5%	21.5%	81.8%	31.7%	19.1%	45.0%
74.8	55.5%	21.5%	81.8%	31.7%	19.0%	44.9%
74.9	55.5%	21.5%	81.8%	31.6%	19.0%	44.9%
75	55.5%	21.4%	81.8%	31.6%	18.9%	44.9%
75.1	55.5%	21.4%	81.8%	31.5%	18.9%	44.9%
75.2	55.5%	21.3%	81.8%	31.4%	18.8%	44.8%
75.3	55.5%	21.3%	81.8%	31.4%	18.7%	44.8%
75.4	55.5%	21.2%	81.8%	31.3%	18.6%	44.7%
75.5	55.5%	21.2%	81.8%	31.3%	18.5%	44.7%
75.6	55.5%	21.1%	81.8%	31.2%	18.5%	44.7%
75.7	55.5%	21.1%	81.8%	31.2%	18.4%	44.7%
75.8	55.5%	21.0%	81.8%	31.1%	18.3%	44.7%
75.9	55.5%	21.0%	81.8%	31.0%	18.2%	44.7%
76	55.5%	20.9%	81.8%	31.0%	18.1%	44.7%
76.1	55.5%	20.9%	81.8%	30.9%	17.9%	44.7%

76.2	55.5%	20.8%	81.8%	30.9%	17.8%	44.7%
76.3	55.5%	20.8%	81.8%	30.8%	17.7%	44.7%
76.4	55.5%	20.7%	81.8%	30.8%	17.6%	44.7%
76.5	55.5%	20.7%	81.8%	30.7%	17.4%	44.7%
76.6	55.5%	20.6%	81.8%	30.6%	17.3%	44.7%
76.7	55.5%	20.5%	81.8%	30.6%	17.2%	44.7%
76.8	55.5%	20.4%	81.8%	30.5%	17.2%	44.7%
76.9	55.5%	20.3%	81.8%	30.5%	17.1%	44.7%
77	55.5%	20.2%	81.8%	30.4%	17.0%	44.7%
77.1	55.5%	20.1%	81.8%	30.4%	16.9%	44.7%
77.2	55.5%	20.1%	81.8%	30.3%	16.7%	44.7%
77.3	55.5%	20.0%	81.8%	30.3%	16.7%	44.7%
77.4	55.5%	19.9%	81.8%	30.2%	16.6%	44.7%
77.5	55.5%	19.8%	81.8%	30.1%	16.6%	44.7%
77.6	55.5%	19.7%	81.8%	30.1%	16.5%	44.7%
77.7	55.5%	19.6%	81.8%	30.0%	16.4%	44.7%
77.8	55.5%	19.5%	81.8%	30.0%	16.4%	44.7%
77.9	55.5%	19.5%	81.8%	29.9%	16.4%	44.7%
78	55.5%	19.4%	81.8%	29.9%	16.3%	44.7%
78.1	55.5%	19.3%	81.8%	29.8%	16.2%	44.7%
78.2	55.5%	19.3%	81.8%	29.8%	16.2%	44.7%
78.3	55.5%	19.2%	81.8%	29.7%	16.1%	44.6%
78.4	55.5%	19.2%	81.8%	29.6%	16.0%	44.6%
78.5	55.5%	19.1%	81.8%	29.6%	16.0%	44.5%
78.6	55.5%	19.1%	81.8%	29.5%	15.9%	44.5%
78.7	55.5%	19.0%	81.8%	29.5%	15.8%	44.4%
78.8	55.5%	19.0%	81.8%	29.4%	15.7%	44.4%
78.9	55.5%	18.9%	81.8%	29.4%	15.6%	44.3%
79	55.5%	18.9%	81.8%	29.3%	15.5%	44.2%
79.1	55.5%	18.9%	81.8%	29.3%	15.4%	44.1%
79.2	55.5%	18.9%	81.8%	29.2%	15.4%	44.0%
79.3	55.5%	18.9%	81.8%	29.1%	15.4%	44.0%

79.4	55.5%	18.9%	81.8%	29.1%	15.3%	44.0%
79.5	55.5%	18.9%	81.8%	29.0%	15.3%	44.0%
79.6	55.5%	18.9%	81.7%	29.0%	15.2%	43.9%
79.7	55.5%	18.9%	81.7%	28.9%	15.1%	43.9%
79.8	55.5%	18.9%	81.7%	28.9%	15.1%	43.8%
79.9	55.5%	18.8%	81.7%	28.8%	15.0%	43.8%
80	55.5%	18.8%	81.7%	28.8%	14.9%	43.8%
80.1				28.7%	14.9%	43.8%
80.2				28.7%	14.8%	43.8%
80.3				28.6%	14.7%	43.8%
80.4				28.6%	14.6%	43.8%
80.5				28.5%	14.6%	43.8%
80.6				28.4%	14.5%	43.8%
80.7				28.4%	14.5%	43.8%
80.8				28.3%	14.4%	43.8%
80.9				28.3%	14.3%	43.8%
81				28.2%	14.2%	43.8%
81.1				28.2%	14.2%	43.8%
81.2				28.1%	14.1%	43.8%
81.3				28.1%	14.0%	43.8%
81.4				28.0%	13.8%	43.8%
81.5				28.0%	13.7%	43.7%
81.6				27.9%	13.6%	43.7%
81.7				27.9%	13.6%	43.7%
81.8				27.8%	13.5%	43.7%
81.9				27.7%	13.4%	43.7%
82				27.7%	13.3%	43.7%
82.1				27.6%	13.2%	43.7%
82.2				27.6%	13.1%	43.7%
82.3				27.5%	13.0%	43.7%
82.4				27.5%	13.0%	43.7%
82.5				27.4%	12.9%	43.7%

82.6	27.4%	12.8%	43.7%
82.7	27.3%	12.8%	43.7%
82.8	27.3%	12.7%	43.6%
82.9	27.2%	12.7%	43.6%
83	27.2%	12.6%	43.5%
83.1	27.1%	12.6%	43.4%
83.2	27.1%	12.5%	43.3%
83.3	27.0%	12.4%	43.2%
83.4	27.0%	12.4%	43.2%
83.5	26.9%	12.3%	43.2%
83.6	26.9%	12.2%	43.2%
83.7	26.8%	12.1%	43.2%
83.8	26.8%	12.0%	43.2%
83.9	26.7%	12.0%	43.2%
84	26.7%	12.0%	43.2%
84.1	26.6%	11.9%	43.2%
84.2	26.5%	11.8%	43.2%
84.3	26.5%	11.7%	43.2%
84.4	26.4%	11.7%	43.2%
84.5	26.4%	11.6%	43.2%
84.6	26.3%	11.5%	43.2%
84.7	26.3%	11.4%	43.2%
84.8	26.2%	11.3%	43.2%
84.9	26.2%	11.3%	43.2%
85	26.1%	11.2%	43.2%
85.1	26.1%	11.1%	43.2%
85.2	26.0%	11.1%	43.2%
85.3	26.0%	11.0%	43.2%
85.4	25.9%	10.9%	43.2%
85.5	25.9%	10.8%	43.2%
85.6	25.8%	10.8%	43.2%
85.7	25.8%	10.7%	43.2%

85.8	25.7%	10.6%	43.2%
85.9	25.7%	10.6%	43.2%
86	25.6%	10.5%	43.2%

Table S3 Risk of Bias Assessment for Case-Control Studies

First	1	2	3	4	5	6	7	8	9	10	11	12	Rating
author's name													
Altarawneh H <sup>5</sup>	Yes	Yes	n/a	Yes	Yes	Yes	No	NR	Yes	No	n/a	Yes	Good
Rane M <sup>6</sup>	Yes	Yes	n/a	Yes	Yes	Yes	NR	NR	Yes	No	n/a	Yes	Good
Wang X <sup>24</sup>	Yes	Yes	n/a	NR	No	No	NR	NR	Yes	No	n/a	Yes	Poor
Altarawneh H <sup>26</sup>	Yes	Yes	n/a	Yes	Yes	Yes	No	NR	Yes	No	n/a	No	Fair
Cerqueira- Silva T <sup>28</sup>	Yes	Yes	n/a	Yes	Yes	Yes	No	NR	Yes	No	n/a	Yes	Good
Carazo S <sup>67</sup>	Yes	Yes	n/a	Yes	Yes	Yes	Yes	NR	Yes	No	n/a	Yes	Good
Vitale J <sup>14</sup>	No	Yes	n/a	Yes	Yes	Yes	CD	NR	Yes	No	n/a	Yes	Fair
Willett B <sup>25</sup>	Yes	Yes	n/a	Yes	Yes	No	NR	NR	Yes	No	n/a	Yes	poor
Chin E <sup>40</sup>	Yes	Yes	n/a	Yes	Yes	Yes	No	NR	Yes	No	n/a	Yes	Good
Ayoub H <sup>42</sup>	Yes	Yes	n/a	Yes	Yes	Yes	No	NR	Yes	No	n/a	Yes	Good
Carazo S <sup>29</sup>	Yes	Yes	n/a	Yes	Yes	Yes	Yes	NR	Yes	Yes	NR	Yes	Good
Altarawneh H <sup>68</sup>	Yes	Yes	n/a	Yes	Yes	Yes	NR	NR	Yes	Yes	No	No	Fair
Powell A <sup>57</sup>	Yes	Yes	n/a	Yes	Yes	Yes	NR	NR	Yes	Yes	no	Yes	Fair
Corrao G <sup>60</sup>	Yes	Yes	No	Yes	Yes	Yes	yes	NR	Yes	Yes	no	Yes	Fair

n/a = not available; NR = not reported; CD, cannot determine.

Quality Assessment for Case-Control Studies (<a href="https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools">https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools</a>):

- 1. Was the research question or objective in this paper clearly stated and appropriate?
- 2. Was the study population clearly specified and defined?
- 3. Did the authors include a sample size justification?
- 4. Were controls selected or recruited from the same or similar population that gave rise to the cases (including the same timeframe)?
- 5. Were the definitions, inclusion and exclusion criteria, algorithms or processes used to identify or select cases and controls valid, reliable, and implemented consistently across all study participants?
- 6. Were the cases clearly defined and differentiated from controls?
- 7. If less than 100 percent of eligible cases and/or controls were selected for the study, were the cases and/or controls randomly selected from those eligible?
- 8. Was there use of concurrent controls?
- 9. Were the investigators able to confirm that the exposure/risk occurred prior to the development of the condition or event that defined a participant as a case?
- 10. Were the measures of exposure/risk clearly defined, valid, reliable, and implemented consistently (including the same time period) across all study participants?

- 11. Were the assessors of exposure/risk blinded to the case or control status of participants?
- 12. Were key potential confounding variables measured and adjusted statistically in the analyses? If matching was used, did the investigators account for matching during study analysis?

Table S4	Risk of Rias	Assessment for	<b>Cohort Studies</b>

Table 54					ior Cor	1				1.0	1.1	10	1.0	1.4	ъ
First	1	2	3	4	5	6	7	8	9	10	11	12	13	14	Rating
author's															
name Smid M <sup>7</sup>	Yes	Yes	NR	Yes	n/a	No	Yes	n/a	n/a	n/a	Yes	n/a	NR	Yes	Poor
Hall V <sup>10</sup>	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	NR	Yes	Yes	Good
	Yes	Yes	Yes	Yes	No	No	Yes				Yes	<del>                                     </del>	Yes	Yes	
Lumley S <sup>18</sup>								n/a	n/a	n/a		n/a			Fair
Hansen C <sup>4</sup>	Yes	Yes	Yes	Yes	n/a	No	Yes	n/a	n/a	n/a	Yes	n/a	Yes	Yes	Fair
Pilz S <sup>11</sup>	Yes	Yes	Yes	Yes	n/a	No	Yes	n/a	n/a	n/a	Yes	n/a	Yes	No	Fair
Sheehan M <sup>13</sup>	Yes	Yes	Yes	Yes	n/a	No	Yes	n/a	n/a	n/a	Yes	n/a	Yes	No	Fair
Wilkins J <sup>15</sup>	Yes	Yes	Yes	Yes	No	No	Yes	n/a	n/a	n/a	Yes	n/a	No	Yes	Fair
Letizia A <sup>16</sup>	Yes	Yes	Yes	Yes	n/a	Yes	Yes	No	No	No	Yes	n/a	Yes	Yes	Good
Abo-Leyah H <sup>17</sup>	Yes	Yes	Yes	Yes	n/a	No	Yes	n/a	n/a	n/a	Yes	n/a	NR	No	Fair
Leidi A <sup>21</sup>	Yes	Yes	Yes	Yes	No	No	Yes	n/a	n/a	n/a	Yes	n/a	Yes	No	Poor
Starrfelt J <sup>27</sup>	Yes	Yes	Yes	Yes	n/a	No	Yes	n/a	n/a	n/a	Yes	n/a	NR	Yes	Fair
Nordstrom P <sup>30</sup>	Yes	Yes	Yes	Yes	n/a	No	Yes	n/a	n/a	n/a	Yes	n/a	Yes	Yes	Fair
Gallais F <sup>34</sup>	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No	No	Yes	No	Yes	No	Fair
Krutikov M <sup>35</sup>	Yes	Yes	Yes	Yes	No	No	Yes	n/a	n/a	n/a	Yes	n/a	NR	Yes	Fair
Harvey R <sup>36</sup>	Yes	Yes	Yes	Yes	No	No	Yes	n/a	n/a	n/a	Yes	n/a	No	No	Poor
Maier H <sup>37</sup>	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No	No	Yes	NR	Yes	No	Fair
Chemaitelly H <sup>38</sup>	Yes	Yes	Yes	Yes	n/a	No	Yes	n/a	n/a	n/a	Yes	n/a	Yes	Yes	Fair
Satwik R <sup>39</sup>	No	Yes	Yes	Yes	No	No	Yes	n/a	n/a	n/a	Yes	n/a	Yes	Yes	Fair
Hall V <sup>9</sup>	Yes	Yes	Yes	Yes	n/a	Yes	Yes	No	No	Yes	Yes	NR	Yes	Yes	Good
Rennert L <sup>12</sup>	Yes	Yes	Yes	Yes	No	No	Yes	n/a	n/a	n/a	Yes	n/a	Yes	Yes	Fair
Berec L <sup>69</sup>	Yes	Yes	Yes	Yes	n/a	No	Yes	n/a	n/a	n/a	Yes	n/a	NR	Yes	Fair
Pouwels K <sup>22</sup>	Yes	Yes	Yes	Yes	n/a	Yes	Yes	Yes	No	Yes	Yes	NR	Yes	Yes	Good
Pritchard E <sup>23</sup>	Yes	Yes	Yes	Yes	n/a	Yes	Yes	Yes	No	Yes	Yes	NR	Yes	Yes	Good
Abu-Raddad L <sup>8</sup>	Yes	Yes	Yes	Yes	n/a	Yes	Yes	No	No	NR	Yes	NR	Yes	Yes	Fair
Breathnach A <sup>19</sup>	Yes	Yes	Yes	Yes	No	No	Yes	n/a	n/a	n/a	Yes	n/a	Yes	No	Fair
Manica M <sup>70</sup>	No	Yes	Yes	Yes	No	No	Yes	n/a	n/a	n/a	Yes	n/a	NR	No	Poor
Jeffery- Smith A <sup>33</sup>	No	Yes	Yes	Yes	No	No	Yes	n/a	n/a	n/a	Yes	n/a	Yes	No	Poor

Chemaitelly H <sup>43</sup>	Yes	Yes	No	Yes	n/a	No	Yes	n/a	n/a	n/a	Yes	n/a	Yes	Yes	Fair
Braeye T <sup>41</sup>	Yes	Yes	Yes	Yes	n/a	No	Yes	n/a	n/a	n/a	Yes	n/a	Yes	Yes	Fair
Office for National Statistics <sup>31</sup>	Yes	Yes	Yes	Yes	Yes	No	Yes	No	No	Yes	Yes	NR	NR	Yes	Good
Petras M <sup>44</sup>	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes	No	Yes	No	Yes	Yes	Good
Abu-Raddad LJ <sup>46</sup>	Yes	Yes	yes	Yes	n/a	Yes	Yes	No	Yes	No	Yes	NR	Yes	No	Fair
Bertollini R <sup>47</sup>	No	Yes	No	Yes	No	Yes	Yes	No	Yes	No	Yes	No	Yes	No	Poor
Chemaitelly H <sup>48</sup>	Yes	Yes	Yes	Yes	n/a	Yes	Yes	No	Yes	No	Yes	NR	Yes	Yes	Good
Vicentini M <sup>49</sup>	Yes	Yes	Yes	Yes	n/a	Yes	Yes	No	Yes	No	Yes	NR	Yes	Yes	Good
Abu-Raddad LJ <sup>50</sup>	No	Yes	No	Yes	No	Yes	Yes	No	Yes	No	Yes	No	Yes	Yes	Fair
Michlmayr D <sup>51</sup>	Yes	Yes	Yes	Yes	n/a	Yes	Yes	No	Yes	No	Yes	NR	Yes	Yes	Good
Lacy J <sup>52</sup>	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes	No	Yes	No	NR	No	Fair
Ridgway JP <sup>53</sup>	Yes	CD	NR	Yes	n/a	Yes	Yes	No	No	No	Yes	NR	NR	Yes	Poor
Spicer KB <sup>54</sup>	Yes	Yes	Yes	Yes	n/a	Yes	Yes	No	Yes	No	yes	NR	Yes	No	Fair
Cohen C <sup>55</sup>	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes	No	yes	No	Yes	Yes	Good
Sun K <sup>56</sup>	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes	No	yes	No	Yes	Yes	Good
Andeweg S <sup>66</sup>	Yes	Yes	NR	Yes	NA	Yes	Yes	No	Yes	No	yes	NR	NR	No	Poor
Murugesan M <sup>58</sup>	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes	No	yes	No	Yes	No	Fair
Dhumal S <sup>59</sup>	Yes	Yes	Yes	Yes	NA	Yes	Yes	No	Yes	No	yes	No	Yes	Yes	Good

Narrainen F <sup>63</sup>	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes	No	yes	No	Yes	No	Fair
Reynolds S <sup>62</sup>	Yes	Yes	Yes	Yes	NA	Yes	Yes	No	Yes	No	yes	Yes	Yes	Yes	Good
Kubale J <sup>64</sup>	Yes	Yes	Yes	Yes	NA	Yes	Yes	No	Yes	No	yes	No	Yes	No	Fair
Rothberg M <sup>65</sup>	Yes	Yes	Yes	Yes	NA	Yes	Yes	No	Yes	No	yes	No	Yes	Yes	Good
Smolenov I <sup>61</sup>	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes	No	yes	Yes	Yes	No	Fair

n/a = not available NR = not reported

## Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies (https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools):

- 1. Was the research question or objective in this paper clearly stated?
- 2. Was the study population clearly specified and defined?
- 3. Was the participation rate of eligible persons at least 50%?
- 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?
- 5. Was a sample size justification, power description, or variance and effect estimates provided?
- 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?
- 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?
- 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?
- 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?
- 10. Was the exposure(s) assessed more than once over time?
- 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?
- 12. Were the outcome assessors blinded to the exposure status of participants?
- 13. Was loss to follow-up after baseline 20% or less?
- 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?

## Section 5 Reference list

- 1. Stevens, G. A. *et al.* Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. *The Lancet* **388**, e19–e23 (2016).
- Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ n71 (2021) doi:10.1136/bmj.n71.
- 3. Berec, L. *et al.* Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia. *PLOS ONE* **17**, e0270801 (2022).
- Hansen, C. H., Michlmayr, D., Gubbels, S. M., Mølbak, K. & Ethelberg, S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. *Lancet Lond. Engl.* 397, 1204–1212 (2021).
- Altarawneh, H. N. et al. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. N. Engl. J. Med. 386, 1288–1290 (2022).
- Rane, M. S. et al. Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2
  infections in an urgent care setting. http://medrxiv.org/lookup/doi/10.1101/2022.02.21.22271298 (2022)
  doi:10.1101/2022.02.21.22271298.
- 7. Šmíd, M. *et al.* Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2. *J. Infect. Dis.* jiac161 (2022) doi:10.1093/infdis/jiac161.
- 8. Abu-Raddad, L. J. *et al.* SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. *EClinicalMedicine* **35**, 100861 (2021).
- Hall, V. J. et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet Lond. Engl. 397, 1459– 1469 (2021).
- Hall, V. et al. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. N. Engl. J. Med. 386, 1207–1220 (2022).
- 11. Pilz, S. et al. SARS-CoV-2 re-infection risk in Austria. Eur. J. Clin. Invest. 51, (2021).
- 12. Rennert, L. & McMahan, C. Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in a University Student Population. *Clin. Infect. Dis.* **74**, 719–722 (2022).
- 13. Sheehan, M. M., Reddy, A. J. & Rothberg, M. B. Reinfection Rates Among Patients Who Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study. *Clin. Infect. Dis.* **73**, 1882–1886 (2021).

- 14. Vitale, J. *et al.* Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy. *JAMA Intern. Med.* **181**, 1407 (2021).
- 15. Wilkins, J. T. *et al.* Serologic Status and SARS-CoV-2 Infection over 6 Months of Follow Up in Healthcare Workers in Chicago: A Cohort Study. *Infect. Control Hosp. Epidemiol.* 1–9 (2021) doi:10.1017/ice.2021.367.
- 16. Letizia, A. G. *et al.* SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. *Lancet Respir. Med.* **9**, 712–720 (2021).
- 17. Abo-Leyah, H. *et al.* The protective effect of SARS-CoV-2 antibodies in Scottish healthcare workers. *ERJ Open Res.* **7**, 00080–02021 (2021).
- Lumley, S. F. et al. An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status. Clin. Infect. Dis. 74, 1208–1219 (2022).
- 19. Breathnach, A. S. *et al.* Prior COVID-19 significantly reduces the risk of subsequent infection, but reinfections are seen after eight months. *J. Infect.* **82**, e11–e12 (2021).
- 20. Manica, M. *et al.* Risk of Symptomatic Infection During a Second Coronavirus Disease 2019 Wave in Severe Acute Respiratory Syndrome Coronavirus 2–Seropositive Individuals. *Clin. Infect. Dis.* **74**, 893–896 (2022).
- Leidi, A. et al. Risk of Reinfection After Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score Matched Cohort Study. Clin. Infect. Dis. 74, 622–629 (2022).
- 22. Pouwels, K. B. *et al.* Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. *Nat. Med.* **27**, 2127–2135 (2021).
- Pritchard, E. *et al.* Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. *Nat. Med.* 1370–1378 (2021).
- Wang, X., Zein, J., Ji, X. & Lin, D.-Y. Impact of Vaccination, Prior Infection, and Therapy on Delta and Omicron Variants. http://medrxiv.org/lookup/doi/10.1101/2022.03.24.22272901 (2022) doi:10.1101/2022.03.24.22272901.
- 25. Willett, B. J. *et al.* SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. *Nat. Microbiol.* **7**, 1161–1179 (2022).

- Altarawneh, H. N. et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N. Engl. J. Med. 387, 21–34 (2022).
- Starrfelt, J. et al. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021. BMC Med. 20, 278 (2022).
- 28. Cerqueira-Silva, T. *et al.* Vaccination plus previous infection: protection during the omicron wave in Brazil. *Lancet Infect. Dis.* S1473309922002882 (2022) doi:10.1016/S1473-3099(22)00288-2.
- Carazo, S. et al. Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study. *Lancet Infect. Dis.* S1473-3099(22)00578–3 (2022) doi:10.1016/S1473-3099(22)00578-3.
- Nordström, P., Ballin, M. & Nordström, A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. *Lancet Infect. Dis.* 22, 781–790 (2022).
- 31. Coronavirus (COVID-19) Infection Survey, characteristics of people testing positive for COVID-19, UK Office for National Statistics.
  https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/c oronaviruscovid19infectionsurveycharacteristicsofpeopletestingpositiveforcovid19uk/25august2021.
- 32. Omicron largely evades immunity from past infection or two vaccine doses | Imperial News | Imperial College London. https://www.imperial.ac.uk/news/232698/omicron-largely-evades-immunity-from-past/.
- 33. Jeffery-Smith, A. *et al.* Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes, September and October 2020. *Euro Surveill. Bull. Eur. Sur Mal. Transm. Eur. Commun. Dis. Bull.* **26**, (2021).
- 34. Gallais, F. *et al.* Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. *EBioMedicine* **71**, 103561 (2021).
- 35. Krutikov, M. *et al.* Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study. *Lancet Healthy Longev.* 2, e362–e370 (2021).

- 36. Harvey, R. A. *et al.* Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection. *JAMA Intern. Med.* **181**, 672–679 (2021).
- 37. Maier, H. E. *et al.* Clinical spectrum of SARS-CoV-2 infection and protection from symptomatic re-infection. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* ciab717 (2021) doi:10.1093/cid/ciab717.
- 38. Chemaitelly, H. *et al.* Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. *Nat. Commun.* **13**, 4675 (2022).
- 39. Satwik, R., Satwik, A., Katoch, S. & Saluja, S. ChAdOx1 nCoV-19 effectiveness during an unprecedented surge in SARS COV-2 infections. *Eur. J. Intern. Med.* **93**, 112–113 (2021).
- Chin, E. T. et al. Protection against Omicron conferred by mRNA primary vaccine series, boosters, and prior infection. http://medrxiv.org/lookup/doi/10.1101/2022.05.26.22275639 (2022)
   doi:10.1101/2022.05.26.22275639.
- 41. Braeye, T. *et al.* Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021. *Vaccine* **40**, 3027–3037 (2022).
- 42. Ayoub, H. H. et al. Estimating protection afforded by prior infection in preventing reinfection: Applying the test-negative study design. http://medrxiv.org/lookup/doi/10.1101/2022.01.02.22268622 (2022) doi:10.1101/2022.01.02.22268622.
- 43. Chemaitelly, H., Bertollini, R. & Abu-Raddad, L. J. Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant. *N. Engl. J. Med.* **385**, 2585–2586 (2021).
- 44. Petráš, M. et al. The Effectiveness of Post-Vaccination and Post-Infection Protection in the Hospital Staff of Three Prague Hospitals: A Cohort Study of 8-Month Follow-Up from the Start of the COVID-19 Vaccination Campaign (COVANESS). Vaccines 10, 9 (2021).
- 45. Altarawneh, H. N. *et al.* Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants. *N. Engl. J. Med.* **387**, 1620–1622 (2022).
- Abu-Raddad, L. J. *et al.* Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study. *PLOS Med.* 18, e1003879 (2021).
- 47. Bertollini, R. *et al.* Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar. *JAMA* **326**, 185 (2021).

- 48. Chemaitelly, H. *et al.* Duration of immune protection of SARS-CoV-2 natural infection against reinfection. *J. Travel Med.* taac109 (2022) doi:10.1093/jtm/taac109.
- 49. Vicentini, M. *et al.* Risk of SARS-CoV-2 Reinfection by Vaccination Status, Predominant Variant, and Time from Previous Infection: A Cohort Study in Italy. *SSRN Electron. J.* (2022) doi:10.2139/ssrn.4132329.
- 50. Abu-Raddad, L. J., Chemaitelly, H. & Bertollini, R. Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections. *N. Engl. J. Med.* **385**, 2487–2489 (2021).
- 51. Michlmayr, D. et al. Observed protection against SARS-CoV-2 reinfection following a primary infection: A Danish cohort study among unvaccinated using two years of nationwide PCR-test data. Lancet Reg. Health Eur. 20, 100452 (2022).
- 52. Lacy, J. *et al.* Protective effect of a first SARS-CoV-2 infection from reinfection: a matched retrospective cohort study using PCR testing data in England. *Epidemiol. Infect.* **150**, e109 (2022).
- 53. Ridgway, J. P., Tideman, S., Wright, B. & Robicsek, A. Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19. *JAMA Netw. Open* **5**, e227650 (2022).
- 54. Spicer, K. B., Glick, C., Cavanaugh, A. M. & Thoroughman, D. Protective Immunity after Natural Infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Kentucky, USA, 2020. *Int. J. Infect. Dis.* **114**, 21–28 (2022).
- 55. Cohen, C. *et al.* SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020–21. *Lancet Infect. Dis.* **22**, 821–834 (2022).
- 56. Sun, K. *et al.* SARS-CoV-2 transmission, persistence of immunity, and estimates of Omicron's impact in South African population cohorts. *Sci. Transl. Med.* **14**, eabo7081 (2022).
- 57. Powell, A. A. et al. Protection against symptomatic disease with the delta and omicron BA.1/BA.2 variants of SARS-CoV-2 after infection and vaccination in adolescents: national observational test-negative case control study, August 2021 to March 2022, England. http://medrxiv.org/lookup/doi/10.1101/2022.08.19.22278987 (2022) doi:10.1101/2022.08.19.22278987.
- 58. Murugesan, M. *et al.* Protective effect conferred by prior infection and vaccination on COVID-19 in a healthcare worker cohort in South India. *PLOS ONE* **17**, e0268797 (2022).
- 59. Dhumal, S. *et al.* SARS-CoV-2 reinfection after previous infection and vaccine breakthrough infection through the second wave of pandemic in India: An observational study. *Int. J. Infect. Dis.* **118**, 95–103 (2022).

- 60. Corrao, G. *et al.* Protective action of natural and induced immunization against the occurrence of delta or alpha variants of SARS-CoV-2 infection: a test-negative case-control study. *BMC Med.* **20**, 52 (2022).
- 61. Smolenov, I. *et al.* Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial. *Lancet Infect. Dis.* **22**, 990–1001 (2022).
- 62. Reynolds, S. L. et al. Duration of Protection Against SARS-CoV-2 Reinfection and Associated Risk of Reinfection Assessed with Real-World Data. http://medrxiv.org/lookup/doi/10.1101/2022.02.25.22271515 (2022) doi:10.1101/2022.02.25.22271515.
- 63. Narrainen, F. *et al.* The protective effect of previous COVID-19 infection in a high-prevalence hospital setting. *Clin. Med.* **21**, e470–e474 (2021).
- 64. Kubale, J. et al. Burden of SARS-CoV-2 and protection from symptomatic second infection in children. http://medrxiv.org/lookup/doi/10.1101/2022.01.03.22268684 (2022) doi:10.1101/2022.01.03.22268684.
- 65. Rothberg, M. B., Kim, P., Shrestha, N. K., Kojima, L. & Tereshchenko, L. G. Protection Against the Omicron Variant Offered by Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Retrospective Cohort Study. *Clin. Infect. Dis.* ciac604 (2022) doi:10.1093/cid/ciac604.
- 66. Andeweg, S. P. *et al.* Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections. *Nat. Commun.* **13**, 4738 (2022).
- 67. Carazo, S. et al. Protection against Omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination. http://medrxiv.org/lookup/doi/10.1101/2022.04.29.22274455 (2022) doi:10.1101/2022.04.29.22274455.
- 68. Altarawneh, H. N. et al. Protection of SARS-CoV-2 natural infection against reinfection with the Omicron BA.4 or BA.5 subvariants. http://medrxiv.org/lookup/doi/10.1101/2022.07.11.22277448 (2022) doi:10.1101/2022.07.11.22277448.
- 69. Berec, L. et al. Real-life protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in the Czech Republic: a whole country retrospective view. http://medrxiv.org/lookup/doi/10.1101/2021.12.10.21267590 (2021) doi:10.1101/2021.12.10.21267590.

70. Manica, M. et al. The risk of symptomatic reinfection during the second COVID-19 wave in individuals previously exposed to SARS-CoV-2. http://medrxiv.org/lookup/doi/10.1101/2021.04.14.21255502 (2021) doi:10.1101/2021.04.14.21255502.